Document:

Finished Product Supply Agreement, dated as of March 24,2004

 Exhibit 10.5 
 EXECUTION COPY 
  
 FINISHED PRODUCT SUPPLY AGREEMENT 
  
 This
FINISHED PRODUCT SUPPLY AGREEMENT (this “Agreement”), dated as of March 24, 2004, is made by and between Barr Laboratories, Inc., a corporation organized and existing under the laws of Delaware (“Barr”), and Galen
(Chemicals) Limited, a company organized and existing under the laws of the Republic of Ireland (“Galen”) and shall become effective as of the Effective Date (as defined herein). Barr and Galen are each sometimes referred to
individually as a “Party” and together as the “Parties.” 
  
 RECITALS 
  
 WHEREAS, this Agreement constitutes the Supply Agreement contemplated by that certain Option and License Agreement, dated as of the date hereof, by and between the Parties (the “License Agreement”); 
  
 WHEREAS, Barr has the capability to manufacture the Licensed
Products (as defined below); and 
  
 WHEREAS, the
Parties desire that Barr supply Galen with the Licensed Products under this Agreement on the terms and subject to the conditions set forth below. 
  
 NOW, THEREFORE, in consideration of the foregoing premises and the representations, covenants and agreements contained herein, the
Parties, intending to be legally bound, hereby agree as follows: 
  
 ARTICLE 1 
 DEFINITIONS 
  
 When used in this Agreement, whether in the singular or plural, each of the following capitalized terms shall have the meanings set forth in this Article
1: 
  
 1.1 “21-Day ANDA” means the Abbreviated
New Drug Application number 76-198, which references the product approved under New Drug Application 18-127, filed with the FDA by Barr in order to obtain regulatory approval to commence sale of the 21-Day Licensed Product (and any supplement or
amendment filed pursuant to FDA requirements). 
  
 1.2
“28-Day ANDA” means the Abbreviated New Drug Application number 76- 238, which references the product approved under New Drug Application 17-716, filed with the FDA by Barr in order to obtain regulatory approval to commence sale of
the 28-Day Licensed Product (and any supplement or amendment filed pursuant to FDA requirements). 
  
 1.3 “21-Day Licensed Product” means 0.4 mg. norethindrone/.035 mg. ethinyl estradiol 21-day oral tablets, described in, and the sale of
which is or will be permitted by, the 21-Day ANDA (to the extent the 21-Day ANDA is or becomes an Approved ANDA). 
  

 1.4 “28-Day Licensed Product” means 0.4 mg. norethindrone/.035 mg. ethinyl estradiol
28-day oral tablets, described in, and the sale of which is or will be permitted by, the 28-Day ANDA (to the extent the 28-Day ANDA is or becomes an Approved ANDA). 
  
 1.5 “Affiliates” means, with respect to a Party, any Person that directly or indirectly, through one or
more intermediaries, controls, is controlled by, or is under common control with, such Party at any time during the period for which the determination of affiliation is being made. For the purposes of this definition, “control”
(including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management, policies or affairs of a Person,
whether through ownership of voting securities or general partnership or managing member interests, by contract or otherwise, including the ownership, directly or indirectly, of securities having the power to elect a majority of the board of
directors or similar body governing the affairs of such Person. Without limiting the generality of the foregoing, a Person shall be deemed to control any other Person in which it owns, directly or indirectly, a majority of the voting interests.

  
 1.6 “ANDAs” means collectively or either, as
the case may be, the 21-Day ANDA and the 28-Day ANDA. 
  
 1.7
“Applicable Law” means all applicable laws, statutes, ordinances, rules, regulations (including Current Good Manufacturing Practices), writs, judgments, decrees, injunctions (whether preliminary or final), orders and other
requirements (including ANDAs, permits, certificates and other product authorizations and approvals) of any Governmental Authority (including the FTC and FDA or any self-regulatory organization or stock exchange). 
  
 1.8 “Approved ANDA” means any of the ANDAs that has been
finally approved by the FDA. 
  
 1.9 “Business
Day” means any day other than a Saturday, Sunday or day on which banks in New York, New York are authorized or obligated by Applicable Law to close. Any reference in this Agreement to “day” whether or not capitalized shall refer
to a calendar day, not a Business Day. 
  
 1.10
“Certificate of Analysis” means a written certification, substantially in the form attached as Schedule 1.10, delivered by Barr to Galen with each shipment of Finished Products. 
  
 1.11 “Commercially Reasonable Efforts” means, with respect
to a Party, the efforts and resources which would be used by that Party consistent with its normal business practices with respect to a product at a similar stage in its development or product life and of similar market potential taking into account
efficacy, safety, the anticipated approved labeling, the competitiveness of alternative products in the market place or under development, the patent and other proprietary position of the product, the likelihood of regulatory approval, the
commercial value of the product and other relevant factors. 
  
 1.12 “Current Good Manufacturing Practices” or “cGMPs” means the current good manufacturing practices and standards as set forth in C.F.R. Parts 210 and 211 and as otherwise established or required by
applicable Governmental Authorities in effect at the time and place for 

  

 2 

 
the manufacture of Licensed Product, and subject to any arrangements, additions or clarifications agreed from time to time between the Parties in the Quality
Agreement. 
  
 1.13 “Damages” means any and all
costs, losses, claims, liabilities, fines, penalties, awards, verdicts, settlements, judgments, interests and expenses, including reasonable attorney’s fees and costs of suit. 
  
 1.14 “Effective Date” means the date on which Galen exercises the Option pursuant to, and in accordance
with, Section 2.5 of the License Agreement. 
  
 1.15
“FDA” means the United States Food and Drug Administration, or any successor agency thereof. 
  
 1.16 “FTC” means the United States Federal Trade Commission, or any successor agency thereof. 
  
 1.17 “Final Packaging” means the labeling and packaging of
Processed Product in accordance with Applicable Law and the ANDAs, including the package inserts and other components reasonably necessary for the sale or distribution of the Finished Product to the ultimate consumer. 
  
 1.18 “Finished Product” shall mean a Licensed Product in its
finished form in Final Packaging, ready for sale to the market or distribution as Professional Samples (as defined herein). 
  
 1.19 “Force Majeure” means any occurrence beyond the reasonable control of a Party that prevents or substantially interferes with the
performance by the Party of any of its obligations hereunder, if such occurs by reason of any act of God, flood, fire, explosion, earthquake, strike, lockout, labor dispute, casualty, accident, war, revolution, civil disorder, terrorist attack,
embargo, any restriction of any Governmental Authority (to the extent such Government Authority has ruling authority over such Party), or other similar event, beyond the reasonable control of such Party, if and only if the Party affected shall have
used Commercially Reasonable Efforts to avoid such occurrence. 
  
 1.20 “Fully Loaded Manufacturing Cost” means, with respect to Finished Product, Barr’s internal and external costs, determined in accordance with United States generally accepted accounting principles, as consistently
applied by Barr in accordance with its past practice and in the ordinary course of its business, incurred in manufacturing, acquiring, packaging, transporting and/or storing such Finished Product (including product testing activities relating to
quality assurance, quality control and regulatory compliance), in each case to the extent related and allocable to the Finished Product supplied to Galen hereunder. Fully Loaded Manufacturing Cost shall not include any cost attributable to general
corporate activities, including, by way of example, executive management, investor relations, business development, legal affairs and finance. Attached as Schedule 1.20 is a non-binding sample calculation of Fully Loaded Manufacturing Cost.

  
 1.21 “Governmental Authority” means any
governmental, regulatory or administrative authority, court, tribunal, arbitrator, agency, commission, official or other instrumentality of any 

  

 3 

 
supranational authority or any federal, state, provincial, municipal, county, city or other political subdivisions thereof. 
  
 1.22 “Licensed Product” means the 21-Day Licensed Product or
the 28-Day Licensed Product, as applicable, and “Licensed Products” means the 21-Day Licensed Product and the 28-Day Licensed Product, collectively. 
  
 1.23 “Person” or “person” means any individual, firm, corporation, partnership, limited
liability company, trust, joint venture, Governmental Authority, or other entity or organization. 
  
 1.24 “Printed Materials” means printed packaging materials relating to any Processed Product and product labels, printed packaging
materials or packaging inserts relating to any Finished Product. 
  
 1.25 “Processing Activities” means activities relating to production of the Licensed Products, spanning from purchasing raw materials to packaging of the Licensed Products including purchasing raw materials, manufacturing,
processing, quality control filling, labeling, packaging, finishing, release and storage and other activities required to be undertaken by Barr or its suppliers and its permitted subcontractors in order to produce Finished Product, and the tests and
analyses conducted in connection therewith. 
  
 1.26
“Processed Product” means a Licensed Product that has undergone the Processing Activities, prior to being in, and as released for, Final Packaging. 
  
 1.27 “Professional Samples” means Processed Product in Final Packaging intended for distribution as
professional samples. 
  
 1.28 “Specifications”
means, for each Licensed Product, such specifications as set forth in Schedule 1.28, as such specifications may be supplemented or modified from time to time hereafter in accordance with the provisions of this Agreement. 
  
 1.29 “Territory” means the United States and its states,
territories and possessions, including the Commonwealth of Puerto Rico and the District of Columbia. 
  
 1.30 “Third Party” means any Person other than Barr, Galen and their respective Affiliates. 
  
 ARTICLE 2 
 SUPPLY BY BARR 
  
 2.1 Commitment to Supply. During the term of this Agreement, upon the terms and subject to the conditions of this Agreement, commencing as of the Effective Date, Barr shall use Commercially Reasonable Efforts
to supply to Galen or its designee, and Galen shall purchase from Barr, all of Galen’s requirements for Finished Product pursuant to purchase orders delivered from time to time by Galen to Barr in accordance with Section 4.2. During the First
License Term (as defined in the License Agreement), neither Barr nor any of its Affiliates shall have the right to manufacture or supply any Licensed Product for or to any other Person. It is expressly understood and agreed by Galen that Barr shall
not be required and have no obligation 

  

 4 

 
to supply either the 21-Day Licensed Product or the 28-Day Licensed Product until such time as Barr receives the Approved ANDA for the applicable Licensed
Product and Galen has exercised the Option (as defined in and in accordance with the License Agreement). 
  
 2.2 Responsibility. Unless otherwise specified herein or expressly consented to in writing by Galen and Barr, as between the Parties, Barr shall
have control of and discretion over performance of all activities necessary to supply Galen with Finished Product as contemplated hereunder, in each case which shall be exercised in Barr’s reasonable judgment in the ordinary course of business.
Unless provided otherwise and only as and if permitted herein, a Party’s sublicensing, subcontracting or designating activities to be performed under this Agreement to an Affiliate or Third Party shall not release such Party from the
performance of any of its responsibilities hereunder. 
  
 ARTICLE 3 
 STANDARD TERMS OF SUPPLY OF PRODUCT 
  
 3.1 Packaging. 
  
 (a) Packaging Layout. Barr shall package the Licensed Products with Galen’s (or its Affiliate’s) trademarks, trade names
and/or trade dress in accordance with the applicable Approved ANDA and any applicable FDA regulations and, only if required by Applicable Law, such packaging shall indicate that Barr, or its applicable Affiliate, is the manufacturer thereof. Barr
shall promptly provide Galen with information regarding the dimensions and parameters of the Printed Materials. At least 120 days prior to the first production of any new “put-up” of a Licensed Product, Galen shall provide Barr with all
artwork, copy or other material developed or produced by Galen for the Printed Materials. Barr will promptly review such suggested layout and make any reasonable objections or comments that it may have to such layout in writing no more than ten (10)
Business Days after receipt. The Parties will then discuss the merits of such objections or comments and use their respective Commercially Reasonable Efforts to mutually agree upon any disputed items with respect to the final layout and content of
the Printed Materials. Unless Galen agrees to provide Barr with authorized film or equivalent master copy, within a reasonable time of receiving such materials, Barr shall, at Galen’s sole cost and expense, provide Galen with proofs or samples
of the Printed Materials to be used with each formulation of each Licensed Product for Galen’s prior review and approval and shall prepare or arrange for the production of camera-ready artwork for the agreed Printed Materials. No change to such
Printed Materials may be made without the prior written approval of Galen, which, in the case of changes required by Applicable Law, will not be unreasonably withheld, conditioned or delayed. Galen hereby grants Barr a non-exclusive, royalty-free,
right and license to use Galen’s trademarks, trade names and/or trade dress and all artwork, copy or other material developed or produced by Galen for the Printed Materials solely for purposes of fulfilling Barr’s obligations under this
Agreement. 
  
 (b) Changes to Packaging.
Galen may from time to time request changes to the trademark, trade name or trade dress of the Printed Materials, which request shall be handled in accordance with Section 3.1 (a). In addition, Galen may from time to time request that Barr submit
for FDA approval changes to the FDA-approved labeling (including tablet color, tablet embossing, package inserts and primary packages) for a Licensed Product. Barr agrees to use its 

  

 5 

 
Commercially Reasonable Efforts to make such submission, obtain FDA approval for and implement such changes, at Galen’s sole cost and expense.

  
 (c) Obsolete Packaging. Barr shall
promptly implement any agreed change or approved change, as the case may be, to the Printed Materials pursuant to Section 3.1 (b), or on such other specific timeframe as agreed by the Parties on a case-by-case basis. In the event that Galen requests
or is required by an applicable Governmental Authority to make changes in the Printed Materials for a Licensed Product, and Barr has components for such materials in stock that it has purchased specifically for such Licensed Product, Galen shall
have the obligation to purchase, at Barr’s cost, the lesser of (a) 6 months’ supply of such components based on forecasts made by Galen for the corresponding Licensed Product with respect to the next 6 months and (b) all of the Barr stock
of such components. 
  
 (d) Option for
Additional Packaging. Galen shall have the option to have Barr manufacture and supply Licensed Product in primary packaging and Final Packaging bearing two different and distinct trademarks, tradenames and/or tradedress (each, a
“Brand”). For the avoidance of doubt, Final Packaging for each Brand includes Professional Sample packaging. If Galen so orders Licensed Product under two different Brands, the production and implementation of the Printed Materials
relating to the additional Brand shall be handled in accordance with Section 3.1 (a) and (b), and Galen shall provide Barr with separate and distinct forecasts and firm orders for each Brand. 
  
 3.2 Manufacturing Regulatory Matters. 
  
 (a) Barr shall maintain the ANDAs and any other regulatory
approvals necessary for Barr to supply Finished Product hereunder. Barr shall promptly advise Galen in writing of any information arising out of its manufacturing activities that may have adverse regulatory compliance and/or reporting consequences
concerning the Finished Product. 
  
 (b) Where
Barr may lawfully do so, Barr shall provide Galen with access to copies of all filings submitted by Barr to any Governmental Authority for each Licensed Product. Barr shall have the final decision-making authority in every case on whether and how to
maintain the ANDAs and any other regulatory approvals necessary for Barr to supply Finished Product hereunder and any other issues in connection with such approvals and on whether and how to communicate with any Governmental Authority;
provided, that Barr will not, except where required by, or to fulfill obligations under, Applicable Law or except where required by a Governmental Authority within the scope of its authority, supplement, amend or otherwise alter the ANDAs or
any other such regulatory approval so as to breach this Agreement or to adversely alter the rights granted to Galen hereunder or under the License Agreement. 
  
 3.3 Quality Agreement. The Parties shall negotiate and agree within thirty (30) days following the date hereof a quality agreement (the
“Quality Agreement”), which shall (a) be on terms consistent with those standard in the industry for transactions similar to this Agreement and (b) become effective as of the Effective Date. Each Party agrees to comply with the
procedures set forth in the Quality Agreement regarding quality and cGMP related responsibilities, complaints and Adverse Event Monitoring and Reporting. To the extent there are any inconsistencies or conflicts between this Agreement and the Quality
Agreement, the 

  

 6 

 
terms and conditions of this Agreement shall control unless otherwise agreed to in writing by the Parties in the form of an amendment to this Agreement. In
the event that the Quality Agreement contains material provisions that differ from Applicable Law, the Applicable Law shall control. 
  
 3.4 Materials Suppliers. In order to fulfill its obligations under this Agreement, Barr may enter into supply agreements with suppliers of the
materials necessary to manufacture the Finished Product. 
  
 3.5
Manufacturing and Regulatory Changes. The Parties will promptly inform each other, with sufficient notice so that the required actions can be taken in due time, of all significant changes to suppliers of materials, formulations, processes,
equipment, facilities, specifications, tests or any item that would affect any regulatory filings for Finished Product. To the extent that such changes are not required by Applicable Law and are made at Barr’s election without the consent of
Galen (which consent shall not be unreasonably withheld), Barr shall bear the costs related to any such changes under this Section 3.5. 
  
 3.6 Compliance, Documentation, Monitoring and Recordkeeping. Barr shall adhere in all material respect to cGMPs as they apply to the Processing
Activities. Barr shall maintain complete and accurate documentation of all validation data, stability testing data, batch records, quality control and laboratory testing and any other data required under cGMPs and other requirements of any relevant
Governmental Authority in connection with the performance of any Processing Activities hereunder. Throughout the term of this Agreement, and for so long thereafter as is required by Applicable Law, Barr shall monitor and maintain reasonable records
respecting its compliance with cGMPs, including through the establishment and implementation of such operating procedures as are reasonably necessary to assure such compliance. 
  
 3.7 Inspection and Audit. Barr shall permit Galen or its representatives to inspect, review and audit: (i) those
portions of each facility at which any Processing Activities are performed by Barr (or its Affiliates, sublicensees or subcontractors) and (ii) any of Barr’s manufacturing and quality control records and other documentation relating to the
Processing Activities (including any internal quality control audits or reviews conducted by Barr and including the opportunity to meet with Barr personnel). Such inspections, reviews and audits shall be for the purpose of ascertaining compliance
with Barr’s obligations under the Quality Agreement and this Agreement and with the ANDAs and cGMPs, and reviewing correspondence, reports, filings and other documents from or to Governmental Authorities to the extent related to the Processing
Activities. Any information obtained by Galen through such inspections, reviews and audits shall be treated as confidential information of Barr. Such audits, reviews and inspections shall be conducted at Galen’s expense during normal business
hours, upon reasonable notice, and no more than twice per year, and in a manner that does not unreasonably interfere with ongoing operations. Galen’s exercise of its inspection rights hereunder shall not discharge any obligation of Barr under
this Agreement, other than its obligation to permit inspection and audit under this Section 3.7. 
  
 3.8 Governmental and Regulatory Inspections. Barr shall promptly notify Galen of any inspections by any Governmental Authorities of the premises
where any Processing Activities are taking place, to the extent such inspection relates to the Processing Activities for the Licensed Product, and shall provide Galen copies of all correspondence, reports, notices, 

  

 7 

 
findings and other material pertinent to such inspections (including all Form 483s) promptly after they are received or produced by or on behalf of Barr from
or to the FDA or any other Governmental Authority. All notices shall be sent to Warner Chilcott, Inc., 100 Enterprise Drive, Rockaway, NJ 07866 Attention: Vice President Regulatory Affairs. 
  
 ARTICLE 4 
 FORECASTING, ORDERING AND SHIPPING 
  
 4.1 Rolling Forecasts. Throughout the term of this Agreement, Galen shall provide Barr, at least sixty (60) days prior to the first day of each calendar quarter, with a rolling forecast
(“Forecast”) prepared in good faith by Galen projecting Galen’s requirements of Finished Product, on a Licensed Product by Licensed Product and Brand by Brand basis, for the twelve (12) month period commencing on the first day
of the aforementioned calendar quarter, specifically indicating such projected requirements for each month during such twelve (12) month period. The first three (3) months of each such Forecast shall be binding on Galen, and Barr may, therefore,
require Galen to pay for, the amounts of such Licensed Product specified therein, whether or not Galen submits a purchase order therefor in accordance with Section 4.2. Moreover, the quantity (on a Licensed Product by Licensed Product and Brand by
Brand basis) set forth in such first three (3) months binding portion of each such Forecast shall be not less than eighty percent (80%), and not more than one-hundred twenty percent (120%), of the quantity therefor set forth in the immediately
preceding Forecast relating to such calendar quarter. 
  
 4.2
Submission of Purchase Orders. Concurrently with the delivery of each Forecast, Galen shall place a purchase order for Finished Product with Barr, in a format agreed upon by the Parties, specifying the quantities of each Finished Product (on
a Licensed Product by Licensed Product and a Brand by Brand basis) to be purchased by Galen with respect to the first calendar quarter of such Forecast, and the place(s) to which and the manner and dates by which delivery is to be made during such
calendar quarter. All purchase orders shall be sent by Galen to the attention of the employee of Barr as may from time to time be designated by Barr. Purchase orders made in accordance with this Article 4 shall be deemed to be accepted by Barr if
Barr has not rejected said purchase orders in writing within ten (10) Business Days of receipt after the same; provided, that Barr shall not reject any purchase order specifying quantities within the quantity limitations set forth above and
which purchase orders are otherwise in accordance with the provisions of this Article 4. Notwithstanding the foregoing, Barr shall promptly notify Galen in writing if at any time Barr has reason to believe that Barr will not be able to fill a
purchase order for any Finished Product in all material respects pursuant to the terms and conditions of this Agreement. To the extent the terms of any purchase order or acknowledgment thereof are inconsistent with the terms of this Agreement, the
terms of this Agreement shall control. 
  
 4.3 Terms of
Delivery. Barr shall execute all accepted purchase orders consistent with this Agreement and deliver Finished Product to Galen’s designated carrier at Barr’s facility, to be delivered within +/- seven (7) days of the delivery date
specified in Galen’s purchase orders in accordance with Section 4.2. Galen shall be responsible for arranging, at its expense, all shipping, freight and insurance for its orders of Finished Product. Title and risk of loss will pass to Galen
when each order of Finished Product is delivered to Galen’s designated carrier at Barr’s 

  

 8 

 
facility. If Galen does not timely indicate in writing its selection of a carrier to Barr, Ban shall be entitled to select an appropriate carrier, which in
any case shall be a carrier Barr uses to ship its other oral contraceptive products in the ordinary course of its business. Barr shall package each order of Finished Product for shipment in accordance with its customary practices therefor, unless
otherwise specified in writing by Galen. 
  
 4.4 Accompanying
Documentation. With each shipment of Finished Product, Barr shall provide Galen with commercially appropriate shipping documentation (including Galen’s purchase order number and the quantity of the Finished Product) and with a Certificate
of Analysis identifying the applicable lot and batch numbers and indicating conformance of the shipment with the Specifications. 
  
 4.5 Retention of Samples. Barr shall properly store and retain appropriate samples (identified by lot and batch number) of Finished Product that it
supplies to Galen in conditions and for times consistent with all Applicable Law and to permit appropriate or required internal and regulatory checks and references (collectively, the “Shipment Samples”). 
  
 ARTICLE 5 
 INSPECTION AND DEFECTIVE PRODUCTS; PRODUCT RECALL 
  
 5.1 Receipt of Finished Product by Galen. Galen shall be entitled to reject any portion or all of any shipment of Finished Product that does not
conform to the Certificate of Analysis or otherwise fails to comply with the warranties set forth in Article 8 (unless such non-conformity was attributable to an act or omission of Galen or the common carrier once the Finished Product was delivered
by Barr to such common carrier); provided, that (i) Galen shall notify Barr within thirty (30) days after receipt of such shipment if it is rejecting a shipment due to obvious physical damage, obvious packaging defect or quantity
discrepancies that are evident upon visual inspection of the packaged Finished Product as shipped by Barr and (ii) in the case of Finished Product having defects other than those obvious defects, Galen shall notify Barr within ninety (90) days after
receipt of such Finished Product. Notwithstanding anything contained herein, Galen shall have no obligation to inspect the Finished Product beyond a visual inspection of each shipment for obvious physical damage or quantity discrepancies that are
evident upon visual inspection of the packaged Finished Product as shipped by Barr. Without in any way limiting Barr’s indemnity obligation as set forth in Section 9.2, if no notice is provided by Galen within the relevant time periods, then
Galen shall be deemed to have accepted the shipment. Any notice of rejection by Galen shall be accompanied by a reasonably detailed statement of its reasons for rejection and a report of any pertinent analysis performed by Galen on the allegedly
nonconforming Finished Product, together with the methods and procedures used. Barr shall notify Galen as promptly as reasonably possible, but in any event within fifteen (15) Business Days after receipt of such notice of rejection, whether it
accepts Galen’s assertions of nonconformity. 
  
 5.2
Replacement Finished Product. Whether or not Barr accepts Galen’s assertion of nonconformity, promptly upon receipt of a notice of rejection, unless otherwise specified by Galen, Barr shall use its Commercially Reasonable Efforts to
provide replacement Finished Product for those rejected by Galen in the original shipment. If the Finished Product rejected by Galen from such original shipment ultimately is found to be nonconforming (whether pursuant to 

  

 9 

 
Section 5.1(c) or if Barr so acknowledges in writing), Barr shall bear all expenses for such replacement Finished Product (including all transportation
and/or disposal charges and cost of manufacture for such nonconforming Finished Product) to the extent Galen previously paid for any corresponding nonconforming Finished Product. If it is determined subsequently that such Finished Product was in
fact conforming (whether pursuant to Section 5.1(c) or if Galen so acknowledges in writing), then Galen shall be responsible not only for the purchase price of the allegedly nonconforming Finished Product (including all transportation charges), but
also, upon receipt and acceptance by Galen in accordance with the procedures (and at the same price charged in the original shipment) set forth above, the replacement Finished Product. Replacement shipments shall also be subject to the procedures
contained in Section 5.1 (a). 
  
 5.3 Independent Laboratory
Analysis. If Barr disagrees with any alleged nonconformity timely notified to Barr under Section 5.1, then an independent laboratory (or other expert) of recognized repute reasonably acceptable to both Parties (the “Independent
Laboratory”) shall analyze (i) a sample from the relevant shipment provided by Galen and (ii) a Shipment Sample as retained by Barr in accordance with Section 4.5, as may be necessary to substantiate whether the shipment rejected by Galen
conformed in all material respects to the Certificate of Analysis and any other pertinent Specifications or otherwise failed to comply with the warranties set forth in Article 8 at the time of delivery to the common carrier. At the same time each
party furnishes to the Independent Laboratory its sample, such party shall also furnish to the other party a split sample of such sample. In conducting its analysis hereunder, the Independent Laboratory shall use the same analytical methodology used
by Barr. Barr shall provide a reasonably detailed description of such analytical methodology to the Independent Laboratory. Both Parties agree to cooperate with the Independent Laboratory’s reasonable requests for assistance in connection with
its analysis hereunder. Both Parties shall be bound by the Independent Laboratory’s results of analysis, which, absent manifest error, shall be deemed final as to any dispute over compliance of the Finished Product in all material respects with
the Certificate of Analysis and/or any other pertinent Specifications and/or the warranties set forth in Article 8. If the analysis of the Independent Laboratory shows that the Finished Product does not conform in all material respects to the
Certificate of Analysis or any other pertinent Specifications or the warranties set forth in Article 8 at the time of delivery to the common carrier, the costs of such analysis shall be paid by Barr. If the analysis of the Independent Laboratory
shows that the Finished Product does conform in all material respects to the Certificate of Analysis and any other pertinent Specifications and the warranties set forth in Article 8 at the time of delivery to the common carrier, the costs of such
analysis shall be paid by Galen. 
  
 5.4 Disposition of
Non-Conforming Finished Product. If Barr acknowledges an alleged nonconformity (or if the Independent Laboratory concludes that the Finished Product was nonconforming in accordance with Section 5.3), Barr promptly (and in any case within thirty
(30) days thereafter) shall make arrangements for the return, reworking or disposal, at Barr’s option, of the nonconforming Finished Product. If Barr requests that Galen dispose of such nonconforming Finished Product, Barr shall give Galen
written instructions as to how Galen or its agent shall, at Barr’s expense, lawfully dispose of any non-conforming Finished Product, and Galen shall provide Barr with written certification of such destruction. Barr shall pay, or reimburse
Galen, for any reasonable return shipping charges or out-of-pocket costs incurred by 

  

 10 

 
Galen for such return shipment or lawful disposal of such nonconforming Finished Product in accordance with Barr’s instructions. 
  
 5.5 Product Recall. Responsibility for carrying out any recall, market
withdrawal or other corrective action related to the Finished Product shall be assigned to the parties and carried out in accordance with Section 4.4 of the License Agreement. 
  
 ARTICLE 6 
 FINANCIAL PROVISIONS 
  
 6.1 Supply Price.
Barr shall submit invoices to Galen for Finished Product promptly after shipment. The invoices shall reflect the supply of Finished Product to Galen at a price per unit equal to two (2) times the Fully Loaded Manufacturing Cost for each SKU of
Finished Product (other than Professional Samples) and the supply of Professional Samples to Galen at a price per unit equal to one and a quarter (1.25) times the Fully Loaded Manufacturing Cost for such Professional Sample. 
  
 6.2 Manner of Payments. All sums due to Barr under this Agreement
shall be payable in United States Dollars by bank wire transfer in immediately available funds to such bank account(s) as Barr shall from time to time designate in writing, unless otherwise agreed by the Parties in writing. 
  
 6.3 Invoices; Timing of Payments. Each invoice shall specify the
purchase order number to which it corresponds and shall reflect the price set forth in Section 6.1. Unless otherwise specified in this Agreement, all amounts due to Barr hereunder shall be paid by Galen within thirty (30) days following the date of
invoice. 
  
 6.4 Interest on Late Payments. If Galen shall
fail to make a timely payment hereunder, any such payment that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at the average one-month London Inter-Bank Offering Rate (LIBOR) for
the United States Dollar as reported from time to time in The Wall Street Journal (or, if such rate is not regularly published, as published in such source as the Parties agree), effective for the first date on which payment was delinquent
and calculated on the number of days such payment is overdue, plus one percent (1%), or such lesser amount that is the maximum amount permitted under Applicable Law. 
  
 6.5 Audit Right. Galen shall have the right to have a nationally recognized independent public accounting firm audit,
but in any case no more than once per calendar year, Barr’s books and records relating to the Processing Activities, for the sole purpose of verifying Barr’s calculation of Fully Loaded Manufacturing Cost. Such audit shall be at reasonable
times during normal business hours and upon reasonable notice to Barr. A copy of such auditing firm’s conclusions of its audit shall be furnished to Barr at least ten (10) Business Days prior to disclosure to Galen to allow Barr an opportunity
to review the accuracy of the auditing firm’s conclusions. The conclusions of such audit firm shall be final and binding on the Parties absent manifest error. Galen shall bear the full cost of such audit, unless such audit discloses a variance
of more than 5% from Barr’s calculation of its Fully Loaded Manufacturing Cost (based on the 

  

 11 

 
aggregate Fully Loaded Manufacturing Cost for all Finished Product hereunder, and not one Finished Product individually), in which event, Barr shall bear the
full cost of such audit. 
  
 6.6 Tax Withholding. Any
payments payable by one Party (the “Withholding Party”) to the other Party under this Agreement may be reduced by the amount required to be paid or withheld pursuant to any Applicable Law, including United States federal, state or
local tax law (“Withholding Taxes”). The Withholding Party shall submit to the other Party a copy of an original receipt received by the Withholding Party showing payment thereof, or if such receipt is not available, other
reasonable proof of payment of any Withholding Taxes paid or withheld, together with an accounting of the calculations of such taxes, as promptly as practicable but in no case later than thirty (30) days after such Withholding Taxes are remitted to
the proper Governmental Authority. The Parties will cooperate reasonably in completing and filing documents required under the provisions of any applicable tax law or under any other Applicable Law in connection with the making of any required tax
payment or withholding payment, or in connection with any claim to a refund of or credit for any such payment. 
  
 ARTICLE 7 
 CONFIDENTIALITY 
  
 7.1 Confidentiality. The Mutual Confidentiality Agreement between Barr
and Galen Holdings, plc, dated as of April 25,2002 (the “Confidentiality Agreement”), shall remain in full force and effect, the terms of which are hereby incorporated by reference, as amended and/or clarified by this Agreement,
including in particular by Section 3.1 (a) (as it affects paragraph 4 of the Confidentiality Agreement) and this Article 7. 
  
 7.2 Amendments and Clarifications. The Parties hereby acknowledge and agree that (a) Galen agrees to be bound by the terms and conditions of the
Confidentiality Agreement as if it were originally a party thereto; (b) the term of the Confidentiality Agreement is amended such that it shall not terminate until the later of (i) five (5) years after the termination of the business relationship
between the parties to the Confidentiality Agreement on its original terms or (ii) ten (10) years following the Term (as defined in the License Agreement); (c) the terms of this Agreement and the transactions contemplated hereunder, and any
information exchanged hereunder shall be deemed “Confidential Information” for purposes of the Confidentiality Agreement and any use or disclosure thereof shall be governed by this Agreement; (d)(i) Barr shall have the right to disclose
the Confidential Information of Galen relating to Finished Product to the extent reasonably necessary for Barr to fulfill its obligations hereunder, and (ii) Galen shall have the right to disclose Confidential Information of Barr relating to the
ANDAs or Finished Product to the extent reasonably necessary for Galen to exercise its rights under Section 11.3, including Schedule 11.3, or 12.3; in each case (x) notwithstanding the last sentence of paragraph 1 of the Confidentiality
Agreement and (y) provided that Barr or Galen, as the case may be, has obtained appropriate undertakings of confidentiality from the recipient of such Confidential Information and shall be liable for any breach by such recipient of such
undertakings; and (e) the legal department of each Party shall be permitted to retain one copy of the other Party’s Confidential Information solely for archival purposes, notwithstanding paragraph 5 of the Confidentiality Agreement. Each Party
acknowledges that any and all other information provided to it by the other Party or its representatives concerning such other Party and its 

  

 12 

 
Affiliates shall remain subject to the terms and conditions of the Confidentiality Agreement after the date hereof and the Effective Date. 
  
 7.3 Unauthorized Use. If either Party becomes aware or has knowledge
of any unauthorized use or disclosure of the other Party’s Confidential Information, it shall promptly notify the disclosing Party of such unauthorized use or disclosure. 
  
 ARTICLE 8 
 REPRESENTATIONS AND WARRANTIES 
  
 8.1
Representations of Barr for the Finished Product. Barr warrants that all such Finished Product supplied hereunder (i) will conform to the Specifications in effect at the time of manufacture and at the time the same is tendered to the common
carrier for delivery hereunder, (ii) will be manufactured, labeled and packaged in accordance with cGMPs and other Applicable Law in effect at the time of manufacture (except to the extent such non-compliance was caused by the Printed Materials or
other materials, in each case solely to the extent provided by Galen to Barr for use in the manufacture of the Finished Product), (iii) will not be altered or misbranded under Applicable Law in effect at the time of manufacture (except to the extent
such non-compliance was caused by the Printed Materials or other materials, in each case solely to the extent provided by Galen for use in the manufacture of the Finished Product) and (iv) will be free and clear of liens and encumbrances except for
liens and encumbrances created by Galen and that may be attached to such Finished Product at the time such Finished Product is provided to Galen. 
  
 8.2 Mutual Representations and Warranties. Each Party hereby represents, warrants and covenants to the other Party that: 
  
 (a) such Party is a corporation or entity duly organized,
validly existing and, to the extent such concept is recognized in non-United States jurisdictions, in good standing under the Applicable Laws of its jurisdiction of incorporation and has all requisite corporate power and authority to enter into this
Agreement and to carry out the provisions hereof; 
  
 (b) the execution and delivery of this Agreement by such Party and the performance of its obligations hereunder does not require any shareholder action or approval, and the Person executing this Agreement on behalf of such Party is duly
authorized to do so by all requisite corporate action; 
  
 (c) except for FDA approval of the AND As, no consent or approval of any Governmental Authority is required in connection with the valid execution, delivery and performance of this Agreement, except where the failure to obtain any of the
foregoing would not have a material adverse impact on the ability of such Party to meet its obligations hereunder; 
  
 (d) assuming the due authorization, execution and delivery by the other Party, this Agreement is a valid obligation binding upon such
Party and is enforceable in accordance with its terms except as enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar Applicable Laws affecting the enforcement of creditors’ rights generally or (ii)
equitable principles of general applicability; 
  

 13 

 (e) the execution, delivery and performance by it of this Agreement and its compliance
with the terms and provisions of this Agreement does not and will not conflict with, result in a breach of, constitute a default under or result in the termination, cancellation or acceleration (whether after the giving of notice or the lapse of
time or both) of any of the terms, rights, obligations or provisions of (i) any other contractual or other obligations of such Party or to which such Party’s assets are subject that relates to the Licensed Products, (ii) the provisions of its
certificate of incorporation, operating documents or bylaws, or (iii) assuming compliance with the matters set forth in subsection (c) above, any order, writ, injunction or decree of any Governmental Authority entered against it or by which it or
any of its property is bound except where such breach or conflict would not materially impact the Party’s ability to meet its obligations hereunder; 
  
 (f) it shall comply in all material respects with all Applicable Laws applicable to its performance under this Agreement; and 

 
 (g) no broker, finder or investment banker is entitled to
any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of such Party. 
  
 8.3 Disclaimer of Warranties. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS
OR WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF APPLICABLE LAW. 
  
 ARTICLE 9 
 INDEMNIFICATION AND INSURANCE 
  
 9.1 By Galen. Galen agrees to defend, indemnify and hold harmless Barr
and its Affiliates and their respective officers, directors, employees, agents and representatives (“Related Parties”) from and against any and all Damages incurred or suffered by such Persons to the extent caused by or arising out
of or in connection with (a) any breach of any representation or warranty, covenant or agreement made by Galen in this Agreement, (b) any gross negligence or willful misconduct of Galen, its Affiliates or their respective Related Parties in the
exercise of any of its rights or the performance of any of its obligations under this Agreement, or (c) subject to Sections 9.2(a) and (b), any liability or other claims, including any claim by a Third Party (a “Third Party Claim”),
relating to or arising from any activities with respect to any Licensed Product by Galen or any of its Affiliates or sublicensees, including the marketing, handling, sale or other disposition of any Licensed Product after the Effective Date.

  
 9.2 By Barr. Barr agrees to defend, indemnify and hold
harmless Galen and its Affiliates and their Related Parties from and against any and all Damages incurred or suffered by such Persons to the extent caused by or arising out of or in connection with (a) any breach of any representation or warranty,
covenant or agreement made by Barr in this Agreement, (b) any gross negligence or willful misconduct of Barr, its Affiliates or their respective Related Parties in the exercise of any of its rights or the performance of any of its obligations under
this Agreement, or (c) subject to Sections 9.1(a) and (b), any liability or other claims, including a Third Party Claim, relating to the failure of Barr (or any of its Affiliates or subcontractors and their Related Parties) 

  

 14 

 
to manufacture or have manufactured Licensed Product under this Agreement in conformity with Applicable Law, the ANDAs, the Specifications or cGMPs.

  
 9.3 Notice of Claims; Third Party Claims. 

 
 (a) Any Person to be indemnified under this Article 9
(the “Indemnified Party”) shall promptly notify in writing the Party from whom indemnification is sought (the “Indemnifying Party”) of any potentially indemnifiable claim in reasonable detail, provided that
any notice failure hereunder shall not limit the obligation of the Indemnifying Party, except to the extent the Indemnifying Party is materially prejudiced thereby. 
  
 (b) The Indemnifying Party shall conduct and control the defense of any indemnifiable claim, but may not
compromise or settle any such claim in any matter that affects the rights or obligations of the Indemnified Party without the approval of the Indemnified Party, such approval not to be unreasonably withheld. No Indemnified Party may compromise or
settle any indemnifiable claim for hereunder without the consent of the Indemnifying Party. The Indemnifying Party shall permit the Indemnified Party to participate in, but not control, the defense of any such claim through counsel of its choice, at
its own cost and expense. 
  
 (c) The Parties
shall cooperate in the defense of any indemnifiable claim and shall inform each other of its progress. The Parties shall cooperate to mitigate all Damages in connection with an indemnifiable claim. 
  
 9.4 Indemnification Payment Adjustments. The amount of any Damages for
which indemnification is provided under this Article 9 shall be net of (a) any amount actually recovered by the Indemnified Party pursuant to any indemnification by or indemnification agreement with any Person and (b) the amount of any insurance
proceeds received and any other amount recovered, if any, by the Indemnified Party with respect to any Damages. If the amount to be netted hereunder from any payment required under Article 9 is determined after payment by the Indemnifying Party of
any amount otherwise required to be paid to an Indemnified Party in accordance with the terms of this Article 9, the Indemnified Party shall repay to the Indemnifying Party, promptly after such determination, any amount that the Indemnifying Party
would not have had to pay pursuant to this Article 9 had such determination been made at the time of or prior to such payment. 
  
 9.5 Survival. If the Option is exercised, the representations and warranties of the Parties contained herein shall survive the termination of this
Agreement and shall remain in full force and effect, regardless of any investigation made by or on behalf of Galen or Barr, for a period of twenty-four (24) months after such termination; provided, that if prior to the end of such 24-month
period, a claim for indemnification with respect thereto shall have been properly made hereunder, any representations and warranties that are the subject of such claim shall survive until such claim has been finally adjudicated or settled.

  
 9.6 Insurance. Each Party will obtain and maintain,
during the term of this Agreement, at its own cost and expense, with reputable and financially sound insurance carriers, comprehensive commercial general liability insurance, including product liability insurance, to cover such Party’s
indemnification obligations hereunder, or self-insurance, in amounts 

  

 15 

 
consistent with such Party’s normal business practices. Each Party will name the other Party as an additional insured on each such insurance policy.
Each such policy or self-insurance shall be in types and amount that are reasonable and customary in the pharmaceutical industry for companies engaged in similar business and operations and amounts that meet all contractual requirements of each
Party’s vendors, distributors or other contractors, at a minimum of fifty million US Dollars (US$50,000,000) coverage. Maintenance of such insurance coverage will not relieve a Party of any responsibility under this Agreement for Damages in
excess of such insurance limits or otherwise. Each Party will provide the other Party, upon reasonable request, with a certificate from the insurer(s) evidencing such insurance coverage. 
  
 9.7 Limitation of Liabilities. EXCEPT WITH RESPECT TO A PARTY’S INDEMNIFICATION OBLIGATIONS HEREUNDER WITH
RESPECT TO THIRD PARTY CLAIMS, NEITHER PARTY WILL BE LIABLE FOR INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL (INCLUDING LOST PROFITS) OR PUNITIVE DAMAGES, HOWEVER CAUSED OR UPON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE, GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT) ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ITS PERFORMANCE HEREUNDER. 
  
 9.8 Sole and Exclusive Remedy. The Parties acknowledge and agree that the remedies provided for in this Agreement shall be the Parties’ sole
and exclusive remedy with respect to the subject matter of this Agreement, except for claims based on fraud or willful misconduct. Notwithstanding the foregoing, the Parties hereto agree that irreparable damage would occur if any provision of this
Agreement were not performed in accordance with the terms hereof and that the Parties shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement in addition to any other remedy to which they are entitled in equity.

  
 ARTICLE 10 
 TERM AND TERMINATION 
  
 10.1 Term. Unless otherwise agreed in writing by the Parties or terminated sooner as permitted hereunder, this Agreement shall become effective on
the Effective Date and shall expire contemporaneously with the License Agreement. 
  
 10.2 Termination. This Agreement may be terminated upon the written consent of both Parties. In addition, either Party shall have the right to terminate this Agreement in any of the following events:

  
 (a) Material Breach. Either Party may
terminate this Agreement by providing written notice of such termination to the other Party, if (i) the other party fails to pay any amount of money due and payable hereunder and not disputed in good faith, and fails to remedy the same after thirty
(30) days written notice or (ii) the other Party is finally adjudicated to have materially breached any provision of this Agreement, which breach materially adversely affects the other Party’s rights under this Agreement, in the aggregate, and
the breaching Party fails to remedy the same within ninety (90) days after written notice (a “Breach Notice”) (or, if applicable, such longer period (not exceeding one hundred twenty (120) days) as would be reasonably necessary for
a diligent party to cure such material breach; provided, that the breaching Party has 

  

 16 

 
commenced and continues diligent efforts to cure during the initial ninety (90) day period following receipt of the Breach Notice. 
  
 (b) Termination of License Agreement. This Agreement
shall terminate automatically without further action by either Party in the event the License Agreement is terminated. 
  
 (c) Bankruptcy. Either Party may, subject to the provisions set forth herein, terminate this Agreement immediately without further
notice to the other Party if, at any time, the other Party shall: (i) file in any court pursuant to any statute a petition for bankruptcy or insolvency, or for reorganization in bankruptcy, or for an arrangement or for the appointment of a receiver,
trustee or administrator of such Party or of its assets; (ii) be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within thirty (30) days after the filing thereof; (iii)
propose or be a party to any dissolution; or (iv) make an assignment for the benefit of its creditors. For avoidance of doubt, all rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to
be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of “intellectual property” as defined thereunder. The Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy
Code; provided, however, that should Barr become a party to a bankruptcy proceeding and such proceeding is not dismissed within thirty (30) days then, to the extent permitted by law, this Agreement and the licenses granted by Barr hereunder
shall be adopted by any bankruptcy trustee or relevant third party charged with the disposition of same, and shall not be rejected by same, it being the Parties’ intent that, in such event, Galen and its Affiliates and sublicensees shall be
entitled to retain the rights granted to them hereunder by Barr. 
  
 ARTICLE 11 
 RIGHTS AND DUTIES UPON TERMINATION 
  
 11.1 Pending Purchase Orders. The termination of this Agreement shall not affect Purchase Orders placed by Galen and
accepted by Barr at the time notice of termination is given and until the time any such termination becomes effective. 
  
 11.2 Outstanding Payment. Payments of amounts owing to either Party under this Agreement as of its expiration or termination shall be due and
payable within the later of: (i) to the extent such amounts can be calculated and a fixed sum determined at the time of expiration or termination of this Agreement, sixty (60) days after the date of such expiration or termination or (ii) ten (10)
Business Days after the date in which such amounts can be calculated and a fixed sum determined. 
  
 11.3 Termination by Galen for Material Breach by Barr. Notwithstanding anything herein or in the License Agreement to the contrary, if Galen elects
to terminate this Agreement pursuant to Section 10.2(a) due to the uncured material breach by Barr of its obligations to supply the Licensed Products under this Agreement, then Barr agrees that Galen shall have the right to manufacture or have
manufactured by any third Person, for supply to Galen or any of its designees, any Licensed Product and, in furtherance thereof, Barr shall grant to Galen a non-exclusive worldwide manufacturing license (including a right of reference to the ANDAs
to the 

  

 17 

 
extent necessary for the manufacture and supply of such Licensed Product in accordance with this Section 11.3), with the right to sublicense, relating solely
to the manufacture and supply of such Licensed Product, until the expiration of the License Agreement, and the provisions set forth on Schedule 11.3 shall apply. 
  
 11.4 Accrued Rights; Surviving Obligations. Unless explicitly provided otherwise in this Agreement, termination,
relinquishment or expiration of this Agreement for any reason shall be without prejudice to and shall not result in the waiver of any rights or remedies which shall have accrued to the benefit to any Party prior to such termination, relinquishment
or expiration, including damages arising from any breach hereunder. Such termination, relinquishment or expiration shall not relieve any Party from obligations accruing to such Party prior to such termination or which are expressly indicated to
survive termination or expiration of the Agreement, including those obligations set forth in Sections 3.6, 4.5, 5.5 and 8.3 and in Articles 6, 7, 9, 11 and 12. 
  

ARTICLE 12 
 GENERAL PROVISIONS

  
 12.1 Further Actions. Each Party agrees to execute,
acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  
 12.2 Expenses. Unless otherwise provided herein, all costs and expenses incurred in connection with this Agreement
and the transactions contemplated hereby shall be paid by the Party which shall have incurred the same and the other Party shall have no liability relating thereto. 
  
 12.3 Force Majeure; Temporary Alternative Manufacture. Neither Party shall be liable to the other Party for loss or
damages, or shall have any right to terminate this Agreement for any default or delay attributable to any Force Majeure; provided, that the affected Party gives prompt notice of any such cause to the other Party and of the period for which
such Force Majeure is expected to continue. The affected Party shall upon giving such notice be excused from its obligations hereunder to the extent of the actual time and the scope of obligations as it is disabled from performing due to the
continuance of the Force Majeure event; provided, further, that such affected Party promptly commences and continues to use its Commercially Reasonable Efforts to (a) cure such disablement and (b) mitigate its effects. If Barr is the
affected Party with respect to a Force Majeure that lasts for more than sixty (60) calendar days and during such period Barr cannot supply any Finished Product to Galen as a result of the Force Majeure, notwithstanding anything herein to the
contrary, Galen may notify Barr of its intention to manufacture or have manufactured by any third Person, for supply to Galen or any of its designees, such Finished Product and, in furtherance thereof, Barr shall grant to Galen a non-exclusive
worldwide manufacturing license (including a right of reference to the ANDAs to the extent necessary for the manufacture of such Finished Product in accordance with this Section 12.3), with the right to sublicense, relating solely to the manufacture
of such Finished Product, until the day that is six months after Barr has given Galen written notice that it is ready and able to resume the performance of its obligations under this Agreement. 
  

 18 

 12.4 Notices. Notices to Barr shall be addressed to: 
  
 Barr Laboratories, Inc. 
 400 Chestnut Ridge Road 
 Woodcliff Lake, NJ
07677-7668, USA 
 Facsimile: (201) 930-3335 
 Attention: President 
  
 with a
copy to: 
  
 Barr Laboratories, Inc. 
 400 Chestnut Ridge Road 
 Woodcliff Lake, New
Jersey 07677 
 Facsimile: (201) 930-3335 
 Attn: General Counsel 
  
 Notices to Galen shall be
addressed to: 
  
 Galen (Chemicals) Limited 
 4 Adelaide Street 
 Dun Laoghaire, Co. Dublin,
Ireland 
 Attention: Senior Vice President, Finance 
 Facsimile No.: 011 353 1 214 8474 
  
 with a copy to: 
  
 Galen Holdings PLC 
 c/o Warner Chilcott, Inc. 
 100 Enterprise
Drive 
 Rockaway, NJ 07866 
 Attention: Executive Vice President, 
 Corporate Development and General Counsel 
 Facsimile No.: (973) 442-3316 
  
 Either Party may change the address to which notices shall be sent by giving notice to the other Party in the manner herein provided. Such notices will be deemed to have
been given on the date delivered in the case of hand delivery or delivery by overnight courier, on the date set forth in the confirmation sheet in the case of facsimile delivery, and on the fifth (5th) Business Day following the date of post mark in the case of delivery by mail. 
  
 12.5 Assignment. Neither Party hereto may assign any of its rights or obligations under this Agreement without the
prior written consent of the other Party; except to an Affiliate, or in connection with a merger, reorganization, change of control or sale of all or substantially all of the applicable business. Any purported assignment in violation of the
foregoing shall be null and void ab initio and of no force or effect. No assignment of this Agreement will relieve the assigning Party from any of its obligations hereunder. In the event of a permitted assignment, 

  

 19 

 
this Agreement shall be binding upon and inure solely to the benefit of the Parties and their respective successors and permitted assigns. 
  
 12.6 Amendment. No amendment, modification or supplement of any
provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
  
 12.7 Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an
instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The failure of either Party to assert its rights under this Agreement or otherwise shall not constitute a waiver of such rights.

  
 12.8 Governing Law. This Agreement and any dispute
arising out of or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. With respect to any claim, action, arbitration, suit, investigation or proceeding (“Proceeding”)
relating to this Agreement, each Party irrevocably agrees and consents to the exclusive jurisdiction of the federal and state courts in Manhattan, New York and waives any objection to venue of any such proceeding brought in any such court.
EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, ANY RIGHT TO A TRIAL BY JURY IN RESPECT TO ANY
SUCH PROCEEDING. 
  
 12.9
Escalation. Before either Party shall be entitled to file a lawsuit in connection with disputes under this Agreement, either Party may, by written notice to the other Party, require the Parties to submit any such disputed matter to the Chief
Executive Officers of the Parties, who shall meet and use good faith efforts to negotiate a resolution within thirty (30) days of receipt of such notice. In the event that the Chief Executive Officers are unable to resolve such dispute within such
30-day period, either Party shall be entitled to seek all legal recourse available to it in connection therewith. The Chief Executive Officers shall issue their resolution in writing. 
  
 12.10 Severability. If any provision hereof should be held invalid, illegal or unenforceable in any respect in any
jurisdiction, the Parties hereto shall negotiate in good faith for a substitute provision for such invalid, illegal or unenforceable provisions which valid provision shall continue the intent and purpose of such invalid provisions, and the validity,
legality and enforceability of the remaining provisions shall not in any way be impaired thereby. 
  
 12.11 Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing
or interpreting any of the provisions of this Agreement. 
  
 12.12
Certain Conventions. As used in this Agreement, the masculine shall include the feminine and neuter, and the singular shall include the plural and the plural shall include the singular, in each case as the context may require. The word
“including” shall be deemed followed by “without limitation”, “but not limited to” or words of similar meaning. Any reference to an Article, Section, subsection or clause is a reference to an Article, Section,
subsection or clause of this Agreement unless otherwise expressly indicated. 
  

 20 

 12.13 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly
construed against either Party. 
  
 12.14 Entire Agreement of
the Parties. This Agreement, together with the Schedules and Exhibits hereto and thereto, constitute and contain the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior
negotiations, correspondence, understandings and agreements whether oral or written, between the Parties respecting the subject matter hereof and thereof; except for the Confidentiality Agreement which shall remain in full force and effect as
modified hereunder, and the terms of which are incorporated by reference. 
  
 12.15 Independent Contractors. The relationship between the Parties created by this Agreement is one of independent contractors and neither Party shall have the power or authority to bind or obligate the other
except as expressly set forth in this Agreement. 
  
 12.16 No
Third Party Beneficiaries. No Person other than the Parties hereto and their respective Affiliates, successors and permitted assigns shall be deemed an intended beneficiary hereunder or have any legal or equitable rights or benefits to enforce
any provision of this Agreement. 
  
 12.17 Counterparts;
Facsimile Signatures. This Agreement may be executed in counterparts and such counterparts taken together shall constitute one and the same agreement. This Agreement may be executed by facsimile signatures, which signatures shall have the same
force and effect as original signatures. 
  

 21 

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this Agreement as
of the date set forth above. 
  

			
	BARR LABORATORIES, INC.
		
	 By:
	 	 /s/ Paul M. Bisaro

	 Name:
	 	 Paul M. Bisaro

	 Title:
	 	 President & COO

	
	GALEN (CHEMICAL) LIMITED
		
	 By:
	 	 /s/ Illegible

	 Name:
	 	 
	 Title:
	 	 

  
 SIGNATURE PAGE TO FINISHED PRODUCT SUPPLY AGREEMENT 
  

 Schedule 1.10 
  
 Certificate of Analysis 
  
 See attached. 
  

 

 
  
 

 
  

			
	 Product: [Product Name]
	 	 
		
	Batch Number:	 	 
	 	 	 Expiration Date: N/A

	 	 	 Page 1 of 4

	Product Description:	 	 
	 Each package contains XXX tablets each containing
	 	 
	 XXX (code XXX), and XXX placebo tablets.
	 	 
		
	 __________________________________________________
 [name of product]
	 	 
		
	 [batch No.]
	 	 
		
	 Description:
	 	 
		
	 XXX tablet
	 	 
		
	 Identification:
	 	 
	 A (HPLC):
	 	 
	 Sample retention times match
	 	 
	 standard retention times
	 	 
		
	 B (Melting Point):
	 	 
	 Not less than XXX°C
	 	 
		
	 CONTENT UNIFORMITY
	 	–
	 [component 1]:
	 	x=
	 Meets USP <905> requirements
	 	RSD:
	 	 	Range:
		
	 [component 2]:
	 	–
	 Meets USP <905> requirements
	 	x=
	 	 	RSD:
	 	 	Range:

  

									
					
	 Signed:
	 	  	 	 	 	 Date:
	 	  
	 	 	Barr Laboratories, Inc.	 	 	 	 	 	 

  
 BARR LABORATORIES • 2 Quaker
Road, PO Box 2900, Pomona, NY 10970 • Telephone (845) 362-1100 
  

 

 
  
 

 
  

			
	 Product: [Product Name]
	 	 
		
	Batch Number:	 	 
	 	 	 Page 2 of 4

		
	 __________________________________________________
 DISSOLUTION (single point):
	 	–  
	-[component 1]:	 	x=
	 	 	Min:
	 	 	Max:
		
	-[component 2]:	 	–  
	 	 	x=
	 	 	Min:
	 	 	Max:
		
	ASSAY:	 	 
	 -[component 1]:
	 	 
	 XXX% of label claim.
	 	 
		
	 -[component 2]:
	 	 
	 XXX% of label claim.
	 	 
		
	IMPURITIES/DEGRADATION	 	 
	PRODUCTS:	 	 
		
	 XXX
	 	 
		
	 Total (Specified and
	 	 
	 Unspecified):
	 	 
	 NMT 4.0%
	 	 
		
	 WATER(KF):
	 	 
	 NMT 4.0%
	 	 

  

									
					
	 Signed:
	 	  	 	 	 	 Date:
	 	  
	 	 	Barr Laboratories, Inc.	 	 	 	 	 	 

  
 BARR LABORATORIES • 2 Quaker
Road, PO Box 2900, Pomona, NY 10970 • Telephone (845) 362-1100 
  

 

 
  
 

 
  

			
	 Product: [Product Name]
	 	 
		
	Batch Number:	 	 
	 	 	 Page 3 of 4

		
	 __________________________________________________
  
 Placebo
	 	 
		
	Description:	 	 
	 XXX tablet.
	 	 
	 Debossed with “XXX” on one side and “XXX”
	 	 
	 on the other side
	 	 Conforms

		
	Identification:	 	 
	 Absence of Spl. peaks corresponding to retention
	 	 
	 Times of Std.
	 	 
		
	Disintegration:	 	 
	 Time XXX minutes. Meets USP <701>
	 	 
	 Requirements
	 	 

  
 Released for XXXXXX Use

  

									
					
	 Signed:
	 	  	 	 	 	 Date:
	 	  
	 	 	Barr Laboratories, Inc.	 	 	 	 	 	 

  
 BARR LABORATORIES • 2 Quaker
Road, PO Box 2900, Pomona, NY 10970 • Telephone (845) 362-1100 
  

 Schedule 1.20 
  
 Sample Calculation of Fully Loaded Manufacturing Cost 
  
 FULLY LOADED MANUFACTURING COST - ESTIMATE 
  

				
	 	  	 Cost /
 Carton (6)

	 (a) COST OF GOODS SOLD
	  	 	 
	 Manufacturing Costs
	  	 	 
	 Materials
	  	$	2.25
	 Direct Labor
	  	 	0.25
	 Allocable Overhead
	  	 	1.81
	 Other 3rd party Costs
	  	 	—  
		
	 Sub - Total Manufacturing Costs
	  	$	4.31
		
	 Packaging Costs
	  	 	 
	 Materials
	  	$	0.29
	 Direct Labor
	  	 	0.86
	 Allocable Overhead
	  	 	2.15
	 Other 3rd party Costs
	  	 	—  
		
	 Sub - Total Packaging Costs
	  	$	3.30
	 	  	
	

		
	 TOTAL COST OF GOODS
	  	$	7.61
	 	  	
	

		
	 (b) ALLOWABLE 3rd PARTY COSTS
	  	 	 
	 IP Acquisition costs
	  	$	—  
	 Royalties to 3rd Parties
	  	 	—  
	 	  	
	

		
	 TOTAL 3rd PARTY COSTS
	  	$	—  
	 	  	
	

		
	 (c) ALL OTHER ALLOWABLE COSTS
	  	 	 
	 Packaging (reflected above)
	  	$	—  
	 Warehousing, containers, insurance, etc.
	  	 	0.27
	 	  	
	

		
	 TOTAL ALL OTHER COSTS
	  	$	0.27
	 	  	
	

		
	 TOTAL COST PER CARTON OF 6
	  	$	7.882
	 	  	
	

	 TOTAL COST PER 1
	  	$	1.314
	 	  	
	

	 TOTAL COST PER TABLET
	  	$	0.047
	 	  	
	

  

 Schedule 1.28  
  
 Specifications 
  
 The Parties acknowledge and agree that specifications for a Licensed Product cannot be determined until such time as the related ANDA becomes an Approved ANDA. As such,
within five (5) business days following Galen’s exercise of the Option under the License Agreement, Barr shall prepare and deliver to Galen, and the Parties shall append as additional pages to this Schedule 1.28, specifications for each
Licensed Product covered by and in accordance with each Approved ANDA. Where both ANDAs have not become Approved ANDAs at the time Galen exercises the Option, Barr shall prepare and deliver to Galen, and the Parties shall append as additional pages
to this Schedule 1.28, specifications for each Licensed Product covered by and in accordance with the second Approved ANDA, such delivery to occur within five (5) business days following the later of (i) the approval of such ANDA and (ii)
Galen’s exercise of the Option. 
  

 Schedule 11.3 
  
 Technology Transfer 
  
 In the event Galen obtains a license pursuant to Section 11.3 to manufacture and supply Licensed Product (the “Manufacturing License”), the following
provisions shall apply in addition to those set forth in Article 4 of the License Agreement: 
  
 1. Transfer of Know-How. 
  
 (a) Provision of Materials. Barr shall provide to Galen (i) on the effective date of the Manufacturing License, one (1) copy (in electronic format to the extent available) of (i) each physical embodiment of any Know-How (as defined
in the License Agreement) of Barr to the extent relating to and necessary for the manufacture and supply of the Licensed Products (the “Manufacturing Know-How”), each to the extent in Barr’s or any of its Affiliates’,
sublicensees’ or subcontractors’ possession or control, and (ii) the ANDAs. 
  
 (b) Access to Personnel. Barr shall permit reasonable access to its personnel during normal business hours having relevant knowledge of, or experience with, such materials by Galen’s technically skilled
personnel in order to permit Galen to become reasonably familiar with the Manufacturing Know-How being transferred. Barr shall provide the first one hundred twenty (120) employee hours devoted to such access without cost to Galen. Galen shall
reimburse Barr for additional, pre-approved employee hours devoted to such access at a rate of $200 per hour. 
  
 2. Inspection of Galen Facilities. Galen shall permit Barr or its representatives to inspect, review and audit: (i) those portions of each facility at which any Processing Activities are performed by Galen (or
its Affiliates, sublicensees or subcontractors) and (ii) any of Galen’s manufacturing and quality control records and other documentation relating to the Processing Activities (including any internal quality control audits or reviews conducted
by Galen and including the opportunity to meet with Galen personnel). Such inspections, reviews and audits shall be for the purpose of ascertaining compliance with Galen’s obligations under this Agreement and with the ANDAs and cGMPs, and
reviewing correspondence, reports, filings and other documents from or to Governmental Authorities to the extent related to the Processing Activities. Any information obtained by Barr through such inspections, reviews and audits shall be treated as
confidential information of Galen. Such audits, reviews and inspections shall be conducted at Barr’s expense during normal business hours, upon reasonable notice, and no more than twice per year, and in a manner that does not unreasonably
interfere with ongoing operations. Barr’s exercise of its inspection rights hereunder shall not discharge any obligation of Galen under this Agreement, other than its obligation to permit inspection and audit under this Section 2. 

 

 3. Regulatory Matters. 
  

(a) Barr shall, or shall cause its relevant Affiliate to, prepare (in consultation with Galen) and file, at Galen’s sole cost and expense, such
supplemental regulatory filings or amendments (“Galen Supplemental Registrations”), in the form required by Applicable Law, to the ANDAs and drug master files pertaining to the Licensed Products as is necessary for Galen to
manufacture or have manufactured such Licensed Products at the designated facility as permitted by the licenses granted hereunder. Galen will provide Barr or its relevant Affiliate with all information and data needed to make such filings. Galen
shall not commence the manufacture of any such Licensed Product until all necessary Galen Supplemental Registrations approvals therefor have been obtained from the applicable Governmental Authorities. Barr shall provide a signed statement to this
effect, if requested by Galen, in the form required by Applicable Law. In addition, Barr shall from time to time, at Galen’s sole cost and expenses, file such other supplements or amendments to the ANDAs, as provided by Galen in the form
required by Applicable Law, to effect any of the following modifications and alterations of the ANDAs in respect of the License Products: (i) change in the manufacturing process, formulation or testing standard relating to such Licensed Product or
(ii) change in the packaging of any Licensed Product. Galen shall not implement any such modification or alteration to any Licensed Product set forth in a Galen Supplemental Registration until all necessary Galen Supplemental Registrations approvals
have been obtained from the applicable Governmental Authorities. 
  
 (b) In the event Barr materially breaches any of the provisions of this Section 3, notwithstanding anything herein to the contrary, in addition to any other rights and remedies to which Galen may be entitled, Galen may elect not to
terminate this Agreement pursuant to Section 10.2(a), and instead to require Barr to appoint Galen as its exclusive agent with respect to all approvals and filings in the Territory in connection with the Licensed Products, and, accordingly, to
promptly take all steps necessary to effect the foregoing appointment, including writing a letter to the appropriate Governmental Authorities in the Territory. In such event, as Barr’s agent, Galen shall, except as prohibited by Applicable Law,
be the lead regulatory party in the Territory, and the rights and obligations of each Party under this Section 3 shall become the rights and obligations of the other Party, as appropriate; provided, that Barr shall retain the final
decision-making authority in every matter in connection with the ANDAs pursuant to Sections 4.1(b)(iii) and 4.1(c) of the License Agreement. 
  
 (c) Barr shall not be liable to Galen for losses incurred by Galen as a direct or indirect result of Galen’s failure to provide information under
this Section 3.Business Purchase Agreement dated April 28, 2005

 Exhibit 10.22 
  
 DATED THE 28th DAY OF APRIL, 2004 
  
 IVEX PHARMACEUTICALS LIMITED (1) 
  
 GALEN HOLDINGS, plc (2) 
  
 GAMBRO NORTHERN IRELAND LIMITED (3) 
  
 GAMBRO BCT, INC (4) 
  

  
 BUSINESS PURCHASE AGREEMENT 
 FOR THE SALE AND PURCHASE OF THE BUSINESS AND ASSETS OF 
 IVEX PHARMACEUTICALS LIMITED 
  

  
 MILLS SELIG 
  
 SOLICITORS 
  
 21 ARTHUR STREET 
  
 BELFAST 
  
 BT1 4GA 
  
 TEL 02890 243878 
  
 FAX 02890 231956 
  
 REF RF/MT 

  
 CONTENTS 
  

					
	 CLAUSE

	  	PAGE

	 1.
	  	INTERPRETATION	  	4
	 2.
	  	SALE AND PURCHASE	  	11
	 3.
	  	CONSIDERATION	  	12
	 4.
	  	COMPLETION	  	12
	 5.
	  	SELLER’S OBLIGATIONS PRIOR TO COMPLETION	  	14
	 6.
	  	RISK	  	15
	 7.
	  	POST COMPLETION	  	15
	 8.
	  	STOCK	  	16
	 9.
	  	RECEIVABLES	  	18
	 10.
	  	CONTRACTS, IVEX MARKETING AUTHORISATIONS AND IVEX MANUFACTURING LICENCES	  	19
	 11.
	  	PREPAYMENTS BY SELLER AND CUSTOMERS	  	21
	 12.
	  	EMPLOYEES	  	23
	 13.
	  	SELLER’S OBLIGATIONS AFTER COMPLETION	  	27
	 14.
	  	VALUE ADDED TAX	  	29
	 15.
	  	WARRANTIES	  	30
	 16.
	  	PROTECTION OF GOODWILL	  	35
	 17.
	  	ANNOUNCEMENTS, ETC.	  	37
	 18.
	  	ASSIGNMENT	  	37
	 19.
	  	COSTS	  	38
	 20.
	  	BUYER’S GUARANTEE	  	38
	 21.
	  	SELLER’S GUARANTEE	  	38
	 22.
	  	ENTIRE AGREEMENT	  	38
	 23.
	  	WAIVER, AMENDMENT	  	39
	 24.
	  	FURTHER ASSURANCE	  	39
	 25.
	  	NOTICES	  	40
	 26.
	  	COUNTERPARTS	  	41
	 27.
	  	GOVERNING LAW AND JURISDICTION	  	41
	 28.
	  	INVALIDITY	  	42
	 29.
	  	THIRD PARTY RIGHTS	  	43

  

			
	 SCHEDULE 1
	  	44
	 Allocation of Consideration
	  	44
	 SCHEDULE 2
	  	45
	 Warranties
	  	45
	 SCHEDULE 3
	  	68
	 Loose Plant
	  	68
	 SCHEDULE 4
	  	79
	 Contracts
	  	79
	 SCHEDULE 5
	  	81
	 Assumed Employees
	  	81

  

 2 

			
	 SCHEDULE 6
	  	84
	 The Buyer’s Guarantee
	  	84
	 SCHEDULE 7
	  	86
	 The Seller’s Guarantee
	  	86
	 SCHEDULE 8
	  	88
	 Data Room Index
	  	88
	 SCHEDULE 9
	  	95
	 Business Intellectual Property and IP Licence
	  	95

  

 3 

 THIS AGREEMENT is made on 28 April 2004 
  
 BETWEEN: 
  

	(1)	IVEX PHARMACEUTICALS LIMITED (No. NI16093) whose registered office is at Old Belfast Road, Millbrook, Larne BT40 2SH (the “Seller”); 

  

	(2)	GALEN HOLDINGS, PLC (No.25836) whose registered office is at Old Belfast Road, Millbrook, Larne BT40 2SH (the “Seller’s Guarantor”); 

  

	(3)	GAMBRO NORTHERN IRELAND LIMITED (No.49717) whose registered office currently is at Arnott House, 12-16 Bridge Street, Belfast BT1 1LS but by the Completion Date will be Old Belfast
Road, Millbrook, Larne BT40 2SH (the “Buyer”); and 

  

	(4)	GAMBRO BCT INCORPORATED, a company incorporated in the State of Colorado, USA, whose registered office is at 10811 West Collins Avenue, Lakewood, Colorado 80215, USA (the
“Buyer’s Guarantor”). 

  
 RECITALS 

 

	(A)	The Seller carries on the Business (as hereinafter defined) and is the beneficial owner, or is otherwise able to procure the transfer, of the Assets (as hereinafter defined).

  

	(B)	The Seller has agreed to sell, and the Buyer has agreed to purchase, the Business as a going concern and the Assets on the terms hereinafter set out. 

  

	(C)	The Buyer’s Guarantor and the Seller’s Guarantor have agreed to guarantee the due performance by the Buyer and Seller respectively of their obligations hereunder.

  
 THE PARTIES AGREE AS FOLLOWS:

  

	1.	INTERPRETATION 

  

	1.1	The following words and expressions shall, unless the context otherwise requires, have the following meanings: 

  
 “Accounts” means the audited financial statements (comprising a
balance sheet, profit and loss account, cash flow statement, notes and directors’ report and auditors’ report) of the Seller for the financial period ended on the Accounts Date in the Agreed Form; 
  
 “Accounts Date” means 30 September 2003; 
  
 “Agreed Form” means, in relation to a document, in the form agreed
between the parties on or prior to the date hereof and for the purposes of identification signed on their behalf; 
  

 4 

 “Assets” means all assets, property or rights of the Seller relating to or connected with or
belonging to or used in the Business which shall include the Goodwill, Books and Records, Contracts, Business Intellectual Property, Loose Plant, and Stock, together with the assets and rights and the benefit of any claims relating to the Business
other than the Excluded Assets; 
  
 “Assumed Employees”
means only those employees engaged in the Business as at Completion and whose names are listed in Schedule 5 of this Agreement; 
  
 “Books and Records” means the lists of customers and suppliers, books of account, financial records, and all other records (including, for the
avoidance of doubt, VAT records) relating to the Business on whatever medium they are stored, other than any books and records contained within the Excluded Assets; 
  
 “Business” means the manufacturing, storage and supply of sterile fluid solution products for Ivex own branded
products and the contract manufacturing, storage and supply of sterile fluid solution products for third parties as conducted by the Seller during the three year period preceding the Completion Date; 
  
 “Business Day” means any day upon which banks in Belfast are open
for business; 
  
 “Business Information” means all
information, know-how and techniques (whether or not confidential and in whatever form held) which in any way relates to: (i) all or any part of the Business and Assets; (ii) any products manufactured and/or sold or services rendered by the
Business; (iii) any formulae, designs, specifications, drawings, data, manuals or instructions used by the Business; (iv) the operations, management, administration, or financial affairs of the Business (including, if any, business plans or
forecasts, information relating to future business development or planning information relating to litigation or legal advice); and (v) the sale or marketing of any of the products manufactured and/or sold or services rendered by the Business,
including, but without limiting the generality of the foregoing words, all customer names and lists, sales and marketing information (including but not limited to targets, sales and market share statistics, market surveys and reports on research);

  
 “Business Intellectual Property” means the
Intellectual Property owned by or licensed to the Seller or any member of the Seller’s Group and used wholly and exclusively in the Business, consisting of the Intellectual Property disclosed in the Data Room, together with the goodwill
relating thereto; 
  
 “Buyer’s Accountants” means
Pricewaterhouse Coopers of Waterfront Plaza, 8 Laganbank Road, Belfast BT1 3LR; 
  

 5 

 “Buyer’s Guarantee” means the guarantee in the form set out in Schedule 7 to be given by
the Buyer’s Guarantor pursuant to Clause 20; 
  
 “Buyer’s Group” means the Buyer, its holding companies and their respective subsidiaries, as well as the associated companies from time to time of such holding companies, all of them and each of them as the context admits;

  
 “Buyer’s Solicitors” means L’Estrange
& Brett of Arnott House 12-16 Bridge Street Belfast BT1 1LS; 
  
 “Consideration” means the sum to be paid for the Assets other than Stock by the Buyer to the Seller on Completion in accordance with Clause 3; 
  
 “Completion” means the completion of the sale and purchase of the Business and Assets in accordance with Clause 4;

  
 “Completion Date” means 10 May 2004 as of 12:01 AM
(Northern Ireland); 
  
 “Contracts” means all contracts
and arrangements relating to the Business entered into by the Seller prior to Completion but which are wholly or partly unperformed at Completion, including those set out in the list in the Agreed Form headed “Contracts” at Schedule 4 to
this Agreement but excluding those contracts which are Excluded Assets; 
  
 “Damaged Goods” means Stock that is past or within six months of its expiration date or Stock which does not conform to any relevant specification as determined in accordance with Clause 8.1 of this
Agreement; 
  
 “Data Room” means the data disclosed by
the Seller to the Buyer before the date of this Agreement set out in the index attached at Schedule 11; 
  
 “Disclosure Letter” means the letter of even date with this Agreement, together with the attachments thereto, addressed by the Seller to the
Buyer disclosing exceptions to the Warranties; 
  
 “Encumbrance” means any mortgage, charge, pledge, lien, security or other third party right or interest (legal or equitable) or restriction over or in respect of the use of the relevant Asset, security or right including any
obligation to create the same; 
  
 “Excluded Assets”
means any assets or rights and the benefit of any claims consisting of or comprised in the following: 
  

	 	(a)	cash in hand and at bank; 

  

 6 

	 	(b)	the equipment provided by Fresenius Kabi Limited to the Seller pursuant to the contract between Fresenius Kabi Limited and the Seller dated 1st April 2000; 

  

	 	(c)	Receivables; 

  

	 	(d)	All items or assets of whatever nature owned by the Seller other than those set out in Schedule 3; 

  

	 	(e)	All production and quality related records including without limitation batch manufacturing records, laboratory records, equipment calibrations, equipment qualifications, process
validations, method validations, standard operating procedures (SOPs), certificates of analysis (COAs) and audit reports in the possession of any member of Seller’s Group that relate to the Business; 

  
 “Goodwill” means the goodwill, custom and connection relating to
the Business as at Completion together with the exclusive right for the Buyer and its successors and assigns to represent itself as carrying on the Business in succession to the Seller and together with the trade name “Ivex” or “Ivex
Pharmaceuticals” associated with the Business; 
  
 “GRL” means Galen Research Laboratories Limited (No NI10870) whose registered office is at Old Belfast Road, Millbrook, Larne BT40 2SK; 
  
 “holding company” has the meaning given to it in Article 4 of the Companies (Northern Ireland) Order 1986 (as amended); 
  
 “Intellectual Property” means patents, know-how, registered and
unregistered trade marks and service marks (including any trade, brand or business names domain names, registered designs, design rights, utility models, copyright (including all such rights in computer software as disclosed in the Data Room, the
Business Information and any databases), moral rights and topography rights (in each case for the full period thereof and all extensions and renewals thereof), applications for any of the foregoing and the right to apply for any of the foregoing in
any part of the world and any similar rights situated in any country; 
  
 “Interim Period” means the period of up to 12 weeks (or such longer period as the parties may agree) commencing on the date of Completion; 
  

“IP Licences” means any licences, authorisations and permissions in any form whatsoever whether express or implied, pertaining to the use,
enjoyment and 

  

 7 

 
exploitation by (i) the Seller or any member of the Seller’s Group of any Intellectual Property or information in connection with the Business as
carried on at Completion, and (ii) any third party of any Business Intellectual Property or information relating to the Business, including those specified in Schedule 12; 
  
 “Ivex Manufacturing Licences” means the facility approvals granted by the Medicines and Healthcare Products
Regulatory Agency (“MHRA”), or its predecessor the Medicines Control Agency to the Seller in connection with the Business, current copies of which have been disclosed in the Data Room; 
  
 “Ivex Marketing Authorisations” means the product marketing
authorisations granted to the Seller and GRL from the MHRA or its predecessor the Medicines Control Agency, the Irish Medicines Board (“IMB”) and Veterinary Medicines Directorate in connection with the Business, current copies of which
have been disclosed in the Data Room; 
  
 “Lease” means
a lease in the Agreed Form having an effective date as of the Completion Date between the Seller and the Buyer in relation to the Buyer’s use of the Property; 
  
 “Liabilities” means all liabilities of the Business at Completion; 
  
 “London Stock Exchange” means London Stock Exchange plc;

  
 “Loose Plant” means the tangible assets of the
Business, including Stability Units, movable plant, machinery, equipment, desk top computers, spare parts, tooling, vehicles and furniture used or intended for use in the Business, being those items listed in Schedule 3 of this Agreement;

  
 “Management Accounts” means the unaudited
management accounts of the Business and the Seller for the period from 1 October 2003 to 31 March 2004 comprising a balance sheet and profit and loss account for that period, copies of which are annexed to the Disclosure Letter; 
  
 “New Licences” means the licences and authorisations to be granted
to Buyer for the Business by the MHRA and others; 
  
 “Pre-emption Agreement” means the pre-emption agreement in the Agreed Form having an effective date as of the Completion Date between the Seller and the Buyer in relation to the Property; 
  
 “Property” means that part of the property at Old Belfast Road,
Millbrook, Larne, County Antrim, Northern Ireland more fully described in the Lease; 
  

 8 

 “Receivables” means all those amounts which are accrued, due and owing to the Seller directly
and exclusively in connection with the Business as at Completion; 
  
 “Regulations” means the Transfer of Undertakings (Protection of Employment) Regulations 1981; 
  
 “Related Persons” means, in relation to any party, its holding companies and the subsidiary undertakings and associated companies from time to
time of such holding companies, all of them and each of them as the context admits; 
  
 “Restricted Period” means the five (5) year period from and after the Completion Date; 
  
 “Restricted Territory” means the United Kingdom and the Republic of Ireland; 
  
 “Retained Employees” means any employee, consultant or agent of any member of Seller’s Group who are not
listed in Schedule 5; 
  
 “Seller’s Accountants”
means PricewaterhouseCoopers, Waterfront Plaza, 8 Laganbank Road, Belfast BT1 3LR; 
  
 “Seller’s Guarantee” means the guarantee set out in schedule 8 to be given by the Seller’s Guarantor pursuant to Clause 21; 
  
 “Seller’s Group” means the Seller, its holding company and their respective subsidiaries as well as the
associated companies from time to time of such holding companies, all of them and each of them as the context admits; 
  
 “Seller’s Solicitors” means Mills Selig of 21 Arthur Street Belfast BT1 4GA; 
  
 “Services Agreement” means the agreement for services in the Agreed Form having an effective date as of the
Completion Date between the Seller’s Guarantor, Rouvex Limited, the Buyer and the Buyer’s Guarantor in relation to the Property and the Business; 
  
 “Stability Units” means the stability rooms 2 and 3 located within the Property; 
  
 “Stock” means the raw materials, packing materials, work in progress and finished goods acquired or produced in
the course of the Business at the Property and held by the Seller at Completion, but excluding any Damaged Goods; 
  
 “Stock Valuation” means a statement of the value of the Stock as determined by a full inventory of the Stock following a physical stock-take
carried out at the Property with representatives of both the Seller and the Buyer present; 
  

 9 

 “Subsidiary” has the meaning given to it in Article 4 of The Companies Order 1986 (as amended);

  
 “Taxation” means any tax and any duty, impost, levy
or governmental charge in the nature of tax whether domestic or foreign and any fine, penalty or interest connected therewith (a) including (without prejudice to the generality of the foregoing) corporation tax, income tax, national insurance and
social security contributions, capital gains tax, inheritance tax, capital transfer tax, value added tax, customs, excise and import duties, any deferred taxation and any other payment whatsoever which the Seller is or may be or become bound to make
to any person as a result of any enactment relating to any of the foregoing (b) but excluding any stamp duty or stamp duty reserve tax payable on this Agreement or any instrument executed pursuant to this Agreement or on any agreement relating to
the Business; 
  
 “Transaction Documents” means this
Agreement as well as the Lease, the Services Agreement, the Pre-emption Agreement, the Buyer’s Guarantee, the Seller’s Guarantee and any other documents referred to in this Agreement pertaining to the sale and purchase of the Business and
the Assets. 
  
 “UK Listing Authority” means the
Financial Services Authority in its capacity as the competent authority for the purposes of Part VI of the Financial Services and Markets Act 2000; 
  
 “VAT” means Value Added Tax or any similar tax from time to time replacing it or performing a similar fiscal function; and 
  
 “Warranties” means the warranties given pursuant to Clause 15 and
Schedule 2. 
  

	1.2	References to the parties hereto include, and in the case of individuals, their respective successors in title, personal representatives, heirs and estates; and references to the
masculine gender shall include the feminine and vice versa. 

  

	1.3	References to statutes or statutory provisions include references to any orders or regulations made thereunder and references to any statute, provision, order or regulation include
references to that statute, provision, order or regulation as re-enacted from time to time before the date hereof (subject as otherwise expressly provided herein) and to any previous statute, statutory provision, order or regulation amended,
modified, re-enacted or replaced by such statute, provision, order or regulation before the date hereof. 

  

	1.4	References to persons shall include bodies corporate and unincorporated, associations, partnerships and individuals. 

  

 10 

	1.5	Headings to Clauses and paragraphs are for information only and shall not form part of the operative provisions of this Agreement and shall be ignored in construing the same.

  

	1.6	References to recitals, Clauses or Schedules are to recitals to, Clauses of and Schedules to this Agreement. 

  

	1.7	The recitals, the Schedules and documents in any Agreed Form comprise part of the operative provisions of this Agreement and references to this Agreement shall, unless otherwise
expressly stated, include references to the recitals, the Schedules and documents in the Agreed Forms. 

  

	1.8	Any undertaking by a party not to do an act or thing shall be deemed to include an undertaking not to permit or suffer such act or thing to be done by another person for the benefit
of the party. 

  

	1.9	References to “include” and “including” shall be deemed to be followed by the phrase “without limitation”. 

  

	1.10	References to the Ivex Manufacturing Licences and the Ivex Marketing Authorisations being granted or transferred to the Buyer shall be interpreted to include the cancellation of
such licences and the issuance of new licences in the name of the Buyer corresponding to the Ivex Manufacturing Licences and the Ivex Marketing Authorisations, as applicable. 

  

	1.11	References to “disclosed” shall be interpreted as meaning fairly and accurately disclosed to the Buyer expressly for the purposes of this Agreement in the Data Room and/or
the Disclosure Letter; and for the purposes of this definition, the expression “fairly and accurately” means that a matter shall be disclosed only if it has been disclosed with reference to a particular warranty identified by its number in
Schedule 2. 

  

	2.	SALE AND PURCHASE 

  

	2.1	Upon the terms and subject to the conditions of this Agreement, the Seller shall sell as beneficial owner and shall transfer or procure the sale and transfer of the Assets and the
Business as a going concern to the Buyer, with effect from Completion, free from any Encumbrances, together with all accrued benefits and rights attaching thereto; and all property rights and risk in those Assets shall vest in the Buyer from
Completion. 

  

	2.2	The Excluded Assets are not included in the sale and purchase pursuant to Clause 2.1. 

  

 11 

	2.3	The Consideration for such sale and purchase shall be as specified in Clause 3. 

  

	2.4	The Property shall be leased by the Seller to the Buyer subject to the terms set out in the Lease. 

  

	3.	CONSIDERATION 

  

	3.1	The Consideration shall be the sum of two million five hundred and seventy five thousand pounds (£2,575,000) payable in cash by telegraphic transfer on Completion, which shall
be apportioned among the Assets as set out in Schedule 1. 

  

	3.2	Further payment shall be made by the Buyer to the Seller for the Stock which shall be determined in accordance with the provisions contained in Clause 8 and when so determined shall
be paid to the Seller in accordance with the provisions of Clause 8.8. 

  

	3.3	Nothing in this Agreement shall pass to the Buyer or shall be construed as acceptance by the Buyer of any Liabilities, debt or other obligation of the Seller other than the
obligations which are expressly and specifically assumed by the Buyer under the terms of this Agreement. 

  

	4.	COMPLETION 

  

	4.1	Completion shall take place at the offices of the Seller (or at such other location as the Seller and Buyer agree) on the Completion Date. 

  

	4.2	On Completion, the Seller shall deliver or, in the case of Clauses 4.2.1 and 4.2.2, make available to the Buyer at the Property: 

  

	 	4.2.1 	the Books and Records; 

  

	 	4.2.2 	the Loose Plant and all other Assets hereby agreed to be sold, title to which can be transferred by delivery (and shall pass upon such delivery) and shall permit the Buyer to enter
into and take possession of the Assets; 

  

	 	4.2.3 	duly executed assignments or registered user agreements of the Business Intellectual Property in the Agreed Form; 

  

	 	4.2.4 	releases under seal or certificates of non-crystallisation of charge of any Encumbrances in Agreed Form to which any of the Assets are subject, duly executed by those entitled to
the benefit thereof; 

  

 12 

	 	4.2.5 	a counterpart of the Lease, the Pre-emption Agreement and the Services Agreement duly executed by the Seller; 

  

	 	4.2.6 	the Contracts and the Business Information duly written up to Completion; 

  

	 	4.2.7 	all such records (or copies if the originals have been properly retained) as are referred to in section 49 of the Value Added Tax Act 1994; 

  

	 	4.2.8 	all documents of title and certificates for the operation and use of, and all service documents within the possession of the Seller pertaining to the Loose Plant and the raw
materials included in the Stock; 

  

	 	4.2.9 	a copy of the minutes of meetings held on the 28th April 2004 of the directors of the Seller, Rouvex Limited and the Seller’s Guarantor in the Agreed Form authorising the execution by that party of this Agreement and of any other documentation that may be necessary or desirable
arising out of or in connection with this Agreement or the transactions contemplated thereby and appointing the relevant signatory or signatories to sign this Agreement and any such other documentation on its behalf; and 

  

	 	4.2.10 	a written resolution signed and dated the 9th
May 2004 by the Seller’s shareholder approving the Seller’s change of name from “Ivex”. 

  

	4.3	Upon compliance by the Seller with the provisions of Clause 4.2, the Buyer shall: 

  

	 	4.3.1 	provide for the electronic transfer of funds of the sum referred to in Clause 3.1 to the client account of the Seller’s Solicitors at Bank of Ireland 4/8 High Street Belfast
BT1 2BA client account number 95454506 sort code 90-21-27 and the receipt of the Seller’s Solicitors therefor shall be a good discharge to the Buyer; 

  

	 	4.3.2 	deliver to the Seller a counterpart of the Lease, the Pre-emption Agreement and Services Agreement duly executed by the Buyer 

  

	 	4.3.3 	deliver to the Seller a copy of the minutes of a meeting of the directors of the Buyer and the Buyer’s Guarantor in the Agreed Form authorising the execution by that party of
this Agreement and of any other documentation that may be necessary or desirable arising out of or in connection with this Agreement or the transactions contemplated thereby and appointing the relevant signatory or signatories to sign this Agreement
and any such other documentation on its behalf. 

  

 13 

	5.	SELLER’S OBLIGATIONS PRIOR TO COMPLETION 

  

	5.1	The Seller undertakes to the Buyer that pending Completion: 

  

	 	5.1.1 	the Business will continue to be carried on in the same manner as it is presently carried on as regards the nature, scope and manner of conducting it and so as to maintain it as a
going concern and will be conducted in a diligent and prudent manner in consultation with the Buyer on any material matters; 

  

	 	5.1.2 	it will use all reasonable endeavours to retain and preserve the Goodwill of and relationship with all customers and suppliers of the Business; 

  

	 	5.1.3	  it will use all reasonable endeavours to retain the full benefit of the Business Intellectual Property; 

  

	 	5.1.4 	the Seller will not knowingly do or knowingly omit or knowingly permit to be done any act or thing or permit the omission of any act or thing which is intended to or may impair or
have a material adverse effect upon the Business or any part of it or the Assets; 

  

	 	5.1.5 	no long term, onerous or unprofitable contracts will be entered into by the Business; 

  

	 	5.1.6	  the Seller will not dismiss any of the employees, except in the event of gross misconduct, and will not engage or employ any person in the Business other than the Assumed
Employees without the Buyer’s prior written consent (such consent not to be unreasonably withheld or delayed); and 

  

	 	5.1.7 	the Seller will not take any other action which is inconsistent with the provisions of this Agreement or which is, or might constitute or result in, a breach of any of the
Warranties or which would or might make any of the Warranties misleading or inaccurate. 

  

	5.2	The Seller shall immediately disclose to the Buyer in writing any matter or thing which arises or becomes known to it before Completion which is or might be a breach of, or might
reasonably be expected to cause or constitute a breach of, or is inconsistent with, or may render inaccurate or misleading, any of the Warranties or which is a breach of, or may otherwise give rise to a claim under, any other provision of this
Agreement. 

  

	5.3	 The Seller shall forthwith disclose to the Buyer in writing any matter or thing which arises or may arise or become known to it before Completion which has or is

  

 14 

	 	 
likely to have a material and adverse effect upon the Business as presently conducted or upon the financial or trading position or prospects of the Business.

  

	5.4	The Seller shall procure that until Completion the Buyer and its advisers shall be given promptly on request such facilities and information (including access to employees)
regarding the Business or the Assets as they or any of them may reasonably require. 

  

	6.	RISK 

  

	6.1	Pending the Completion Date, possession and risk of loss of the Assets shall be retained by the Seller. The Assets shall be at the risk of the Buyer as from the Completion Date.

  

	6.2	The Seller shall continue to carry on the Business for its own benefit and at its own risk up to the Completion Date. 

  

	6.3	All profits and receipts of the Business (other than profits earned or receivable in respect of work in progress) and all losses and outgoings incurred or payable by the Business up
to the Completion Date shall belong to, and be paid and discharged by, the Seller. 

  

	6.4	All profits and receipts of the Business and all losses and outgoings incurred or payable by the Business as from the Completion Date shall belong to, and be paid and discharged by,
the Buyer. 

  

	6.5	Nothing in this Agreement shall have the effect of making the Buyer liable in any way under any guarantees or warranties given by the Seller to any customer in relation to products
sold or services rendered by the Seller prior to the Completion Date, the liability for which shall remain absolutely with the Seller. 

  

	7.	POST COMPLETION 

  

	7.1	The Buyer undertakes to the Seller that as soon as is reasonably practicable following Completion, the Buyer shall take all steps necessary to facilitate the payment of and shall
pay all stamp duty in respect of the granting of the Lease to the appropriate tax authority. 

  

	7.2	The Buyer shall with effect from Completion indemnify the Seller against all liabilities, obligations, costs, claims and demands arising from or in respect of the non payment of
stamp duty referred to in Clause 7.1 above. 

  

 15 

	8.	STOCK 

  

	8.1	Commencing within five (5) Business Days after Completion, the Seller shall perform a stock-take and within fourteen (14) Business Days of Completion, deliver to the Buyer the Stock
Valuation. During the stock-take representatives of both the Seller and Buyer shall jointly use all their reasonable endeavours to identify any Damaged Stock. Any such Damaged Stock shall be destroyed or otherwise dealt with by the Seller (unless
expressly agreed to the contrary). The Stock shall be valued on a basis consistent with those accounting standards, principles and policies applied in the preparation of the Accounts and otherwise prepared in accordance with generally accepted
accounting standards, principles and policies in the United Kingdom. Further, the Seller undertakes and agrees that the Stock Valuation at Completion will not exceed two million and five hundred thousand pounds (£2,500,000.00).

  

	8.2	The Stock shall be valued at cost excluding any VAT on the Stock paid by the Seller. The Seller shall comply with any reasonable requests of the Buyer’s representatives for
evidence or information to verify the cost of the Stock. 

  

	8.3	The Buyer shall notify the Seller within fourteen (14) Business Days (or within such longer period as shall be agreed in writing between the parties) of receipt of the Stock
Valuation, whether or not the Buyer accepts the calculations therein for the purposes of this Agreement. 

  

	8.4	If the Buyer notifies the Seller that it does not accept the Stock Valuation: 

  

	 	8.4.1 	it shall deliver to the Seller a notice in writing (the “Notice”) setting out its reasons in full for such non-acceptance and specify the adjustments which,
in its opinion, should be made to the Stock Valuation in order to comply with the requirements of this Agreement; 

  

	 	8.4.2 	the parties shall, within fourteen (14) Business Days from the date of the Notice (the “Negotiation Period”), meet and discuss the objections of the Buyer
and use their best efforts to reach agreement upon the adjustments (if any) required to be made to the Stock Valuation; and 

  

	 	8.4.3 	if, on expiry of the Negotiation Period, both parties have failed to agree and accept the Stock Valuation, Clause 8.6 shall apply. 

  

	8.5	If the Buyer is satisfied with the Stock Valuation (either as originally submitted or after adjustments agreed between the Seller and the Buyer) then the Stock Valuation
(incorporating any agreed adjustments) shall constitute the agreed Stock Valuation for the purposes of this Agreement. 

  

 16 

	8.6	In the event that the parties are not able to agree on the Stock Valuation by the expiry of the Negotiation Period pursuant to Clause 8.4 above, any of the matters in dispute with
respect to the determination of the value of the Stock shall be referred for final settlement to a firm of chartered accountants nominated jointly by the Seller and the Buyer or, failing such nomination within fourteen (14) days after the
Negotiation Period by either the Seller or the Buyer, nominated at the request of either of them by the President for the time being of the Ulster Society of the Institute of Chartered Accountants in Ireland. The accountants shall be entitled to
call for submissions from both the Buyer and the Seller as to objections in relation to the Stock Valuation and may call for and inspect such documents as they may reasonably consider necessary. In making their determination, the accountants shall
act as experts and not as arbitrators, their decision shall (in the absence of manifest error) be final and binding on the parties and their fees shall be borne and paid by the Seller and the Buyer in such proportions as the accountants determine.

  

	8.7	The accountants appointed as experts pursuant to this Clause 8 shall, in giving their determination, state what adjustments (if any) are necessary to the Stock Valuation in such
form as it stands at that time, in respect of the matters in dispute in order to comply with the requirements of this Agreement and shall give their reasons therefore and shall make such determination as soon as is reasonably practicable after their
appointment and in any event by not later than thirty (30) days after their appointment. 

  

	8.8	The Buyer shall pay to the Seller in cash the lesser of £2,500,000 or a sum equal to the actual value of the Stock at Completion as stated in the Stock Valuation and as
determined in accordance with the provisions of this Clause 8 in the following proportions and by the following dates: 

  

	 	8.8.1 	the first 25 per cent. of such value of the Stock by no later than ninety (90) days after the Completion Date; 

  

	 	8.8.2 	the second 25 per cent. Of such value of the Stock by no later than one hundred and eighty (180) days after the Completion Date; 

  

	 	8.8.3 	the third 25 per cent. of such value of the Stock by no later than two hundred and seventy (270) days after the Completion Date; and 

  

	 	8.8.4	  the final 25 per cent. of such value of the Stock by no later than one (1) year after the Completion Date. 

  

 17 

	8.9	If any such payment is not made by the dates indicated in Clause 8.8 above, interest will be payable thereon, calculated on a daily basis (after as well as before judgment) from the
due date specified in each of Clauses 8.8.1 - 8.8.4 to the date of actual payment at two per cent. per annum above the base lending rate of Bank of Ireland Belfast from time to time. 

  

	9.	RECEIVABLES 

  

	9.1	The Buyer shall not acquire the Receivables, which shall remain the property and the responsibility of the Seller. 

  

	9.2	The Seller and the Buyer shall cause to be prepared from the accounting records of the Business, a list of the Receivables showing within 10 Business Days from the date hereof,
(inter alia) the names of the debtors and the amounts owing to the Seller or any member of the Seller’s Group by each of the relevant debtors. 

  

	9.3	Notwithstanding that the Receivables are excluded from the Assets hereby agreed to be sold, the Buyer agrees that it will, as agent for and at no cost to the Seller, use all
reasonable endeavours (but without being obliged to incur any expenditure) short of commencing legal proceedings to collect the Receivables (to the extent not collected upon Completion), hold the sums of money representing the same upon trust for
the Seller, and record such receipt separately in its books subject to the following terms and conditions or such other terms, conditions or arrangements as may be agreed from time to time in writing between the Seller and the Buyer:

  

	 	9.3.1 	Without the prior written consent of the Seller the Buyer shall not effect any settlement compromise or release any claim in respect of any of the Receivables nor, without such
consent, institute, carry on, defend, compromise, abandon or submit to judgment in any legal proceedings or join in and submit to arbitration or give security or indemnities for costs, pay any sum of money into court or obtain payment of money
lodged in court. 

  

	 	9.3.2 	If it becomes apparent that recovery of any of the Receivables is not likely to be possible within a reasonable period not to exceed ninety (90) days unless legal proceedings are
instituted, the Buyer will advise the Seller in writing and furnish the Seller with particulars of the steps taken by the Buyer to effect recovery. Where the debtor in question is a continuing debtor of the Business after Completion, the Seller
shall consult with the Buyer to determine what action is required in respect of the debtor(s) in question; 

  

 18 

	 	9.3.3 	Within ten (10) Business Days of the end of each month commencing after Completion the Buyer shall provide the Seller with a statement of the Receivables collected in that month
(or, in the case of the first such month, the period between Completion and the end of such month) and shall remit to the Seller the amounts so received during that period; and 

  

	 	9.3.4 	After the expiration of six (6) months from Completion the obligations of the Buyer under this Clause 9.3 to collect Receivables on behalf of the Seller shall cease, save that if
thereafter any payments are made to the Buyer in respect of Receivables, the Buyer shall remit the same to the Seller as soon as practicable following receipt. 

  

	10.	CONTRACTS, IVEX PRODUCT LICENCES AND IVEX MANUFACTURING LICENCES 

  

	10.1	The Seller undertakes with effect from Completion to assign to the order of the Buyer, or to procure the assignment to the order of the Buyer, all the Contracts which are capable of
assignment without the consent of other parties or without breaching the terms of such Contracts. 

  

	10.2	In so far as any of the Contracts are not assignable to the Buyer without the agreement of or novation by or consent to the assignment from another party, this Agreement shall not
constitute an assignment or attempted assignment if such assignment or attempted assignment would constitute a breach of such Contracts. 

  

	10.3	If any of the Contracts cannot be assigned or novated to the Buyer without the consent of a third party, then each of the Seller and the Buyer shall use their respective reasonable
endeavours to obtain such consent. 

  

	10.4	In any case where the consent in Clause 10.3 above is refused or otherwise not obtained and until it is obtained or where any of the Contracts are incapable of transfer to the Buyer
by assignment or by other means: 

  

	 	10.4.1 	the Seller shall hold those Contracts and any monies, goods or other benefits received thereunder as agent of and trustee for the Buyer and shall forthwith upon receipt of the same
account for and pay or deliver to the Buyer such monies, goods and other benefits; 

  

	 	10.4.2 	 the Buyer shall perform those Contracts in accordance with their terms and conditions as sub-contractor to the Seller, provided that sub-contracting is permissible
under the terms of the Contract in question; and where sub-contracting is not permissible, the Buyer shall perform the Contracts in accordance with their terms and conditions as agent for the Seller and 

  

 19 

	 	 
indemnify and keep indemnified the Seller against all obligations, debts, costs, claims, demands, reasonably incurred expenses and damages in respect thereof
incurred by the Buyer after Completion; provided the Buyer shall not be liable to pay or perform any such claims, costs, expenses or demands to the extent that such claims, costs, expenses or demands arise from or have increased due to any actions
taken or omissions made by the Seller or any member of the Seller’s Group prior to the Completion; and 

  

	 	10.4.3 	the Seller shall give all reasonable assistance to the Buyer to enable the Buyer to enforce the rights of the Seller under the Contracts and shall at all times act with regard to
the Contracts in accordance with the Buyer’s reasonable instructions from time to time and will provide access to all relevant books, documents and other information in relation to such Contracts as are within the Seller’s possession or
the possession of the Seller’s Group and as the Buyer may reasonably request in writing from time to time; and the Buyer agrees to reimburse the Seller for any out of pocket expenses reasonably incurred in fulfilling the Seller’s
obligations under this Clause. 

  

	10.5	To the extent that any payment is made to the Seller in respect of the Contracts on or after Completion, the Seller shall receive the same as trustee, shall record such payment
separately in its books and shall account to the Buyer for the same within five (5) Business Days of receipt. 

  

	10.6	To the extent permitted by the competent authority, the Seller undertakes with effect from Completion to permit the Buyer to operate the Business under the Ivex Manufacturing
Licences for the Interim Period or until the Buyer is granted New Licences, whichever is the earlier. 

  

	10.7	 In consideration for the permission granted by the Seller in Clause 10.6 and for so long as the Buyer is operating under the Ivex Manufacturing Licences, the Buyer
will procure that no acts are performed or amendments or omissions made to the quality systems, processes and procedures currently employed by the Seller or its agents or representatives in carrying on the Business which may affect either directly
or indirectly the validity of the Ivex Manufacturing Licences and the Buyer shall hold harmless and indemnify and keep indemnified the Seller and each member of the Seller’s Group against all losses, claims, expenses and damage (including
reasonable legal and other professional fees and expenses reasonably and properly incurred) that result from the Buyer being in breach of the provisions of this Clause 10.7; provided the Buyer shall not be liable to pay or perform any such claims,
costs, expenses or demands to the extent that such claims, costs, expenses or demands arise from or have increased due to any 

  

 20 

	 	 
actions taken or omissions made by the Seller or any member of the Seller’s Group prior to the Completion. 

  

	10.8	Both parties will use all their reasonable endeavours and perform all such acts that may be reasonably necessary during the Interim Period to ensure the New Licences are granted and
each party will provide the other with any information they may reasonably request on the progress of such applications. 

  

	10.9	Pending the grant to the Buyer of the New Licences, the Seller shall: 

  

	 	10.9.1 	in so far as it can do so legally, hold the Ivex Marketing Authorisations as nominee and trustee for and on behalf of the Buyer and shall agree to transfer the Ivex Marketing
Authorisations as the Buyer may from time to time reasonably direct in writing; 

  

	 	10.9.2 	knowingly do nothing which might render the Ivex Manufacturing Licenses and the Ivex Marketing Authorisations liable to be cancelled or revoked. 

  

	10.10 	The Buyer confirms that it assumes all responsibility for regulatory, pharmacovigilance and medical information activities, effective from the Completion Date in respect of the Ivex
Marketing Authorisations. The Buyer also confirms that it will utilise systems and procedures in place which comply fully with the provisions of The Medicines for Human Use (Marketing Authorisations etc) Regulations 1994 (S.I. 1994 No. 3144), Volume
9 of The Rules Governing Medicinal Products in the European Union (effective as of December 2001) and Article 98 of Directive 2001/83/EC. 

  

	11.	PREPAYMENTS BY SELLER AND CUSTOMERS 

  

	11.1	The following provisions shall apply in respect of any prepayments to or by the Seller or Seller’s Group in relation to the Business only: 

  

	 	11.1.1 	the Seller shall account to the Buyer for all prepayments received by the Seller or the Seller’s Group in respect of any Contracts not wholly completed or discharged at
Completion by the Seller to the extent that such prepayments exceed the actual costs incurred by the Seller (if any) in partially performing such Contracts prior to Completion; and 

  

	 	11.1.2 	the Buyer shall account to the Seller for all payments made by the Seller in respect of any Contracts not wholly completed or discharged at Completion by suppliers of goods and
services to the extent that such payments exceed the value of goods and/or services already supplied prior to Completion. 

  

 21 

	11.2	Save as expressly stated otherwise in the Services Agreements, all rates, water, gas, electricity and telephone charges, salaries, wages, and other outgoings and costs of a periodic
nature which are chargeable by reference to a period commencing before and ending after Completion shall be apportioned on a time basis pro rata (provided that any such outgoings or costs chargeable by reference to the extent of the use of any
property or rights shall be apportioned between the Seller and the Buyer according to the extent of such use). 

  

	11.3	Where any amounts are to be apportioned under this Agreement, the Seller shall provide the Buyer with details of the apportionments with supporting vouchers or similar
documentation, and in the absence of dispute between the Seller and the Buyer, the appropriate payment shall be made by or to the Seller in accordance with the terms of this Clause 11. If the amount of any apportionment is in dispute, the matter
shall be referred for final settlement to a firm of chartered accountants nominated jointly by the Seller and the Buyer or, failing such nomination, within fourteen (14) days after request by either the Seller or the Buyer, nominated at the request
of either of them by the President for the time being of the Ulster Society of the Institute of Chartered Accountants in Ireland. The accountants shall be entitled to call for and inspect such documents as they may reasonably consider necessary. In
making their determination, the accountants shall act as experts and not as arbitrators, their decision shall (in the absence of manifest error) be final and binding on the parties and their fees shall be borne and paid by the Seller and the Buyer
in such proportions as the accountants determine. The amount determined to be due in accordance with this Clause shall be paid within fourteen (14) days of the date of determination, together with interest calculated on a daily basis (as well after
as before judgment), from the date of determination until the date of actual payment, at the rate of two (2) per cent per annum above the base lending rate from time to time of Bank of Ireland, Belfast. 

  

	11.4	In relation to any expenditure or outgoing of the Business which is consideration for a taxable supply and which is apportioned under this Clause 11.4, that part of the amount of
the expenditure or outgoing which is input tax for the purposes of VAT shall be apportioned to the party which is entitled to recover such input tax or obtain credit for it pursuant to the Value Added Tax Act 1994. 

  

	11.5	Any payment due between the parties pursuant to this Clause 11.5 (save as otherwise provided for in Clause 11.3) shall be paid within thirty (30) days of Completion.

  

 22 

	12.	EMPLOYEES 

  

	12.1	The Seller and the Buyer acknowledge and agree that the sale and purchase of the Business and Assets pursuant to this Agreement will constitute a relevant transfer for the purposes
of the Regulations and that such transactions will not operate so as to terminate any of the contracts of employment of the Assumed Employees. 

  

	12.2	The Buyer undertakes to the Seller that it shall give the Seller such information as will enable the Seller to perform the duty imposed on it by regulation 10.2 (d) of the
Regulations. 

  

	12.3	The Buyer undertakes to indemnify the Seller against all liabilities, obligations, costs, claims and demands arising from or in respect of the Buyer’s treatment of any of the
Assumed Employees after Completion provided that and to the extent that such claims do not arise due to any act or omission on the part of the Seller on or prior to Completion. 

  

	12.4	The Buyer shall discharge and hereby undertakes to indemnify the Seller against all liabilities, obligations, costs, claims and demands arising from or in respect of the Assumed
Employees before Completion in respect of any breach of Regulation 10(3) of the Regulations by the Buyer. To the extent required by law, the Buyer will indemnify the Seller against any claim arising directly from the resignation of an Assumed
Employee on or prior to Completion on account of any proposal of the Buyer to change terms and conditions of employment or working conditions for that Employee, provided (in both cases of the indemnifications in this clause 12.4) the Buyer shall not
be liable to pay or perform any such claims, costs, expenses or demands to the extent that such claims, costs, expenses or demands arise from or have increased due to any actions taken or omissions made by the Seller or any member of the
Seller’s Group prior to the Completion. 

  

	12.5	The Buyer agrees that for a period of 12 months after Completion the Assumed Employees will continue to receive basic salary and contractual benefits which are overall no less
favourable than the salary and contractual benefits for the Assumed Employees at Completion. 

  

	12.6	If the contract of employment of any Assumed Employee is found (or alleged) not to have effect after Completion as if originally made with the Buyer, the Buyer agrees that:

  

	 	12.6.1 	in consultation with the Seller, it will within fourteen (14) days of being informed of such finding or allegation make to the relevant Assumed Employee an offer in writing to
employ him under a new contract of employment to take effect on the termination referred to below; and 

  

 23 

	 	12.6.2 	any such offer of employment made by the Buyer will be on terms and conditions which, when taken as a whole, do not differ in any material way from the terms and conditions of
employment of that Assumed Employee immediately before Completion (save as to the identity of the employer). 

  
 Upon that offer being made (or at any time after the offer should have been made if no offer is made), the Seller will terminate the Seller’s
employment of the relevant Assumed Employee, and the Buyer shall indemnify and keep the Seller indemnified against all losses, damages, actions, awards, penalties, fines, proceedings liabilities (including any liability for Taxation), obligations,
costs, claims, demands and expenses (including legal and other professional fees and expenses) arising out of the Buyer’s employment of that Assumed Employee from Completion until the termination of such employment. 
  

	12.7	The Seller undertakes to the Buyer: 

  

	 	12.7.1 	to perform and observe, pending Completion, all the Seller’s obligations and those of any of its predecessors (whether arising under common law, statute, equity or otherwise)
under or in connection with the contracts of employment of the Assumed Employees (or any of the said obligations the Seller would have had under or in connection with the said contracts but for the Regulations); 

  

	 	12.7.2 	to pay to the Assumed Employees all sums to which they are entitled up to and including Completion (whether arising under common law, statute, equity or otherwise) including,
without limitation, all wages and salaries, sick pay, maternity pay, any liability for Taxation, accrued holiday pay, expenses, accrued bonus, commission and other sums payable in respect of any period up to Completion; 

  

	 	12.7.3 	to comply in all respects with Regulation 10 of the Regulations (and to provide to the Buyer such information that the Buyer may reasonably request in writing in order to verify
such compliance); 

  

	 	12.7.4 	not to alter (whether to take effect prior to, on or after Completion) any of the terms of employment or engagement of any of the Assumed Employees; 

  

	 	12.7.5 	not to make any deduction from the salary or other wages due to any of the Assumed Employees (otherwise than in respect of PAYE and National Insurance contributions) unless such
deduction shall previously have been approved in writing by such of the Assumed Employees; 

  

 24 

	 	12.7.6 	not to terminate or take any steps to terminate the contract of employment of, nor to dismiss (constructively or otherwise), any of the Assumed Employees other than in accordance
with the provisions of paragraph 5.1.6 above; 

  

	 	12.7.7 	not to transfer or move or redeploy any of the Assumed Employees from working within the Business, or induce any such employee to resign his employment from the Business or to agree
to transfer or move or be redeployed from the Business (without the prior written consent of the Buyer); 

  

	 	12.7.8 	to fully indemnify and keep the Buyer and the Buyer’s Group indemnified against all losses, damages, costs, actions, awards, penalties, fines, proceedings, claims, demands,
liabilities (including any liability for Taxation), and expenses (including, legal and other professional fees and expenses) which the Buyer or any of such owners may suffer, sustain, incur, pay or be put to by reason or on account of or arising
from: 

  

	 	12.7.8.1 	any failure by the Seller to comply with its obligations under this Clause 12.7 

  

	 	12.7.8.2 	any claim or other legal recourse by all or any of the Assumed Employees in respect of any fact or matter concerning or arising from employment with the Seller prior to Completion.

  

	 	12.7.8.3 	any claim or other legal recourse by any trade union or staff association recognised by the Seller or employee representatives in respect of all or any of the Assumed Employees
arising from or connected with the failure by the Seller to comply with its legal obligations to such trade union or staff association or employee representatives; 

  

	 	12.7.8.4 	the employment or termination of employment prior to Completion of any agent or contractor or the Assumed Employees of the Seller whose employment is transferred to the Buyer by the
Regulations; 

  

	 	12.7.8.5 	any act or omission done or omitted to be done by the Seller in relation to the Assumed Employees or any other employee of the Seller which by virtue of the Regulations is deemed to
be an act or omission of the Buyer; 

  

 25 

	 	12.7.8.6 	without prejudice to sub-Clause 12.7.8.5 above, any claim or demand or other legal recourse against the Buyer by any other person or agent or employee or contractor of the Seller
who claims (whether correctly or not) that the Buyer has inherited liability from the Seller in respect of them by virtue of the Regulations; and 

  

	 	12.7.8.7 	any claim or legal recourse by any Retained Employees or other individuals who have or allege to have provided services for or to the Seller’s Group in connection with the
Business who are not Assumed Employees. 

  

	 	12.7.8.8 	without prejudice to clause 12.7.8.7 any costs or claims associated with the employment of Terence Dalrymple and Robert Sanderson and any costs or claims associated with the
termination of his employment. 

  

	12.8	If, as a result of the provisions of the Regulations, any contract of employment or collective agreement not disclosed in the Disclosure Letter to the Buyer shall have effect as if
originally made between the Buyer and any of the Assumed Employees or a trade union: 

  

	 	12.8.1 	the Buyer may, upon becoming aware of the application of the Regulations to any such contract of employment or collective agreement and in consultation with the Seller, terminate
such contract or agreement in line with proper redundancy procedures, using reasonable endeavors to comply with any applicable Regulations, provided that such endeavours do not prejudice the indemnity provided by the Seller in clause 12.7; and

  

	 	12.8.2 	the Seller shall indemnify and shall keep indemnified the Buyer against all losses, damages, costs, actions, proceedings, claims, demands, liabilities (including, without
limitation, any liability for Taxation) and expenses (including, without limitation, legal and other professional fees and expenses) which the Buyer may suffer, incur, sustain, pay or be put to by reason or on account of or arising out of such
termination or arising from such contracts of employment or collective agreement before and after Completion if such is not terminated by the Buyer. 

  

	12.9	Without prejudice to the other provisions of this Clause, the Seller shall, at its own expense, give the Buyer such assistance as the Buyer may reasonably require to contest any
claim resulting from or in connection with this Agreement by any person employed in the Business at or prior to Completion. 

  

 26 

	12.10 	The Seller will, upon request by the Buyer and at the Seller’s expense, provide to the Buyer such information or documents as the Buyer may reasonably require relating to the
terms and conditions of employment, pension and life assurance arrangements, health, welfare or any other matter concerning any of the Assumed Employees or relating to collective agreements, or collective or individual grievances of the Assumed
Employees in the period prior to Completion. 

  

	13.	SELLER’S AND BUYER’S OBLIGATIONS AFTER COMPLETION 

  

	13.1	The Seller shall promptly refer to the Buyer all enquiries relating to the Business and assign to the Buyer all orders directly and exclusively relating to the Business which it
receives on or after Completion. 

  

	13.2	The Seller shall notify and keep informed the Buyer of any claims against the Seller brought by any third party in respect of any products or services supplied by the Seller prior
to Completion in relation to the Business and the Seller shall not, without the Buyer’s prior written consent (such consent not to be unreasonably withheld or delayed), take any other steps in relation to such claims which might reasonably be
expected to damage the commercial interests of the Buyer. If the Buyer considers that it is desirable to take preventative action with a view to avoiding such claims against the Seller, the Buyer shall bear the cost of that action.

  

	13.3	On or for a period of five years after Completion (or such shorter period as shall be required under the governing law with respect to the particular type of information), the
Seller will give or procure to be given to the Buyer all such information and other assistance (including, without limitation, particulars of customers, suppliers and others who have dealt with the Seller in connection with the Business) as the
Buyer may reasonably require for the conduct of the Business and for the purpose of implementing the provisions of this Agreement. During the first two (2) years after Completion, the Seller shall bear the cost of such procurement; thereafter, the
Buyer shall bear the cost of procurement and assistance. 

  

	13.4	Not later than two (2) Business Days after execution of this Agreement, the Seller shall send to each of the Assumed Employees a letter, in the Agreed Form, explaining that the
Assumed Employee’s employment will be transferred to the Buyer at Completion pursuant to the Regulations. 

  

	13.5	 The Seller will, if so required by the Buyer on or at any time after Completion and at the Buyer’s expense, send a circular (in Agreed Form) to persons who

  

 27 

	 	 
have had dealings with the Seller in connection with the Business announcing the transfer to the Buyer of the Business and the Goodwill.

  

	13.6	The Seller will give to the Buyer reasonable access to the books, accounts, records and returns of the Seller relating to or in connection with the Business as the Buyer may
reasonably require (including the right to take copies and extracts on reasonable advance written notice) and will keep them in good order and, for a period of six (6) years following Completion, the Seller will also retain those items referred to
in paragraph (e) of Excluded Assets and shall allow the Buyer reasonable access thereto the terms of which are set out in the Services Agreement. 

  

	13.7	The Seller shall indemnify the Buyer and keep it indemnified against all outgoings, debts, liabilities, obligations, actions, proceedings, costs, damages, claims and demands of
whatever nature relating to and payable in respect of the Business or the Assets which are attributable to the period up to and including Completion and including any act or omission on the part of the Seller in relation to the Contracts or any
defects in, or alleged defects in, goods supplied or services provided prior to the Completion and in particular any claim under any warranty or under the Sale of Goods Act 1979 or the Sale and Supply of Goods Act 1994; provided the Seller shall not
be liable to pay or perform any such claims, costs, expenses or demands to the extent that such claims, costs, expenses or demands arise from or have increased due to any actions taken or omissions made by the Buyer prior to the Completion .

  

	13.8	The Buyer shall indemnify the Seller and keep it indemnified against all outgoings, debts, liabilities, obligations, actions, proceedings, costs, damages, claims and demands of
whatever nature relating to and payable in respect of the Business or the Assets which are attributable to the period after Completion; provided the Buyer shall not be liable to pay or perform any such claims, costs, expenses or demands to the
extent that such claims, costs, expenses or demands arise from or have increased due to any actions taken or omissions made by the Seller prior to or following the Completion. 

  

	13.9	The Buyer will give to the Seller at Seller’s expense reasonable access to books, accounts, records, returns and personnel of the Seller relating to or in connection with the
Business as the Seller may reasonably require (including the right to take copies and extracts in reasonable advance written notice) in the event that the Seller is required by any governmental agency or other investigative body to make such records
available for inspection. 

  

	13.10 	 During the period of six (6) years after Completion and without prejudice to any of the Warranties, if any information relating to the Business is not in possession

  

 28 

	 	 
of the Buyer or readily discoverable by the Buyer but is in the possession or under control of or available to the Seller or any other member of the
Seller’s Group, the Seller shall procure that such information is provided to the Buyer promptly on request. 

  

	14.	VALUE ADDED TAX 

  

	14.1	All amounts expressed in this Agreement as being payable by any party hereto are expressed exclusive of any value added tax which may be chargeable thereon, and the amount of any
such value added tax shall be payable in addition thereto. 

  

	14.2	The Seller and the Buyer shall use all reasonable endeavours to secure that the conditions of article 5(1) of the Value Added Tax (Special Provisions) Order 1995 SI 1268 and of
section 49 of the Value Added Tax Act 1994 are fulfilled so that the sale of the Business and Assets hereunder is properly treated as neither a supply of goods nor a supply of services for the purposes of value added tax. 

 

	14.3	The Seller and the Buyer shall each give notice to H.M. Customs and Excise of the transfer of the Business and Assets to the Buyer, to the extent such notice is required by law or
regulation. 

  

	14.4	The Seller shall on Completion deliver to the Buyer all records referred to in section 49(1) of the Value Added Tax Act 1994 in respect of the Business and shall not make any
request to H.M. Customs and Excise for such records to be retained by the Seller. The Buyer hereby undertakes to preserve such records for such periods as may be required by law and shall, during that period, afford the relevant government agencies
and/or the Seller reasonable access to them at the request of the Seller. 

  

	14.5	In the event that H.M. Customs and Excise determine that value added tax is chargeable on the sale of the Business and Assets hereunder or any of them, the Seller shall immediately
notify the Buyer of such determination and the Buyer agrees that such value added tax shall be in addition to the Consideration and the Buyer shall (against production by the Seller of tax invoices in respect thereof) pay the amount of any such
value added tax forthwith to the Seller, but such payment shall be without prejudice to the right of the Buyer under this Agreement to call upon the Seller to make or join in an appeal against the aforesaid determination. 

 

	14.6	 All value added tax payable in respect of goods and services supplied or deemed to be supplied by the Seller in connection with the Business prior to Completion,
and all interest payable thereon and penalties attributable thereto, shall be paid to H.M. Customs and Excise by the Seller. The Seller shall be entitled to receive 

  

 29 

	 	 
and to retain for its own benefit (i) all reimbursement or credit from H.M. Customs and Excise for value added tax borne by the Seller on goods and services
supplied to the Seller prior to Completion and (ii) any payments received in respect of value added tax overpaid to H.M. Customs and Excise prior thereto. 

  

	15.	WARRANTIES 

  

	15.1	The Seller warrants to the Buyer in the terms of the Warranties which shall remain in full force and effect as of the execution of this Agreement as well as on Completion; affirms
that such Warranties are made, where so qualified, based on the Seller’s knowledge after commercially reasonable inquiry; and acknowledges that the Buyer is entering into this Agreement in reliance on the Warranties. 

 

	15.2	Each of the Warranties shall be construed as a separate Warranty and (save as expressly provided to the contrary) shall not be limited by the terms of any of the other Warranties.

  

	15.3	Save in the case of fraud or fraudulent concealment by the Seller, the Seller shall be under no liability in respect of any claim under the Warranties and any such claim shall be
wholly barred and unenforceable unless written notice of such claim setting out full details of the relevant claim (including the grounds (if known) on which such claim is based and the amount claimed to be payable in respect thereof ) shall have
been served upon the Seller by the Buyer promptly after it becomes likely that a claim will be made and, in any event: 

  

	 	15.3.1 	in the case of a claim under the Warranties (other than the Warranties relating to Taxation), by not later than 5.00 p.m. two (2) years from the date hereof;

  

	 	15.3.2 	the Seller shall obtain and use its best endeavours to maintain in force a liability insurance in respect of the finished goods and Stock manufactured by the Seller prior to
Completion naming the Buyer as a co-insured or beneficiary at no cost to the Buyer for the first two years following Completion. Thereafter, any premium in respect of such insurance for the third and fourth years of its term shall be paid to the
Seller by the Buyer within fourteen Business Days of the Seller providing the Buyer with a copy of the appropriate insurance premium demand. The Seller’s obligation during the third and fourth years in respect of the Stock warranty shall be
limited to its deductible amount thereunder; and 

  

	 	15.3.3 	 the liability of the Seller for any claim specified in such notice shall absolutely determine and cease (unless the amount payable in respect of the relevant claim
has been agreed by the Seller within three months of the 

  

 30 

	 	 
date of such written notice) if legal proceedings have not been instituted in respect of such claim by the due service of process on the Seller within six
months of the date of such written notice. For the purpose of this clause 15.3, legal proceedings shall not be deemed to have been instituted unless they shall have been properly issued and validly served upon the Seller.

  

	15.4	Save in the case of fraud or fraudulent concealment or in the case of claims related to Stock which are indemnified on a pound per pound basis, the Seller shall be under no
liability in respect of any claim under the Warranties: 

  

	 	15.4.1 	where the liability of the Seller in respect of that claim would (but for this paragraph) have been less than £25,000 (a “de minimis claim”)

  

	 	15.4.2 	unless and until and only to the extent that the liability in respect of a de minimis claim (not being a claim for which liability is excluded under clause 15.4.1 above) when
aggregated with the liability of the Seller in respect of all other de minimis claims shall exceed £100,000. 

  

	15.5	Save in the case of fraud or fraudulent concealment, the aggregate liability of the Seller in respect of all claims under the Warranties other than for Stock shall not in any
circumstances exceed the sum of two million five hundred and seventy five thousand pounds (£2,575,000); and as a separate cap on any claims relating to Warranties for the Stock, the aggregate liability of the Seller shall not exceed the Stock
Valuation but only to the extent that the Seller has received payment for the Stock Valuation. 

  

	15.6	The Seller shall be under no liability in respect of any claim under the Warranties to the extent that the facts or circumstances giving rise thereto are disclosed in the Disclosure
Letter or the Data Room. 

  

	15.7	No liability (whether in contract, tort or otherwise) shall attach to the Seller in respect of any claim under the Warranties to the extent that: 

  

	 	15.7.1 	the claim or the events giving rise to the claim would not have arisen but for an act or omission of the Buyer following execution of this Agreement where the Buyer knew or ought
reasonably to have known that such act or omission may give rise to any such claim; 

  

	 	15.7.2 	the claim is based upon a liability which is contingent only, unless and until such contingent liability becomes an actual liability or until the same is finally adjudicated;

  

 31 

	 	15.7.3 	allowance, provision or reserve in respect of the matter giving rise to the claim shall have been made in the Accounts; 

  

	 	15.7.4 	the claim occurs wholly or partly out of or the amount thereof is increased as a result of: 

  

	 	15.7.4.1 	any change in the accounting principles or practices of the Buyer’s Group introduced or having effect after the Completion Date unless the same is introduced to bring the
accounting principles and practices into line with generally accepted accounting principles and practices in the UK in relation to a business of the type carried on by the Business; or 

  

	 	15.7.4.2 	any increase in the rates of Taxation made after the date hereof; or 

  

	 	15.7.4.3 	any change in law or regulation or in its interpretation or administration by the courts of Northern Ireland, by the Inland Revenue or by any other fiscal, monetary or regulatory
authority (whether or not having the force of law); or 

  

	 	15.7.5 	the loss or damage giving rise to the claim is recoverable by the Buyer’s Group under any policy of insurance maintained by either the Seller or the Buyer or would have been so
recoverable but for any change in the terms of Stock insurance as a result of the Buyer’s operation of the Business since the date of this Agreement; and provided that the Seller shall remain liable for any amount not so recovered under the
policy of insurance and shall indemnify and keep indemnified the Buyer in relation to any excess on such policy and any direct or consequential increase in insurance premiums payable by the Buyer as a direct result of any such recovery, or

  

	 	15.7.6 	the claim relates to a claim or liability for Taxation and would not have arisen but for the Buyer’s winding-up or cessation after Completion of the Business or part of it.

  

	15.8	In assessing any liabilities, damages or other amounts recoverable by the Buyer from the Seller as a result of any claim under the Warranties, there shall be taken into account any
amount of any tax relief obtained by the Buyer’s Group and any amount by which any Taxation for which the Buyer’s Group is or may be liable to be assessed or accountable is reduced or extinguished, in each case when the relief or tax
benefit arises directly or indirectly and solely in consequence of the matter which gives rise to such claim. 

  

	15.9	 No liability will arise and no claim may be made under any of the Warranties to the extent that the matter giving rise to such claim is remediable unless within the

  

 32 

	 	 
period of 30 days following the Buyer becoming aware of such matter, the Buyer shall have given written notice thereof to the Seller and such matter shall
not have been remedied to the reasonable satisfaction of the Buyer within the period of 30 days following the date of service of such notice. 

  

	15.10 	Clause 15.11 shall apply in circumstances where: 

  

	 	15.10.1 	any claim is made against the Buyer’s Group which may give rise to a claim by the Buyer against the Seller under the Warranties other than the Warranties applying to Taxation
(the “General Warranties”); or 

  

	 	15.10.2 	the Buyer’s Group is or may be entitled to make recovery from some other person of any sum in respect of any facts or circumstances by reference to which the Buyer’s Group
has or may have a claim against the Seller under the General Warranties; or 

  

	 	15.10.3 	the Seller shall have paid to the Buyer’s Group an amount in respect of a claim under the General Warranties and subsequent to the making of such payment the Buyer’s Group
recovers from some other person a sum which is referable to that payment. 

  

	15.11 	In the circumstances provided in Clause 15.10, the Buyer shall and shall procure that the Buyer’s Group shall: 

  

	 	15.11.1 	(prior to taking any action against the Seller under the General Warranties in the case of Clause 15.10.1 and Clause 15.10.2 and subject to the Buyer’s Group being indemnified
and secured to the reasonable satisfaction of the Buyer by the Seller against all reasonable costs and expenses which may properly be incurred by reason of such action) promptly and diligently take all such action as the Seller may request, and at
Seller’s expense, including the institution of proceedings and the instruction of professional advisers approved by the Seller (always acting reasonably) to act on behalf of the Buyer’s Group to avoid, dispute, resist, compromise, defend
or appeal against any such claim against the Buyer’s Group as is referred to in Clause 15.10.1 or to make such recovery by the Buyer’s Group as is referred to in Clause 15.10.2 or Clause 15.10.3, as the case may be, in accordance with the
instructions of the Seller, to the intent that such action shall be delegated entirely to the Seller provided that the Buyer shall not be obliged to take any action which is reasonably likely to damage or prejudice the commercial interests of the
Business; 

  

 33 

	 	15.11.2 	not settle or compromise any liability or claim to which such action is referable without the prior written consent of the Seller, such consent not to be unreasonably withheld or
delayed; and 

  

	 	15.11.3 	in the case of Clause 15.10.3 only, promptly repay to the Seller an amount equal to the amount so recovered or, if lower, the amount paid by the Seller to the Buyer, less in each
case any reasonable costs incurred by the Buyer. 

  

	15.12 	The Buyer shall as soon as is reasonably practicable: 

  

	 	15.12.1 	inform the Seller in writing of any fact, matter, event or circumstance which comes to Buyer’s actual notice or to the notice of the Buyer’s Group whereby it appears that
the Seller is or may be liable to make any payment in respect of any claim under the Warranties or whereby it appears the Buyer’s Group shall become or may become entitled to recover from some other person a sum which is referable to a payment
already made by the Seller in respect of such a claim; 

  

	 	15.12.2 	thereafter keep the Seller fully informed of all developments in relation thereto; and 

  

	 	15.12.3 	unless prevented from doing so by law or order of court, provide all such information and documentation (no matter how it is recorded or stored) as the Seller shall reasonably
request in connection therewith and also in connection with any proceedings instituted by or against the Buyer’s Group under Clause 15.13. 

  

With respect to any such recovery, the Seller shall pursue collection of the sum at its own cost and without injury to the Buyer’s operation of
the Business. 
  

	15.13 	No liability in respect of any claim for Taxation under the Warranties shall become payable: 

  

	 	15.13.1 	in the case of a claim for Taxation involving an actual payment of tax or the loss or set off of a relief against Taxation, prior to the date on which a payment of Taxation becomes
finally due and payable under or in consequence of the claim for Taxation in question; or 

  

	 	15.13.2 	in the case of a claim for Taxation involving the loss of or reduction of a right to repayment of Taxation, prior to the day on which any repayment or increased repayment of
Taxation which, but for such claim for Taxation would have been available, would have been due. 

  

 34 

	15.14 	In the event that the Seller is obligated or shall wish to take out insurance against any of its Warranty liabilities hereunder, the Buyer undertakes to provide such information as
the prospective insurer may require before effecting such insurance. 

  

	15.15 	The Buyer hereby warrants to the Seller that as of the date of this Agreement it has no knowledge of any fact which might lead to claims against the Seller under the Warranties.

  

	15.16 	The Buyer’s Group will take or procure the taking of all such steps and action as are necessary or as the Seller may require in order to mitigate any claim under the Warranties
and the Buyer’s Group shall act in accordance with such request. Nothing in this agreement shall or shall be deemed to relieve the Buyer of any common law or other duty to mitigate any loss or damage incurred by it. 

  

	16.	PROTECTION OF GOODWILL 

  

	16.1	In consideration of the Buyer entering into the sale and purchase of the Business and Assets, the Seller undertakes to and with the Buyer that it shall not and shall procure that
the Seller’s Group shall not, whether directly or indirectly and whether alone or in conjunction with or on behalf of any other person, whether as principal, shareholder, director, employee, agent, consultant or otherwise:

  

	 	16.1.1 	during the Restricted Period, carry on or be engaged, concerned or interested (save as the holder of shares or debentures in a listed company which confer not more than three per
cent of the votes which could be cast at a general meeting of the company) in any business which is in competition with the Business as at Completion within the Restricted Territory; 

  

	 	16.1.2 	during the Restricted Period, solicit or endeavour to solicit the custom of any person, firm or company who or which was either at Completion or during the period of two (2) years
prior to Completion a client or customer of the Seller; 

  

	 	16.1.3 	use any trade or domain name or e-mail address used by the Business or any name intended or likely to be confused with any such trade or domain name or e-mail address;

  

	 	16.1.4 	 for a period of one (1) year from Completion, offer employment to or solicit or entice away or endeavour to solicit or entice away from the Buyer any Assumed
Employees, whether or not such person would commit any 

  

 35 

	 	 
breach of his contract of employment or terms of engagement by reason of his leaving the service of the Buyer; PROVIDED THAT this restriction will not apply
to any advertisement for recruitment made available generally through any recruitment agency or advertisement available to the public. 

  

	16.2	In consideration of the Buyer entering into this Agreement, the Seller undertakes to and with the Buyer that it shall and shall procure that Seller’s Guarantor and the
Seller’s Group shall : 

  

	 	16.2.1 	unless required by law or the rules of any governmental or regulatory organisation, keep confidential and not use or reveal to any person any of the trade secrets, secret or
confidential operations, processes or dealings or any other information relating primarily and directly to the Business including (without limitation) customer lists and names, sales targets and statistics, market share statistics, surveys and
reports and pricing information relating to sales and purchases in respect of the Business until such time as the same falls into the public domain otherwise than by reason of a breach of this undertaking; or 

  

	 	16.2.2 	attempt or knowingly assist or procure any other person to do any of the foregoing things. 

  

	16.3	The provisions of Clause 16.1 shall not prevent or restrict any member of the Seller’s Group from acquiring the whole or any part of a business which, or the share capital of a
company or group of companies whose business or a part of whose business, includes operations the carrying on of which would otherwise amount to a breach of the undertaking contained in Clause 16.1 (the “Competitive Operations”), as part
of a larger acquisition or series of related acquisitions PROVIDED THAT the relevant member of the Seller’s Group shall within the following twelve months use their best endeavours to sell the Competitive Operations as soon as is reasonably
practicable following such acquisition save that the relevant member of the Seller’s Group shall not be obliged to sell the Competitive Operations if those Competitive Operations comprise a minor part of the business or business of such
company, group of companies or businesses acquired or in which the Seller’s Group has acquired an interest. For the purpose of this Clause 16.3, “minor part” of the business of such company, group of companies or business shall be
part of its overall business in which the turnover of the Competitive Operations does not exceed nineteen per cent (19%) of the gross turnover per annum of the Company, group of companies or business acquired 

  

	16.4	 The restrictions contained in this Clause 16 are considered reasonable by the parties hereto and the Seller acknowledges that, in the light of the total price paid
under this Agreement and the manner of computation thereof, the nature of the 

  

 36 

	 	 
Business and all other relevant matters, the provisions of this Clause 16 are considered reasonably necessary for the protection of the interests of the
Buyer. 

  

	16.5	In the event that any restriction in this Clause 16 shall be found to be unenforceable but would be enforceable if some part thereof were deleted or the area of operation or the
period of application reduced, such restriction shall apply with such modification as may be necessary to make it legal and enforceable. 

  

	16.6	Each undertaking contained in this Clause 16 shall be construed as a separate undertaking and if one or more of the undertakings contained in this Clause 16 is held to be against
the public interest or unlawful or in any way an unreasonable restraint of trade the remaining undertakings shall continue to bind any member of the Seller’s Group. 

  

	17.	ANNOUNCEMENTS, ETC. 

  

	17.1	No party shall disclose the making of this Agreement nor its content (except those matters set out in the press release in the Agreed Form) and each party shall procure that each of
its Related Persons and its professional advisers shall not make any such disclosure without the prior consent of the other party unless disclosure is to its professional advisers or required by law or the rules or standards of the London Stock
Exchange or the Listing Rules of the UK Listing Authority or the rules and requirements of any other regulatory body provided that this Clause 17.1 does not apply to announcements, communications or circulars made or sent by the Buyer after the
execution of this Agreement to customers, clients, regulatory agencies, employees, or suppliers of the Business to the extent that it informs them of the Buyer’s acquisition of the Assets and the Business or to any announcements containing only
information which has become generally available. 

  

	17.2	The restrictions contained in Clause 17.1 shall apply without limit of time and whether or not this Agreement is terminated. 

  

	18.	ASSIGNMENT 

  
 This Agreement is personal to the parties and accordingly, save for any assignment by the Buyer to a member of the Buyer’s Group, neither party
without the prior written consent of the other (such consent not to be unreasonably withheld or delayed) shall assign, transfer or declare a trust of the benefit of all or any of any other party’s obligations nor any benefit arising under this
Agreement. 
  

 37 

	19.	COSTS 

  
 Unless expressly otherwise provided in this Agreement, each of the parties shall bear its own legal, accountancy and other costs, charges and expenses
connected with the sale and purchase of the Assets and the Business. 
  

	20.	BUYER’S GUARANTEE 

  
 In consideration of the Seller entering into this Agreement, the Buyer’s Guarantor gives in favour of the Seller the Buyer’s Guarantee.

  

	21.	SELLER’S GUARANTEE 

  
 In consideration of the Buyer entering into this Agreement, the Seller’s Guarantor gives in favour of the Buyer the Seller’s Guarantee.

  

	22.	ENTIRE AGREEMENT 

  

	22.1	Each party, on behalf of itself and as agent for each of its Related Persons, acknowledges and agrees with the other party (each such party acting on behalf of itself and as agent
for each of its Related Persons) that: 

  

	 	22.1.1 	this Agreement, together with any other Transaction Documents, constitutes the entire and only agreement between the parties and their respective Related Persons relating to the
subject matter of the Transaction Documents; 

  

	 	22.1.2 	neither it nor any of its Related Persons has been induced to enter into any Transaction Document in reliance upon, nor has any such party been given, any warranty, representation,
statement, assurance, covenant, agreement, undertaking, indemnity or commitment of any nature whatsoever other than as are expressly set out in the Transaction Documents and, to the extent that any of them has been, that party (acting on behalf of
itself and as agent on behalf of each of its Related Persons) unconditionally and irrevocably waives any claims, rights or remedies which any of them might otherwise have had in relation thereto; 

  

	 	22.1.3 	 the only remedies available to it in respect of the Transaction Documents (and, where appropriate, to its Related Persons) are damages for breach of contract or
Warranty and, for the avoidance of doubt, neither it nor its Related Persons, where appropriate, has any right to rescind or terminate any Transaction Documents either for breach of contract or for negligent or 

  

 38 

	 	 
innocent misrepresentation or otherwise, save in the event of fraud or fraudulent misrepresentation on the part of the Seller, 

 
 PROVIDED THAT the provisions of this Clause 22 shall not exclude any
liability which any of the parties or, where appropriate, their Related Persons would otherwise have to any other party or, where appropriate, to any other party’s Related Persons or any right which any of them may have in respect of any
statements made fraudulently by any of them prior to the execution of this Agreement or any rights which any of them may have in respect of fraudulent concealment by any of them. 
  

	23.	WAIVER, AMENDMENT 

  

	23.1	A waiver of any term, provision or condition of, or consent granted under, this Agreement shall be effective only if given in writing and signed by the waiving or consenting party
and then only in the instance and for the purpose for which it is given. 

  

	23.2	No failure or delay on the part of any party in exercising any right, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial
exercise of any such right, power or privilege preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 

  

	23.3	No breach of any provision of this Agreement shall be waived or discharged except with the express written consent of the Seller and the Buyer. 

  

	23.4	The rights and remedies herein provided are cumulative with and not exclusive of any rights or remedies provided by law. 

  

	23.5	No variation to this Agreement shall be effective unless made in writing and signed by all the parties. 

  

	24.	FURTHER ASSURANCE 

  

	24.1	At any time after Completion, the Seller shall at the Buyer’s expense execute all such documents and do or procure to be done such acts and things as the Buyer may from time to
time reasonably require for the purpose of vesting in the Buyer the Seller’s and the Seller’s Groups’ rights and interests in the Business and full legal and beneficial title to the Assets free from Encumbrance and giving to the Buyer
the full benefit of this Agreement and the other Transaction Documents. 

  

	24.2	 Each of the Seller and the Buyer covenants that it will give all assistance and accord every facility reasonably required by the Buyer’s Accountants, the
Seller’s 

  

 39 

	 	 
Accountants or any valuer or accountant appointed in accordance by the terms of this Agreement for the purposes of preparing any certificate, statement,
accounts or making any determination necessary or desirable for the purpose of this Agreement, and shall allow them or him access to any assets, accounts, books, records or other information relating to the Business held by the Buyer or the Seller.

  

	24.3	The terms of this Agreement shall, insofar as they are not performed at Completion and subject as specifically otherwise provided in this Agreement, continue in force after and
notwithstanding Completion. 

  

	25.	NOTICES 

  

	25.1	Any notice, demand or other communication given or made under or in connection with the matters contemplated by this Agreement shall be in writing and shall be delivered personally
or sent by confirmed fax, registered post, prepaid first-class post (air mail if posted to or from a place outside the United Kingdom) or courier service: 

  
 In the case of the Seller and the Seller’s Guarantor to: 
 Galen Holdings, Plc 
  
 Old Belfast Road 
 Millbrook 
 Larne 
 Northern Ireland BT40 2SH 

Fax:          02828 279448 
 Attention: Company Secretary 
  
 In the case of the Buyer to: 
 Old Belfast Road 
 Millbrook 
 Larne 
 Northern Ireland BT40 2SH 
 Fax:          to be determined by
the Completion Date 
 Attention: Company Secretary 
  

In the case of the Buyer’s Guarantor to: 
 General Counsel 
 Gambro BCT, Inc. 
 10810 W. Collins Avenue 
 Lakewood, CO 80215 
 Fax: 303-205-2519 
  
 and shall be deemed to have been duly given or made as follows: 
  

	 	(a)	if personally delivered, upon delivery at the address of the relevant party; 

  

 40 

	 	(b)	if sent by registered post or first class post within the United Kingdom, two business days after the date of posting as evidenced by postal receipt; 

  

	 	(d)	if sent by fax, when despatched as evidenced by the sender’s confirmation of deliver; and 

  

	 	(e)	if sent by courier, as of the time of delivery to the addressee; 

  
 provided that if, in accordance with the above provisions, any such notice, demand or other communication would otherwise be deemed to be given or made
after 5.00 p.m. on a business day, such notice, demand or other communication shall be deemed to be given or made at 9.00 a.m. on the next business day. 
  

	25.2	A party may notify the other party to this Agreement of a change to its name, relevant addressee, address or fax number for the purposes of Clause 25.1 provided that such
notification shall only be effective on: 

  

	 	(a)	the date specified in the notification as the date on which the change is to take place; or 

  

	 	(b)	if no date is specified or the date specified is less than five business days after the date on which notice is given, the date falling five business days after notice of any such
change has been given. 

  

	26.	COUNTERPARTS 

  
 This Agreement may be executed in any number of counterparts which together shall constitute one agreement. Any party may enter into this Agreement by
executing a counterpart and this Agreement shall not take effect until it has been executed by all parties. 
  

	27.	GOVERNING LAW AND JURISDICTION 

  

	27.1	This Agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of or in any way relating to this Agreement or its formation) shall be governed by
and construed in accordance with the laws of Northern Ireland. 

  

 41 

	27.2	Each of the parties to this Agreement irrevocably agrees that the courts of Northern Ireland shall have exclusive jurisdiction to hear and decide any suit, action or proceedings,
and/or to settle any disputes, which may arise out of or in connection with this Agreement (respectively, “Proceedings” and “Disputes”) and, for these purposes, each party irrevocably submits to the jurisdiction of the courts of
Northern Ireland. 

  

	27.3	Each party irrevocably waives any objection which it might at any time have to the courts of Northern Ireland being nominated as the forum to hear and decide any Proceedings and to
settle any Disputes and agrees not to claim that the courts of Northern Ireland are not a convenient or appropriate forum for any such Proceedings or Disputes and further irrevocably agrees that a judgment in any Proceedings or Disputes brought in
any court referred to in this Clause 27 shall be conclusive and binding upon the parties and may be enforced in the courts of any other jurisdiction. 

  

	27.4	Without prejudice to any other permitted mode of service the parties agree that service of any claim form, notice or other document (“Documents”) for the purpose of any
Proceedings begun in Northern Ireland shall be duly served upon it if delivered personally or sent by registered post, in the case of: 

  

	 	(a)	the Seller to its registered office (marked for the attention of the Company Secretary); 

  

	 	(b)	the Buyer to its registered office (marked for the attention of the Company Secretary) 

  

	 	(c)	the Buyer’s Guarantor to the General Counsel in Lakewood, Colorado 

  
 or such other person and address in the United Kingdom as a party shall notify the other parties in writing from time to time. 
  

	28.	INVALIDITY 

  
 If any provision of this Agreement is or becomes invalid, illegal or unenforceable in any respect under the law of any jurisdiction having a bona fide
interest in the provisions of this Agreement, such provision shall be modified to conform as closely as possible to the intent of the parties and: 
  

	 	(a)	the validity, legality and enforceability under the law of that jurisdiction of any other provision; and 

  

 42 

	 	(b)	the validity, legality and enforceability under the law of any other jurisdiction of that or any other provision 

  
 shall not be affected or impaired in any way. 
  

	29.	THIRD PARTY RIGHTS 

  
 The operation of the Contracts (Rights of Third Parties Act) 1999 is hereby excluded. 
  
 IN WITNESS whereof this Agreement has been executed by the authorized representatives of the parties or, where appropriate, as a deed to be
effective on the date first above written. 
  

 43 

  
 SCHEDULE 1 

 
 Allocation of Consideration 
  
 The Consideration payable pursuant to Clause 3.1 shall be apportioned among the Assets as
follows: 
  

			
	 	  	£

	 •      Goodwill
	  	1
	 •      Books and Records
	  	1
	 •      Contracts
	  	1
	 •      Business Intellectual Property
	  	1
	 •      Tangible Assets itemised in Schedule 3
	  	2,574,996

  

 44 

  
 SCHEDULE 2 

 
 WARRANTIES 
  
 PART A (GENERAL) 
  

	1.	CAPACITY 

  

	1.1	Powers and authority 

  
 The Seller has all requisite corporate power to enter into and perform this Agreement together with all other Transaction Documents and the transactions and matters contemplated thereby and has taken all necessary
action to authorise the entry into and performance of this Agreement, the other Transaction Documents and the transactions and matters contemplated thereby. This Agreement and all other Transaction Documents, when executed by the Seller, will
constitute valid, binding and enforceable obligations on the Seller and the Seller’s Guarantor in accordance with their respective terms and the Seller does not require the consent, approval or authority of any other person to enter into or
perform its obligations under this Agreement and its entry into and performance of this Agreement will not constitute any breach or default under any contractual, governmental or public obligation binding upon it and it is not engaged in any
litigation or arbitration proceedings which might have an effect upon its capacity or ability to perform its obligations under this Agreement and no such legal or arbitration proceedings have been threatened against it. 
  

	2.	ACCOUNTS 

  

	2.1	The Accounts 

  

	 	2.1.1 	comply with the provisions of The Companies (Northern Ireland) Order 1986 as applicable and have been prepared in accordance with the requirements of United Kingdom generally
accepted accounting principles and practices and give a true and fair view of all the assets and liabilities and of the state of affairs, financial position and results of the Seller as at and up to the Accounts Date; 

  

	 	2.1.2 	make adequate provision for depreciation of the Assets, having regard to the Assets’ original cost and estimated life. 

  

	2.2	Accounting policy 

  
 The Accounts have been prepared on a basis consistent with the basis upon which the audited accounts of the Seller were prepared for the financial period
ended 30 September 2002. 
  

 45 

	2.3	Accounting and other records 

  

	 	2.3.1 	All books, accounts and records required by law to be maintained in connection with the Business have at all times been fully, properly and accurately maintained and are properly
written up to date and will be so kept up to Completion, and all returns and payments for the purposes of VAT have been made. 

  

	 	2.3.2 	All such books, accounts and records referred to in paragraph 2.3.1 of this Schedule 2 Part A duly and accurately record all matters required by law to be entered therein and
accurately present and reflect in accordance with generally accepted accounting principles and standards all transactions entered into in relation to the Business. 

  

	2.4	Valuation of Stock 

  
 The accounting policies and bases and the method of valuing Stock used in the preparation of the Accounts were the same as those adopted in the accounts
of the Business for the period commencing 1 April 2002 and ending immediately preceding execution of this Agreement. Any slow-moving Stock and non-recoverable work-in-progress included in the Accounts were written down appropriately and any
redundant or obsolete Stock included in the Accounts were wholly written-off and the value attributed to the remaining Stock, and the raw material included in work-in-progress and finished Stock did not exceed the lower of cost and net realisable
value as at the Accounts Date. 
  

	2.5	Management Accounts 

  
 The Management Accounts have been properly prepared in accordance with good accounting practice and on a basis consistent with that previously adopted in
preparing the Accounts; the Management Accounts fairly state the trading performance and profitability for the period(s) to which they relate; and (save as expressly disclosed therein) there were no unusual, exceptional, non-recurring or
extraordinary items which materially affected such accounts. 
  

	3.	CHANGES SINCE THE ACCOUNTING DATE 

  
 Since the Accounts Date: 
  

	3.1	the Business has been carried on in the ordinary and usual course, both as regards the nature, scope and manner of conducting the same and so as to maintain the same as a going
concern; 

  

	3.2	the Business has paid its creditorswithin the times agreed with such creditors, and there are no debts currently outstanding that have been due for more than four (4) weeks;

  

 46 

	3.3	there has been no unusual change in the Stock levels of the Business; 

  

	3.4	the Business has not been adversely affected by the loss of or material reduction in orders from any customer or the loss of or material reduction in any source of supply or by any
abnormal factor not affecting similar businesses to a like extent and the Seller is not aware of any facts that are likely to give rise to any such material adverse effects; 

  

	3.5	except for usual and customary wage increases, no material alterations have been made in the terms of employment or conditions of service of any Assumed Employees or in the pension
or other benefits of any Assumed Employee or their dependents; 

  

	3.6	none of the Assets listed in Schedule 3 have been lost, damaged or destroyed; 

  

	3.7	there has been no material adverse change in the financial position or trading prospects of the Business nor so far as the Seller is aware is any such material change expected;

  

	3.8	so far as the Seller is aware no member of the Seller’s Group has done or omitted to do anything that might prejudicially affect the Goodwill. 

  

	4.	TITLE TO THE ASSETS 

  

	4.1	Except as disclosed in the Data Room or the Disclosure Letter, the Assets itemised in Schedule 3 together with the benefits accruing to the Buyer under the Lease and the Services
Agreement, are in the opinion of the Seller, in all material respects those necessary for the continuation of the Business as carried on at Completion. 

  

	4.2	All documents which in any way affect the right, title or interest of the Seller in or to any of the Assets and which attract stamp duty have been duly stamped within the requisite
period for stamping. 

  

 47 

	5.	LITIGATION 

  

	5.1	There are no litigation, arbitration, prosecution or other legal proceedings relating to the Business which are material to the Business which have been served on the Seller or the
Seller’s Group and, so far as the Seller is aware, there are no claims, facts or events subsisting at the date hereof which are likely to give rise to any such proceedings and there are no judgements outstanding against the Seller which affects
or may affect any of the Assets. 

  

	5.2	Details of all material customer claims, complaints or returns relating to the Business that have occurred during the twelve (12) months preceding the execution of this Agreement
have been disclosed in the Disclosure Letter or the Data Room. 

  

	6.	LICENCES 

  
 The Seller is not aware of any reason why any licences and permissions required for the carrying on of the Business should be suspended or revoked.

  

	7.	CONFIDENTIAL AGREEMENTS 

  

	7.1	Save as disclosed in the Disclosure Letter and so far as the Seller is aware no members of the Seller’s Group have entered into any confidentiality or other agreement which
restricts the free use or disclosure of any information used in the Business and prior to the date hereof, the Seller is not aware of breach of any such agreement. 

  

	7.2	The Seller has not been notified of any breach of any legislation, orders, provisions, directions and conditions relating to the Assets or the conduct of the Business which would
have a material adverse effect on the Business. 

  

	8.	EMPLOYEES 

  

	8.1	The particulars of the Assumed Employees as disclosed in the Data Room show all remuneration and other benefits which the Seller is bound to provide to each Assumed Employee.

  

	8.2	Since the Accounts Date, the Seller has not been engaged or involved in any material dispute with any Assumed Employee or any labour troubles involving the Business which are
material and, so far as the Seller is aware, no industrial action involving such employees, official or unofficial, exists at the date hereof. 

  

	8.3	 The Seller has disclosed to the Buyer in the Data Room true and complete copies of all contracts of employment and other documents relating to the employment of

  

 48 

	 	 
the Assumed Employees who are senior managers, directors or project managers and a sample contract of employment for all other employees.

  

	8.4	Neither the Seller nor any member of the Seller’s Group has made any offer to employ any person in the Business which has yet to be accepted or rejected.

  

	8.5	Details of persons who previously worked in the Business or are currently working in the Business who are on maternity leave or other leave of absence and are included as Assumed
Employees are fully and accurately disclosed in the Data Room. 

  

	8.6	Neither the Seller nor any member of the Seller’s Group has offered or agreed any future variations in the terms or conditions of employment of any of the Assumed Employees.

  

	8.7	All contracts of employment between the Seller and the Assumed Employees may be terminated by three months’ notice or less without giving rise to any claim for damages or
compensation. 

  

	8.8	Full particulars of any existing or threatened litigation or dispute involving or relating to any of the Assumed Employees and of all matters and circumstances of which the Seller
is aware which could give rise to any legal claim, right of action or other liability whatsoever in respect of any of them are disclosed in the Data Room. 

  

	8.9	With express reference to this warranty, full and up to date particulars of all collective agreements, arrangements and other understandings which the Seller or any member of the
Seller’s Group have with any trade union, staff association or other body representing the employees engaged in the Business are disclosed in the Data Room and the Seller has disclosed to the Buyer in the Data Room all documents relating to
such agreements, arrangements and understandings. The Seller has complied with all its obligations under Regulation 10 of the Transfer of Undertakings (Protection of Employment) Regulations 1981, the Collective Redundancies and Transfer of
Undertakings (Protection of Employment) (Amendment) Regulations 1995 and under the aforementioned collective agreements, arrangements and understandings and there is no existing or threatened litigation or dispute involving or relating to any trade
union, staff association or other body representing or willing to represent the said employees. 

  

	8.10	No notification of an intended application for Union Recognition under the Trade Union and Labour Relations (Northern Ireland) Order 1995 or under similar or related Northern
Ireland or U.K. legislation, including the Employment Relations Act 1999 has been received by the Seller. 

  

 49 

	8.11	The Seller is not aware of any disclosure or any application made to any relevant body under Public Interest Disclosure legislation in Great Britain or in Northern Ireland.

  

	8.12	There is no existing or, so far as the Seller is aware, threatened industrial action or trade dispute involving or relating to the Assumed Employees engaged in the Business.

  

	8.13	There are no existing or, so far as the Seller is aware, threatened enquiries or investigations involving or relating to the Business or the Assumed Employees by the Equality
Commission or other similar authority. 

  

	8.14	There are no outstanding liabilities for industrial training levy or for any other statutory or governmental levy or charge relating to the Business. 

  

	8.15	The Seller has complied with the Fair Employment and Treatment (Northern Ireland) Order 1998 (“the Fair Employment Order”) in all respects. 

  

	8.16	(a)    The Seller has registered with the Equality Commission in accordance with Article 48 of the Fair Employment Order; 

  

	 	(b)	The Seller has filed appropriate monitoring returns with the Equality Commission within the prescribed time-limits and the Equality Commission has not rejected these or required
further information; 

  

	 	(c)	The Seller has conducted a review of its employment practices within the last three years in accordance with Article 55 of the Fair Employment Order and has not been requested or
required to amend or change the review or the recommendations in any way by the Equality Commission; 

  

	 	(d)	The Seller maintains proper records of employees and applicants as required by the Fair Employment Order and the Seller has a proper system for ensuring that the information is not
misused in any way that contravenes the Fair Employment Order; 

  

	 	(e)	The Equality Commission has not made any recommendation, direction or notice under Articles 56-61 of the Fair Employment Order to the Seller; 

  

	 	(f)	The Seller is not in default nor an unqualified person as defined in Article 62 of the Fair Employment Order; 

  

	 	(g)	The Seller has not received any notification from the Equality Commission or elsewhere that any of its suppliers is an unqualified person as defined by Article 62 of the Fair
Employment Order; 

  

 50 

	 	(h)	The Seller has not been notified by the Equality Commission of any complaint made against it to the Fair Employment Tribunal or an Industrial Tribunal within the last twelve months,
no questionnaire has been issued to the Seller in accordance with the Fair Employment Order or other discrimination legislation including the Sex Discrimination (NI) Order 1976, the Race Relations (NI) Order 1997 or the Disability Act within the
last twelve months and there is no case outstanding with the Fair Employment Tribunal or Industrial Tribunal in which the Seller is involved or on appeal from it. 

  

	8.17	The Seller is not aware of any actual, threatened or potential claim to be made against it or any member of the Seller Group arising out of the provisions in respect of goods,
services and facilities contained in the Fair Employment and Treatment (Northern Ireland) Order 1998, the Race Relations (Northern Ireland) Order 1997, the Sex Discrimination (Northern Ireland) Order 1976 or the Disability Act.

  

	8.18	The Seller has disclosed in the Data Room and in the Disclosure Letter all arrangements and obligations in relation to the Assumed Employees. 

  

	9.	THE CONTRACTS 

  

	9.1	Ultra Vires 

  
 None of the Contracts are ultra vires the Seller or any member of the Seller’s Group. 
  

	9.2	Full Force 

  
 To the best of the knowledge of any member of Seller’s Group after due and proper enquiry, all the Contracts are in full force and effect and have been duly complied with and nothing has occurred whereby any of
the Contracts are or are likely to be subject to early termination or which has given or is likely to give rise to any claim under any of them by any party to any of them which is material to the Business. 
  

	9.3	Nature of the Contracts 

  
 The contracts to which the Seller or Seller’s Group is a party which have been disclosed include, to the best of the Seller’s knowledge after
due and proper enquiry, any contract which: 
  

	 	(a)	was entered into otherwise than in the ordinary and usual course of the Business; 

  

 51 

	 	(b)	is of an unusual or abnormal nature, or not fully on an arm’s length basis; 

  

	 	(c)	is of a loss-making nature (that is to say the contract is of a nature where the selling price received, after any normal discounts or rebates, is less than the total of (i) direct
material costs, (ii) direct packaging material costs and (iii) direct labour costs associated with providing any such product or service to a customer of the Business,; 

  

	 	(d)	cannot readily be fulfilled or performed by the Seller or the Seller’s Group on time without exceptional expenditure of money; or 

  

	 	(e)	is of a long term nature (that is to say is for a fixed term of more than six months or incapable of performance in accordance with its terms within six months after the date on
which it was entered into or undertaken); 

  

	 	(f)	is incapable of termination in accordance with its terms by the Seller on sixty (60) days’ notice or less 

  

	 	(g)	involves payment by the Seller by reference to fluctuations in the index of retail prices or any other index or in the rate of exchange for any currency; 

 

	 	(h)	involves the supply of goods the aggregate sales value of which will represent in excess of 10 per cent of the anticipated turnover of the Business in the twelve (12) months
following Completion. 

  

	10.	EFFECT OF AGREEMENT 

  

	10.1	So far as the Seller or any member of the Seller’s Group is aware, the execution and delivery of this Agreement and the fulfillment and performance of and compliance with the
terms of this Agreement: 

  

	 	(a)	do not conflict with or violate the terms, provisions or conditions of any of the Contracts or any law, undertaking, judgment, order, injunction or decree of any court against the
Seller’s Group; 

  

	 	(b)	do not entitle any person to terminate any existing contractual obligation. 

  

	10.2	The Seller nor any of the Seller’s Group is not aware of any intention of any significant customer of or supplier to the Business to cease in dealing or to substantially reduce
the existing level of its dealings with the Business. 

  

 52 

	11.	INFORMATION SUPPLIED 

  

	11.1	All information contained in this Agreement and all matters contained in the Disclosure Letter and all other information relating to the Business given by the Seller or the
Seller’s Solicitors to the Buyer or the Buyer’s Solicitors are true, accurate and complete in all material respects. 

  

	11.2	There is no fact or matter relating to the Business which is known to the Seller or any member of the Seller’s Group which has not been disclosed in the Disclosure Letter or
the Data Room and the Seller is not aware of any matter which renders any such matters or information untrue, incomplete or misleading. 

  

	12.	LOOSE PLANT 

  
 The Loose Plant is adequate for and fit for the purpose of carrying on the Business and is in reasonably good repair and condition and working order and
has been regularly maintained and is used exclusively in connection with the Business. 
  

	13.	STOCK 

  
 The Stock is fit for purpose and of merchantable quality; and is capable of being used effectively in the ordinary course of business; and the
work-in-progress of the Business is at its normal level. 
  

	14.	INSURANCE 

  

	14.1	All the Assets and the Property are and at all times prior to Completion will be insured to their full replacement or reinstatement value in accordance with the details disclosed in
the Data Room. 

  

	14.2	So far as the Seller or any member of the Seller’s Group is aware, there are no outstanding claims or circumstances likely to give rise to a claim thereunder and, so far as the
Seller or any member of the Seller’s Group is aware, nothing has been done or omitted to be done which has made or could make any policy of insurance void or voidable or whereby its renewal may be refused or its premiums are likely to be
increased. 

  

	14.3	So far as the Seller or any member of the Seller’s Group is aware, none of the such policies of insurance is subject to any special or unusual terms or restrictions.

  

 53 

	15.	STATUTORY RESTRICTIONS 

  

	15.1	The Seller has, so far as the Seller or any member of the Seller’s Group is aware, not committed or omitted to do any act or thing in relation to the Business which could give
rise to any fine or penalty. 

  

	15.2	The Seller is not and has not been a party in relation to the Business to any agreement, practice or arrangement which in whole or in part: 

  

	 	15.2.1 	contravenes any of the provisions of the Restrictive Trade Practices Acts 1976 and 1977 (or is subject to registration under those Acts), the Resale Prices Act 1976, the Trade
Descriptions Acts 1968 and 1972, the Fair Trading Act 1973, the Competition Act 1980 or the Competition Act 1998 (or is notifiable under such Act); 

  

	 	15.2.2 	contravenes any of the provisions of the European Communities Act 1972 or Articles 85 or 86 of the EC Treaty (or any regulations or directives made pursuant to the Treaty) or the
EEA Agreement; or 

  

	 	15.2.3 	contravenes any other anti-trust, anti-monopoly or anti-cartel legislation or consumer law, Act, Regulation, Order or the like made in or pertaining to the United Kingdom or other
relevant territory. 

  

	15.3	The Seller is not and has not engaged in any anti-competitive practice, as defined in the Competition Act 1980, in relation to the Business. 

  

	15.4	No investigations or enquiries by or on behalf of any governmental or other body in respect of the Seller, the Business or any of the Assets are pending or in existence and the
Business is not subject to any undertaking or order under United Kingdom or EC competition legislation or from any other regulatory body under the competition legislation in any other jurisdiction in which the Business is conducted.

  

	15.5	So far as the Seller or any member of the Seller’s Group is aware, neither the Seller nor any of its officers, agents or employees has done or omitted to do any act or thing
which is or could be in contravention or breach of or the subject of enquiry, investigation or proceedings under the provisions of any Act, Order, Regulation or the like whether made in or pertaining to the United Kingdom or elsewhere giving rise to
any fine, penalty, default, proceedings or other such liability in relation to the Business or any of the Assets. 

  

	16.	DEFECTIVE PRODUCTS/ SERVICES 

  
 There are no outstanding claims against the Seller in respect of defects in quality or delays in delivery or completion of contracts or deficiencies of
design or performance of equipment or otherwise relating to liability for goods or services 

  

 54 

 
supplied or to be supplied by the Seller and, so far as the Seller or any member of the Seller’s Group is aware, no such claims are threatened or
anticipated. 
  

	17.	INSOLVENCY OF SELLER 

  

	17.1	No order has been made or petition presented, meeting convened or resolution passed for the winding up of the Seller nor has any receiver been appointed or any distress, execution
or other process been levied in respect of the Business or the Assets or any of them. 

  

	17.2	No composition in satisfaction of the debts of the Seller or scheme of arrangement of its affairs or compromise or arrangement between it and either or both of its creditors or
members or any class of either or both of its creditors or members has been proposed, sanctioned or approved. 

  

	17.3	No distress, distraint, charging order, garnishee order, execution or other process has been levied or applied for in respect of the whole or any part of the Business or the Assets.

  

	17.4	No event has occurred causing, or which upon intervention or notice by any third party may cause, any floating charge created by the Seller to crystallise over the Business or the
Assets or any of them or any charge created by it to become enforceable over the Business or the Assets or any of them nor has any such crystallisation occurred nor is such enforcement in process. 

  

	18.	COMPLIANCE 

  

	18.1	So far as the Seller or any member of the Seller’s Group is aware, all legislation and all orders, provisions, directions and conditions relating to the Assets or the conduct
of the Business (including VAT) have been duly complied with in all respects. 

  

	18.2	So far as the Seller or any member of the Seller’s Group is aware, all necessary licences, consents, permits, agreements, arrangements and authorities (public and private) have
been, or are being, obtained to enable the Seller to carry on the Business effectively in the manner in which it is now carried on and all such licences, consents, permits, agreements, arrangements and authorities are valid and subsisting and the
Seller knows of no reason why any of them should be suspended, cancelled or revoked or the benefit of them should not continue to be enjoyed by the Buyer or other owners for the time being of the Business and the Assets or any part of them.

  

 55 

  
 SCHEDULE 2 

 
 PART B 
  
 INTELLECTUAL PROPERTY 
  

For the purposes of this Part B of Schedule 2, any reference to “Business Intellectual Property” shall include a reference to “IP Licences”.

  

	1.	Full details of all the Business Intellectual Property are disclosed in the Data Room which is complete and accurate in all material respects. All such Business Intellectual
Property is used, enjoyed and exploited exclusively in connection with the Business. 

  

	2.	Save in respect of any Business Intellectual Property which is the subject of a valid and enforceable IP Licence which has been granted to the Seller (details of which are disclosed
in the Data Room, the Seller is the sole legal and beneficial owner of all Business Intellectual Property (including the subject matter thereof) free from all claims, liens, charges, equities, encumbrances, licences and adverse rights of any
description. No Business Intellectual Property is held jointly or in common with any other person. 

  

	3.	None of the Business Intellectual Property is subject to any challenge or attack by a third party or competent authority. All renewal and registration fees for the protection of the
registered Business Intellectual Property have been paid. 

  

	4.	Accurate and complete particulars of all IP Licences are disclosed in the Data Room. All such IP Licences are valid and enforceable. There are no other outstanding agreements or
arrangements whereby a licence, sub-licence or other permission to use has been granted to or by, or is obliged to be granted to or by, the Seller in respect of any of the Business Intellectual Property owned or used by the Seller, save for those
licences or agreements set out in Schedule 12. 

  

	5.	Neither the Seller nor, so far as the Seller or any member of the Seller’s Group is aware, is any other party is in breach of any IP Licence and all such licences are in full
force and effect and will not terminate or be capable of termination by reason of the execution and performance of this Agreement. 

  

	6.	 So far as the Seller or any member of the Seller’s Group is aware, none of the activities involved in the conduct of the Business infringe or have infringed
any intellectual property of third parties or constitute or have constituted breach of confidence, passing off or actionable unfair competition in any jurisdiction. No 

  

 56 

	 	 
such activities give or have given rise to any obligation to pay any royalty, fee, compensation or any other sum whatsoever. 

  

	7.	The Seller is not, and has not within the six years preceding the date of this Agreement, been party to or threatened with any legal proceedings relating to any Business
Intellectual Property and the Seller is not aware of (and has not knowingly acquiesced in) any infringement of the Business Intellectual Property or any breach of confidence, passing off or actionable unfair competition in any jurisdiction in
relation to the Seller or the Business. 

  

	8.	The Seller has in its exclusive possession and control all Business Information used, enjoyed or exploited in the Business (or held with a view to such use, enjoyment or
exploitation). None of the same is known or accessible to any person except the Seller, other than persons who have given the Seller written confidentiality undertakings in respect thereof that have been disclosed hereunder.

  

	9.	Save in the ordinary course of business or with its employees, the Seller has not entered into any confidentiality or other agreement, nor is subject to any duty, which restricts
the free use or disclosure of such information as is referred to in paragraph 8 above. 

  

	10.	There are no outstanding or potential claims against the Seller under any contract or under section 40 of the Patents Act 1977 for employee compensation in respect of any
Intellectual Property. 

  

	11.	Where information of a confidential nature has been developed or acquired by the Seller or any member of the Seller’s Group for the purposes of the Business in the five-year
period prior to the date of this Agreement, such information (except insofar as it has fallen into the public domain through no fault of the Seller or any member of the Seller’s Group) has been kept strictly confidential and has not been
disclosed otherwise than subject to an obligation of confidentiality being imposed on the person to whom the information was disclosed. The Seller is not aware of any breach of such confidentiality obligations by any third party.

  

 57 

  
 SCHEDULE 2 

 
 PART C 
  
 PENSIONS 
  

	1.	Other than disclosed in the Data Room there are no agreements, arrangements, customs or practices (whether legally enforceable or not) for the payment of or contribution to any
superannuation, pension, life assurance, death benefit, sickness or accident benefits schemes or arrangements in respect of the Assumed Employees or their dependants and no proposal to establish any such scheme or arrangement has been announced to
the Assumed Employees. 

  

	2.	As regards the Seller’s Scheme (which term, for purposes of this Schedule 2, Part C, is intended to mean the pension scheme offered by Seller for which Assumed Employees are
eligible), full and accurate details of the Scheme have been disclosed as set out below: 

  

	 	2.1	copies of all current Trust Deeds and Rules governing the Seller’s Scheme; and 

  

	 	2.2	copies of the current Member’s Handbook and any announcement to Members which has not yet been incorporated into the handbook; 

  

	3.	Full details of the Assumed Employees who are members of the Seller’s Scheme are disclosed in the Data Room and no other Assumed Employees are or will before Completion become
members of the Seller’s Scheme. 

  

	4.	All contributions due to be paid in respect of the Seller’s Scheme by the Seller and any of its officers or employees have been duly paid, and the rates at which contributions
are being paid are in accordance with the advice contained in the latest actuarial report of the Seller’s Scheme. 

  

	5.	The only participating employee in the Standard Life Occupational Pension Scheme is James McKelvey and all contributions due to be paid in respect of this scheme have been paid in
full. 

  

	6.	The Seller’s Scheme is an exempt approved scheme within the meaning of section 592 of the Income and Corporation Taxes Act 1988 and there is no reason why approval may be
withdrawn. 

  

 58 

	7.	The Seller’s Scheme is a contracted-out scheme within the meaning of the Pension Schemes (NI) Act 1993 and there is in force a contracting-out certificate covering the Seller
and there is no reason why the certificate should be cancelled. 

  

	8.	All death in service and incapacity benefits provided by the scheme are fully insured and all insurance premiums due to be paid in respect of the Seller’s Scheme have been duly
paid. 

  

	9.	No power has been exercised to provide additional benefits in respect of any of the Assumed Employees or to admit any of the Assumed Employees on special terms.

  

	10.	There are no actions, proceedings or claims (other than routine claims for benefits) outstanding, pending or threatened by the Assumed Employees in respect of the Seller’s
Scheme relating to any act, event, omission or other matter arising out of or in connection with the Seller’s Scheme. 

  

	11.	The Seller’s Scheme has, so far as the Seller is aware, at all times complied with and been administered in accordance with all applicable laws, regulations and requirements
(including without limitation those of the Board of the Inland Revenue and of trust law). 

  

 59 

  
 SCHEDULE 2 

 
 PART D 
  
 PROPERTY 
  

	1.	In relation to the Lease, VAT is not currently chargeable on the rent or any other payment to be made under the Lease and no election has been made to date by Seller to waive
exemption from VAT in respect of the lease. 

  

	2.	The Seller has not received written notice of and is not aware of any allegation of breach of the requirements of: 

  
 the Clean Air (NI) Order 1981 
 the Construction (Design and Management) Regulations (NI) 1995 SR 209. 
 the Factories Act (NI) 1965 
 the Offices and Shop Premises Act (NI) 1966 
 the Fire Services (NI) Order 1984 
 the Health
and Safety at Work etc. (NI) Order 1978 
 the Pollution Control and Local Government (NI) Order 1978 
 the Environmental Protection Act 1990 
 the
Waste and Contaminated Land (NI) Order 1997 
 the Industrial Pollution Control (NI) Order 1997 
 the Food and Environmental Protection Act 1985 
 the Planning (NI) Order 1991 
 the Water and Sewerage Services (NI) Order 1973 (as amended) 
 the Water (NI) Order 1999 
 the Radioactive
Substances Act 1993 or 
 the Public Health Acts 
  
 or other legislation concerning health, safety or environmental matters or any regulations, orders, notices or directions made under any of such
legislation which in any such case affect any of the Property. 
  

	3.	Where required, a fire certificate has been issued in respect of the Property. 

  

	4.	So far as the Seller or any member of the Seller’s Group is aware (and without having obtained a survey thereof) there are (and there have been) no structural or other defects
in respect of the buildings and structures on or comprising any of the Property. 

  

	5.	The Seller, as the landlord, has good title to grant the Lease; 

  

	6.	 So far as the Seller is aware, no written notices of breaches of any covenants or conditions have been received by the Seller from the landlords of the Superior
Leases 

  

 60 

	 	 
nor have the landlords of the Superior Leases refused to accept the rent payable pursuant to the Superior Leases (if demanded); 

 

	7.	“The Superior Leases” shall mean a lease dated 30th November 1990 between the Department of Economic Development (1) and the Lessor (2) as comprised in Folio AN22184L County Antrim and a lease dated 21st May 1998 between the Department of Economic Development (1) and Galen Limited (2) (whose interest is now vested in the Lessor) as comprised in Folio AN46925L
County Antrim copies of which leases have been provided to the Lessee prior to the execution of this Lease; 

  

	8.	So far as the Seller is aware, the Property complies in all respects with current fire regulations and the current requirements of the insurers of the Property; and

  

	9.	So far as the Seller is aware, and without having obtained any survey there are no latent or patent defects in the buildings and structures on or comprising the Property and the
Seller has not received any notice regarding or relating to any material used in the construction of the buildings and its structures on or comprising the Property. 

  

 61 

  
 SCHEDULE 2 

 
 PART E 
  
 TAXATION 
  

	1.	The Seller is not involved in any dispute with the Inland Revenue, Customs & Excise or other appropriate fiscal authority concerning any matter in any way affecting either the
Business or any of the Assets to be transferred under this Agreement. 

  

	2.	No circumstances exist whereby any power within section 212 of the Inheritance Tax Act 1984 could be exercised in relation to any of the Assets. 

  

	3.	There is no Inland Revenue charge over any of the Assets outstanding for unpaid inheritance tax as provided by sections 237 and 238 of the Inheritance Tax Act 1984.

  

	4.	None of the Assets are or could be subject to the Value Added Tax Capital Goods Scheme provided for in Part XV of the Value Added Tax Regulations 1995 (SI 1995/2518).

  

	5.	Neither the Seller (nor any relevant associate as defined in Schedule 10 of the Value Added Tax Act 1994) has elected to waive exemption (or applied for written permission to elect)
in accordance with that Schedule in relation to the Property (or any of the Assets which constitute an interest in or right over land). 

  

	6.	None of the Assets are chargeable assets of a business which, if transferred to a body corporate treated as a member of a group under section 43 of the Value Added Tax Act 1994 as a
going concern, would give rise to a liability on that body corporate or the representative member of the group of which that body corporate is a member under section 44 of the Value Added Tax Act 1994. 

  

	7.	There is no reason why any part of the Consideration payable by the Buyer that is apportioned under this Agreement to those of the Assets which are plant or machinery for the
purposes of Part 2 of the Capital Allowances Act 2001 should not, assuming such apportioned Consideration represents capital expenditure incurred for the purposes of the Buyer’s trade, qualify in full for writing down allowances; none of such
Assets are leased (as in the meaning of section 67 of such Act); and the Seller accepts that no election may be made in respect of any of such Assets pursuant to section 267 of such Act. 

  

 62 

	8.	In respect of any Assets which are plant and machinery for the purposes of Part 2 of the Capital Allowances Act 2001 and which are fixtures (as defined in section 173(1) of the
Capital Allowances Act 2001) at Completion either (a) no person has been or will have become entitled to allowances in respect of any Expenditure incurred on the provision of the fixture, or (b) if any person has become so entitled that person has
been, is or will be required to bring the disposal value of the fixture into account under section 24 of the Capital Allowances Act otherwise than by virtue of subsection (7) of section 6.1. 

  

	9.	None of the Contracts, other than any relating to the acquisition of the Assets, involve any future liabilities which when incurred will not be deductible in computing profits for
corporation tax purposes. 

  

	10.	The Inland Revenue has not agreed to operate any special arrangement (being an arrangement which is not based on a strict application of the relevant legislation) in relation to the
Business, whether in respect of benefits provided to its officers or employees, the valuation of its stock, the depreciation of its assets or any administrative or other matter whatsoever. 

  

	11.	None of the Assets are wasting assets within section 44 of the Taxation of Chargeable Gains Act 1992 which do not qualify for capital allowances. 

  

	12.	All documents in the possession or under the control of the Seller which establish or are necessary to establish the title of the Seller to the Assets have been duly stamped and any
applicable stamp duties or charges in respect of such documents have been duly accounted for and paid, and no such documents which are outside the United Kingdom would attract stamp duty if they were brought in to the United Kingdom.

  

 63 

  
 SCHEDULE 2 

 
 PART F 
  
 ENVIRONMENTAL AND HEALTH AND SAFETY 
  

	1.	Interpretation 

  
 In this Schedule: 
  

			
	          “Environment”
	  	means all or any of the air, water and land including air within buildings and other material or man-made structures above or below the ground;
		
	          “Environmental Laws”
	  	means all laws, regulations, codes of practice, common law, regulations, directives and other measures imposed by any relevant body to which the Business or the Property is or has been
subject in so far as they relate to the pollution or protection of the Environment or the protection of the health of humans, animals or plants;
		
	          “Environmental Licences”
	  	means any permits, licences, consents or other authorisations required under any Environmental Laws for the operation of the Business and the occupation or use of the
Property;
		
	          “Hazardous Substances”
	  	means any material or artificial substance capable of causing Harm to man or any other living organism or the Environment;
		
	          “Harm”
	  	means harm to the health of living organisms or the Environment, and in the case of human beings, includes harm to his property; “harmful” has a corresponding
meaning;
		
	          “Health and Safety Laws”
	  	means all applicable statutes, statutory legislation, common law, treaties, regulations, directives, codes of practice, guidance notes including but without limitation the Factories Act 1961,
the Offices, Shops and Railway Premises Act 1963, the Fire Precautions Act 1971, the Health and Safety at Work etc. Act 1974 and the Construction (Design and Management) Regulations 1994 concerning the health and safety of those who work for the
Business, whether as employees or otherwise, visit the Property or are in any way affected by the activities of the Business or by persons working for the Business.

  

 64 

	2.	Environmental Warranties 

  

	2.1	So far as the Seller or any member of the Seller’s Group is aware, the Seller has obtained and complied at all times with all Environmental Licences which are in full force and
effect and there are no facts or circumstances which may lead to revocation, suspension, variation or non-renewal of such Environmental Licences. 

  

	2.2	The Business has at all times been operated in compliance with Environmental Laws and the Business and the Property comply with all conditions, limitations, obligations,
prohibitions and requirements contained in any Environmental Laws and there are no facts or circumstances which may lead to any breach of Environmental Laws. 

  

	2.3	All information provided by and on behalf of the Seller to any statutory authority and all records and data required to be maintained by the Seller under the provisions of any
Environmental Laws regarding the operation of the Business or any processes carried on at or emissions, discharges or waste disposal from the Property is complete and accurate. 

  

	2.4	No Hazardous Substances have been emitted from the Property. 

  

	2.5	There have been no claims, investigations or other proceedings against or threatened against the Seller or any of its directors, officers or employees in respect of Harm to the
Environment caused by the operation of the Business or occupation of the Property, under Environmental Laws or for any other breach or alleged breach of any Environmental Licence and there are no facts or circumstances which may lead to any such
claims, investigations or proceedings. 

  

	2.6	The Seller has adequate environmental insurance cover having regard to the operation of the Business. No claims have been made or are contemplated under such insurance policies.

  

	2.7	There have been no landfills, underground storage tanks or mining operations (whether permitted by Environmental Laws or otherwise) carried out at the Property and no such
operations are proposed by the Seller. 

  

	2.8	The Seller has never been required to hold nor has the Seller held or applied for a waste disposal licence or waste management licence under any Environmental Laws in respect of the
Business or Property. 

  

 65 

	2.9	Copies of all current environmental audit reports and assessments, assessment on substances hazardous to health obtained by the Seller, correspondence between the Seller and any
relevant enforcement authority, copies or details of any waste disposal contracts to which the Seller is a party have been disclosed to the Buyer in the Data Room. 

  

	3.	Health and Safety Warranties 

  

	3.1	So far as the Seller or any member of the Seller’s Group is aware, the Busineass complies with all conditions, limitations, obligations, prohibitions and requirements contained
in any Health and Safety Laws and there are no facts or circumstances which will result in any breach of any Health and Safety Laws in respect of the Business. 

  

	3.2	The Seller has carried out all necessary risk assessments in respect of the Business as specified under the Health and Safety Laws and the current results of any such assessments
and any review of such assessments have been considered by the Seller in giving these warranties. The Seller has disclosed all the facts and circumstances which were taken into account in preparing any such assessment. 

  

	3.3	A list of all current health and safety policy statements prepared by the Seller, health and safety reports and assessments prepared by or for the Seller or any member of the
Seller’s Group, audits, records of accidents and reportable diseases, permits, notifications, certificates and records required by Health and Safety Laws to be prepared by or for the Seller or any member of the Seller’s Group, together
with any correspondence for the period from the Accounts Date to the date of this Agreement between the Seller and any relevant enforcement authority, including but not limited to the Health and Safety Executive and the relevant local authority, has
been disclosed to the Buyer in the Data Room; and any such documentation created by or delivered to Seller prior to the Completion Date will be disclosed to the Buyer immediately. 

  

	3.4	No correspondence has been received by the Seller from any occupier, employee, contractor, trade union, staff organisation, local authority or statutory official that the Property
suffers from defects in design, construction or fitting out which adversely affects the health of people working at or visiting the Property. 

  

	3.5	The Seller has not received any prohibition or improvement notices from any enforcement body, including but without limitation the Health and Safety Executive and the relevant local
authority, with regard to breaches of Health and Safety Laws or otherwise in respect of the Business or any other activities of the Seller on the Property. 

  

 66 

	3.6	There have been no claims, proceedings or, to the Seller’s knowledge, investigations against or threatened against the Seller or any of its directors, officers or employees in
respect of accidents, injuries, illness, disease or any other harm to the health and safety of employees, contractors or any other persons caused by breaches of Health and Safety Laws or otherwise in respect of the Business or other activities of
the Seller on the Property; and, so far as Seller or Seller’s Group is aware, there are no facts or circumstances that may lead to any such claims, proceedings or investigations. 

  

	3.7	The Seller has adequate employer’s liability and public liability insurance cover having regard to the activities carried out by the Business or otherwise on the Property. No
claims in respect of health and safety have been made against the Seller. 

  

	3.8	All information provided by and on behalf of the Seller to any statutory authority and all records and data required to be maintained by the Seller under the provisions of any
Health and Safety Laws in respect of the Business are complete and accurate. 

  

 67 

  
 SCHEDULE 3 

 
 Loose Plant 
  
 Total value £ 2,574,996 
  

					
	Plant No.

	  	 Description

	  	 Location

	911	  	Well water press unit	  	Boiler House
	935	  	Schubert filler	  	Fill Room 2
	960	  	Hot foil printer atlas	  	Print Room 3
	961	  	Hot foil printer PB & E ST25	  	Print Room 1
	962	  	Hot foil printer PB & E SK25	  	Print Room 2
	992	  	Bassaire filter	  	Fill Room 1
	993	  	Bassaire filter	  	Fill Room 1
	994	  	Bassaire filter	  	Fill Room 2
	999	  	Multivac AG800	  	Packing Room 4
	9001	  	Saxon sealer	  	Inspection Room 3
	9012	  	3 - head filler	  	Fill Room 3
	9013	  	Multivac R530 no.1	  	Packing Room 1
	9015	  	Busch R5 vacuum pump	  	Ivex Mezzanine
	9016	  	Bassaire filter	  	Fill Room 3
	9017	  	Bassaire filter	  	Fill Room 3
	9018	  	Bassaire filter	  	Fill Room 1
	9019	  	Bassaire filter	  	Fill Room 1
	9020	  	3 - head filler	  	Fill Room 3
	9021	  	3 - head filler	  	Fill Room 1
	9022	  	3 - head filler	  	Fill Room 1
	9024	  	3 - head filler	  	Fill Room 2
	9025	  	3 - head filler	  	Fill Room 3
	9026	  	3 - head filler	  	Fill Room 3
	9027	  	3 - head filler	  	Fill Room 1
	9038	  	Ponzini still	  	Still Room
	9040	  	Demin system	  	Demin Room
	9041	  	Steam generator	  	Steam Room
	9042	  	3 - head filler	  	Fill Room 3
	9043	  	3 - head filler	  	Fill Room 2
	9044	  	3 - head filler	  	Fill Room 3
	9045	  	3 - head filler	  	Fill Room 1
	9046	  	3 - head filler	  	Fill Room 3
	9049	  	Steam header	  	Steam Room
	9050	  	Sec Autoclave no.1	  	Sterilizer Compound
	9051	  	WFI loop and storage vessel	  	WFI Loop
	9052	  	Tanks T1a & T1b & filler line	  	Compound Room
	9053	  	Tanks T2a & T2b & filler line	  	Compound Room
	9054	  	Tanks T3 & filler line	  	Compound Room
	9055	  	Chiller unit	  	WFI Loop
	9056	  	Fill Room No. 2 static conveyor	  	Fill Room 2
	9058	  	Inspection room no.2 conveyor	  	Inspection Room 2
	9059	  	Inspection room 3 conveyor	  	Inspection Room 3
	9061	  	Fill room no. 1 stand conveyor	  	Fill Room 1
	9066	  	Hot foil printer atlas	  	Print Room 3
	9068	  	3 - head filler	  	Fill Room 1
	9069	  	Inspection room no.1 conveyor	  	Inspection Room 1

  

 68 

					
	9088	  	Multivac R530 no.3	  	Packing Room 3
	9089	  	Busch R5 vacuum pump	  	Ivex Mezzanine
	9090	  	Fill room 3 outlet conveyor	  	Fill Room 3
	9091	  	Multivac no.3 conveyor	  	Packing Room 3
	9124	  	Fill Room 3 stand conveyor	  	Fill Room 3
	9126	  	Tank T4a and filler line	  	Tank T4A Mix Room
	9127	  	3 – head filler	  	Fill Room 1
	9128	  	3 – head filler	  	Fill Room 2
	9129	  	3 – head filler	  	Fill Room 3
	9130	  	3 – head filler	  	Fill Room 1
	9131	  	3 – head filler	  	Fill Room 1
	9132	  	3 – head filler	  	Fill Room 2
	9134	  	Bassaire filter	  	Fill Room 3
	9135	  	Bassaire filter	  	Fill Room 3
	9136	  	Bassaire filter	  	Fill Room 2
	9137	  	Bassaire filter	  	Fill Room 2
	9138	  	Blissmatic case erector	  	Box Room
	9140	  	Fill room 2 mobile conveyor	  	Fill Room 2
	9141	  	Bassaire filter	  	Fill Room 2
	9142	  	3 – head filler	  	Fill Room 3
	9143	  	3 – head filler	  	Fill Room 3
	9145	  	Multivac R530 no.2	  	Packing Room 2
	9146	  	Busch R5 vacuum pump	  	Ivex Mezzanine
	9147	  	Fill Room 1 Swan neck conveyor	  	Fill Room 1
	9148	  	Multivac no.1 conveyor	  	Packing Room 1
	9150	  	Sec Autoclave no.2	  	Sterilizer Compound
	9151	  	LPHA 55320 Vacuum Pump No.1	  	Still Room
	9157	  	Sec Autoclave no.3	  	Sterilizer Compound
	9158	  	3 – head filler	  	Fill Room 2
	9159	  	3 – head filler	  	Fill Room 2
	9160	  	3 – head filler	  	Fill Room 2
	9161	  	3 – head filler	  	Fill Room 2
	9162	  	Model proteus labelling system	  	Inspection Area
	9163	  	Autoclave trolleys	  	Sterilizer Compound
	9166	  	Print Blocks	  	Entire Facility
	9173	  	Polyfuser Bassaire Filter No.1	  	Fill Room 2
	9174	  	Polyfuser Bassaire Filter No.2	  	Fill Room 2
	9175	  	SEC Autoclave No.4	  	Sterilizer Compound
	9176	  	Getinge-Kemiterm Still	  	Still Room
	9177	  	Washing Machine No.1	  	Laundry
	9178	  	Washing Machine No.1	  	Laundry
	9179	  	Tumble Dryer No.1	  	Laundry
	9180	  	Tumble Dryer No.1	  	Laundry
	9185	  	LTE Stability Room 2	  	Warehouse
	9186	  	LTE Stability Room 3	  	Warehouse
	9187	  	Cerberus B vial filler and capper	  	Sterility Test Room
	9188	  	PBE Hot Foil Printer	  	Print Room 2
	9189	  	PBE Hot Foil Printer	  	Print Room 1
	9193	  	Hand Sealer No.1	  	Inspection Room 1
	9195	  	LPHA 55320 Vacuum Pump No.2	  	Still Room
	 	  	Counterbalance forklift Toyota 3FB15-53301	  	Main facility
	 	  	Box Van DKZ 7314	  	Main facility
	 	  	Lorry IJI 1438	  	Main facility
	000734	  	Degasser	  	Chemistry Lab

  

 69 

 Computer assets to be transferred 
  

			
	 Software Description

	  	Quantity

	 Microsoft Office 2000 Standard
	  	35
	 Microsoft Windows 2000 Server CAL
	  	30
	 Microsoft Exchange 2000 CAL
	  	30
	 Microsoft System Management Server CAL
	  	30
	 eTrust AntiVirus Licenses
	  	35
	 Esker Tun
	  	10
	 Microsoft Project 2000
	  	5
	 Valprobe
	  	3
	 Microsoft Windows 2000 Professional
	  	30
	 Microsoft Access 2000
	  	5
	 Avery Label Pro
	  	1
	 Astrow
	  	1
	 OPW
	  	1
	 Windows NT Workstation
	  	5
	 Millennium
	  	5

  
 Plus additional six
(6) scanned pages below 
  

 70 

 Instrument Log Numbers 
  

					
	IVEX NUMBER

	  	 EQUIPMENT

	  	 LOCATION

	1	  	DIONEX AS40 AUTOMATED SAMPLER 97090436	  	CHEMISTRY LAB
	2	  	DIONEX INJECTOR 97090195	  	CHEMISTRY LAB
	3	  	DIONEX IP20 ISOCRATIC PUMP 97090564	  	CHEMISTRY LAB
	4	  	DIONEX ED40 ELECTROCHEMICAL DETECTOR 97080509	  	CHEMISTRY LAB
	6	  	DELL HARD DRIVE 36780347	  	CHEMISTRY LAB
	9	  	SMART UPS GS9829135975	  	CHEMISTRY LAB
	10	  	DIGITAL PC HARD DRIVE PC83407877	  	CHEMISTRY LAB
	11	  	DIGITAL COMPUTER SCREEN A182925604	  	CHEMISTRY LAB
	12	  	WATERS LC MODULE 1MX5AM5380M	  	CHEMISTRY LAB
	13	  	DIGITAL KEYBOARD 70880556	  	CHEMISTRY LAB
	14	  	HP LAZERJET 4L PRINTER NLCC511145	  	CHEMISTRY LAB
	15	  	SMART UPS GS9828021316	  	CHEMISTRY LAB
	16	  	WATERS 410 DIGITAL REFRACTOMETER B97410109M	  	CHEMISTRY LAB
	17	  	WATERS LC MODULE 1 MX6DM2589M	  	CHEMISTRY LAB
	19	  	LAZERJET 4L PRINTER NLCC588120	  	CHEMISTRY LAB
	21	  	DIGITAL COMPUTER SCREEN 8Q54213085	  	CHEMISTRY LAB
	22	  	HIAC ROYCO 300A LIQUID SYRINGE SAMPLER 97030317	  	CHEMISTRY LAB
	23	  	HIAC ROYCO 9064 96120248	  	CHEMISTRY LAB
	24	  	ELONEX PC SCREEN 30383830	  	CHEMISTRY LAB
	25	  	DIGITAL PC HARD DRIVE PC54004599	  	CHEMISTRY LAB
	29	  	UNICAM UV3 052505	  	CHEMISTRY LAB
	30	  	DIGITAL PC HARD DRIVE PC 540098	  	CHEMISTRY LAB
	32	  	DIGITAL KEYBOARD C0131604	  	CHEMISTRY LAB
	33	  	CORNING 928 CHLORIDE METER 2479	  	CHEMISTRY LAB
	34	  	CORNING FLAME PHOTOMETER 405 405/1228	  	CHEMISTRY LAB
	36	  	BELLING DRYING OVEN 001297	  	CHEMISTRY LAB
	37	  	METTLER DL77 AUTOTITRATOR 3113018078	  	CHEMISTRY LAB
	39	  	GALLENKAMP MAGNETIC STIRRER OC43860	  	CHEMISTRY LAB
	40	  	EPSON LX850 PRINTER 44D7024549	  	CHEMISTRY LAB
	44	  	METTLER AE200 BALANCE J38216	  	CHEMISTRY LAB
	48	  	METTLER BASBAL 3000 BALANCE J54834	  	CHEMISTRY LAB
	49	  	CORNING CHLORIDE METER 925 4320	  	CHEMISTRY LAB
	57	  	CARBOLITE FURNACE 1/80/8	  	CHEMISTRY LAB
	59	  	ADVANCED OSMOMETER 3D3 95111182E	  	CHEMISTRY LAB
	61	  	DELL HARD DRIVE QGKW5 44443599	  	CHEMISTRY LAB
	63	  	DELL KEYBOARD M9902 30820	  	CHEMISTRY LAB
	64	  	RENTOKIL UV LAMP 03868 - chem lab wall	  	CHEMISTRY LAB
	65	  	INTEGRITEST II PLUS 6155	  	CHEMISTRY LAB
	66	  	LOVIBOND Ph Eur COLOUR DISC BY 2158	  	CHEMISTRY LAB
	67	  	LOVIBOND Ph Eur COLOUR DISC Y 1922	  	CHEMISTRY LAB
	68	  	LOVIBOND Ph Eur COLOUR DISC B 2473	  	CHEMISTRY LAB
	69	  	LOVIBOND Ph Eur COLOUR DISC GY 1923	  	CHEMISTRY LAB
	70	  	UV LAMP 1208	  	CHEMISTRY LAB
	73	  	ROTARY EVAPORATOR 1061566	  	CHEMISTRY LAB
	74	  	MELTING POINT APPARATUS IC9802	  	CHEMISTRY LAB
	76	  	LIGHT BOX	  	CHEMISTRY LAB
	78	  	CALCULATOR - ANDY	  	CHEMISTRY LAB
	81	  	CALCULATOR - PAULA	  	CHEMISTRY LAB
	82	  	CALCULATOR - ANGELA	  	CHEMISTRY LAB
	83	  	CALIBRATED RULER	  	CHEMISTRY LAB
	84	  	CALCULATOR - MICHAEL	  	DOCUMENTATION OFFICE
	90	  	CALCULATOR - ALAN	  	DOCUMENTATION OFFICE
	91	  	DELL COMPUTER SCREEN 9172702003	  	QC OFFICE
	92	  	DELL HARD DRIVE QGKWC44443596	  	QC OFFICE
	93	  	DELL KEYBOARD M9902 30817	  	QC OFFICE
	100	  	DIGITAL PC SCREEN 7M70151595	  	QC OFFICE
	101	  	DIGITAL PC KEYBOARD B1130074	  	QC OFFICE
	102	  	YOKOGAWA MEMORY CARD READER 44XY0021	  	QC OFFICE
	103	  	DIGITAL HARD DRIVE PC63206986	  	QC OFFICE
	104	  	HP 690C PRINTER SG75RIN3MQ	  	QC OFFICE
	105	  	CALCULATOR	  	AUTOCLAVES
	106	  	CALCULATOR	  	PRODUCTION
	107	  	CALCULATOR	  	PRODUCTION
	108	  	CALCULATOR	  	PRODUCTION
	109	  	CALCULATOR	  	PRODUCTION
	110	  	CALCULATOR	  	PRODUCTION
	111	  	CALCULATOR	  	PRODUCTION
	112	  	CALCULATOR	  	PRODUCTION
	113	  	CALCULATOR	  	PRODUCTION
	114	  	1G WEIGHT 13081	  	CHEMISTRY LAB
	115	  	100G WEIGHT 22617	  	CHEMISTRY LAB
	121	  	DESKJET 895Cxi ES91P1C1YN	  	CHEMISTRY LAB
	122	  	SPECAC PRESS N/A	  	CHEMISTRY LAB
	123	  	INSERT FOR DISCS 840-062600	  	CHEMISTRY LAB
	124	  	INSERT FOR PLASTICS 0504	  	CHEMISTRY LAB
	125	  	INSERT FOR POWDERS 0337	  	CHEMISTRY LAB
	126	  	GALLENKAMP OVEN SG97/12/058	  	CHEMISTRY LAB
	127	  	FLUORIMETER 1087	  	CHEMISTRY LAB
	129	  	PB8000 METTLER TOLEDO BALANCE	  	PRODUCTION

  

 71 

 Instrument Log Numbers 
  

					
	131	  	WATER BATH	  	DEVELOPMENT LAB
	132	  	LIGHT BOX A2010	  	DEVELOPMENT LAB
	133	  	INTEGRITY TESTER W10468	  	CHEMISTRY LAB
	135	  	CALIPERS RS2488	  	CHEMISTRY LAB
	137	  	CALCULATOR-CITIZEN LH830N 980603	  	INSPECTION
	138	  	5G WEIGHT 22106	  	CHEMISTRY LAB
	140	  	CALCULATOR (ANNE-MARIE)	  	DEVELOPMENT LAB
	141	  	GALLENKAMP INCUBATOR WITH FAN 60oC+-2.5oC INCUBATOR#3 SOP/MIC-050	  	MICRO LAB
	142	  	BURRO CATERING CANTEEN	  	MICRO LAB
	144	  	DIGITAL PORTABLE THERMOMETER (B)	  	MICRO LAB
	147	  	DIGITAL PORTABLE THERMOMETER (3)	  	MICRO LAB
	150	  	YOKOGAWA HYBRID RECORDER HR2300 TYPE:3760320 SERIAL NO:44UF0055	  	MICRO LAB
	151	  	HAVEN AUTOMATION LIMITED TEMPCAL CALIBRATOR INSTNO:83435-2 CERTNO: 004211T	  	MICRO LAB
	152	  	HULME MARTIN HEAT SEALER	  	MICRO LAB
	153	  	DIGITAL PORTABLE THERMOMETER (2)	  	MICRO LAB
	156	  	SARTORIUS HD8 AIR SAMPLER INST NO:47051353 CERT NO: 80110	  	MICRO LAB
	157	  	GALLENKAMP INCUBATOR WITH FAN INCUBATOR#6 30-35oC SOP/MIC-050	  	MICRO LAB
	159	  	DIGITAL PORTABLE THERMOMETER (G)	  	MICRO LAB
	160	  	UPHEP PH METER PH3	  	MICRO LAB
	163	  	FALCON PIPETTE-AID MO11	  	MICRO LAB
	164	  	ORION PH METER AND PROBE MODEL 410A	  	MICRO LAB
	167	  	PIPETMAN P100 PIPETTE 0627760	  	MICRO LAB
	170	  	DIGITAL MONITOR SERIAL NO:1K71639279	  	MICRO LAB
	171	  	DIGITAL HARD DRIVE SERIAL NO: IPC013	  	MICRO LAB
	172	  	DIGITAL KEYBOARD SERIAL NO:5L72825817	  	MICRO LAB
	173	  	HEWLETT PACKARD LASER JET 4L PRINTER SERIAL NO: NLBB382644	  	MICRO LAB
	174	  	ATI-6000 KINETIC PHOTOSPECTOMETER (1)	  	MICRO LAB
	175	  	ATI-6000 KINETIC PHOTOSPECTOMETER (2)	  	MICRO LAB
	177	  	DIGITAL PORTABLE THERMOMETER (7)	  	MICRO LAB
	179	  	ENVAIR LAMINAR AIR FLOW MO 27	  	MICRO LAB
	182	  	GILSON PIPETMAN P200 C14339G	  	MICRO LAB
	183	  	GILSON PIPETMAN P1000 N19509A	  	MICRO LAB
	184	  	FLASHPOINT GAS LIGHTER	  	MICRO LAB
	185	  	DISPENSETTE III 09V 6631	  	MICRO LAB
	186	  	GEPRITLE SICHERHEIT OPTIFIX BOTTLE TOP DISPENSER 002469	  	MICRO LAB
	187	  	BENCH LAMP	  	MICRO LAB
	189	  	BBL ANAEROBIC JAR	  	MICRO LAB
	190	  	GENLAB INCUBATOR 30-35oC	  	MICRO LAB
	191	  	LMS COOLED INCUBATOR	  	MICRO LAB
	194	  	CALCULATOR JIM	  	STORES
	196	  	LAF UNIT	  	MICRO LAB
	212	  	MAX/MIN DIGITAL THERMOMETER	  	MICRO LAB
	213	  	MAX/MIN DIGITAL THERMOMETER	  	MICRO LAB
	214	  	MAX/MIN DIGITAL THERMOMETER	  	MICRO LAB
	215	  	MAX/MIN DIGITAL THERMOMETER	  	MICRO LAB
	216	  	MAX/MIN DIGITAL THERMOMETER	  	MICRO LAB
	217	  	MAX/MIN DIGITAL THERMOMETER	  	MICRO LAB
	218	  	MAX/MIN DIGITAL THERMOMETER	  	MICRO LAB
	219	  	MAX/MIN DIGITAL THERMOMETER	  	MICRO LAB
	222	  	ISO-TECH ILM 350 LIGHT METER L436355	  	CHEMISTRY LAB
	223	  	ET-086 OVEN TEMPERATURE PROBE	  	CHEMISTRY LAB
	224	  	ELEANOR CASIO fx-82 SUPER SCIENTIFIC CALCULATOR	  	PRODUCTION
	225	  	DIANE-CITIZEN LH 830N CALCULATOR	  	PRODUCTION
	227	  	IVEX STABILITY ROOM 2	  	STORES
	228	  	IVEX STABILITY ROOM 3	  	STORES
	229	  	WILLIS-SHARP SCIENTIFIC CALCULATOR EL-531GH	  	PRODUCTION
	230	  	PRINTER FOR THE LOOP-EPSON LX 300-PRODUCTION OFFICE	  	PRODUCTION
	231	  	AFICIO 401 PHOTOCOPIER-PRODUCTION OFFICE	  	PRODUCTION
	232	  	HP DESKJET 880c PRINTER-PRODUCTION OFFICE	  	PRODUCTION
	233	  	DIGITAL COMPUTER SCREEN (PO) 7M62209596	  	PRODUCTION
	234	  	DIGITAL HARD DRIVE (PO) PC63504088	  	PRODUCTION
	235	  	IBICO-EC-100S CALCULATOR-MULTIVAC 1	  	PRODUCTION
	236	  	AURORA DT350 CALCULATOR-MULTIVAC 3	  	PRODUCTION
	237	  	METTLER TOLEDO SCALES-INSP LINE 1 CAROL’S LINE 2588783-2*5	  	PRODUCTION
	238	  	METTLER PJ6 SCALES MO6677 INSP LINE 2	  	PRODUCTION
	239	  	METTLER PJ6000 BALANCE-CL RM1 H54595	  	PRODUCTION
	240	  	METTLER PJ6 SCALES CL RM2-J27201	  	PRODUCTION
	241	  	DIGITAL KEYBOARD-PRODUCTION OFFICE	  	PRODUCTION
	242	  	COMPOUND ROOM-EPSON LX 300 PRINTER	  	PRODUCTION
	243	  	METTLER TOLEDO SCALES CL RM3 III7430267	  	PRODUCTION
	254	  	GELLMAN CLOCK/CALCULATOR (MICRO)	  	MICRO LAB
	256	  	PJ3600 METTLER BALANCE I18023	  	PRODUCTION
	257	  	PJ3600 BALANCE K80221 DISPENSARY	  	PRODUCTION
	258	  	SPIDER 1-35 2115014883 DISPENSARY	  	PRODUCTION
	260	  	HEWLETT PACKARD LASER JET 2100TN PRINTER SN:NLCB040916	  	MICRO LAB
	262	  	MET ONE LASER PARTICLE COUNTER SN:9414623230	  	MICRO LAB
	263	  	SCIENTIFIC CALCULATOR LABS	  	MICRO LAB
	264	  	SCIENTIFIC CALCULATOR LABS	  	MICRO LAB
	265	  	SCIENTIFIC CALCULATOR LABS	  	MICRO LAB
	266	  	DIGITAL TIMER	  	MICRO LAB

  

 72 

 Instrument Log Numbers 
  

					
	267	  	CASIO fx 825X SCIENTIFIC CALCULATOR	  	MICRO LAB
	268	  	PAUL MAGUIRES CALCULATOR	  	PRODUCTION
	270	  	BAG PLANT CALCULATOR	  	BAG PLANT
	271	  	DIGITAL TIMER LABS	  	CHEMISTRY LAB
	272	  	TOC METER ACCESS 643 SER NO:1195	  	CHEMISTRY LAB
	273	  	TOC METER PRINTER LX300	  	CHEMISTRY LAB
	274	  	JENWAY CONDUCTIVITY METER SER NO:2089	  	CHEMISTRY LAB
	275	  	50MG CALIBRATED WEIGHT SER NO:233961097	  	CHEMISTRY LAB
	276	  	302 PH METER (MICRO) SER NO:T101374	  	CHEMISTRY LAB
	279	  	CALCULATOR CITIZEN SN:991103	  	PRODUCTION
	280	  	CALCULATOR CITIZEN SN:991103	  	PRODUCTION
	281	  	CALCULATOR SCIENTIFIC	  	CHEMISTRY LAB
	282	  	CALCULATOR SCIENTIFIC	  	CHEMISTRY LAB
	283	  	RIBO 292960 LOVIBOND DISC	  	CHEMISTRY LAB
	285	  	KB60.2 METTLER TOLEDO BALANCE SER NO:23335874 DISPENSARY	  	PRODUCTION
	286	  	CALCULATOR	  	PRODUCTION
	287	  	CALCULATOR	  	PRODUCTION
	288	  	CALCULATOR	  	PRODUCTION
	289	  	COMPAQ MONITOR 043CG24KF535	  	DEVELOPMENT LAB
	290	  	COMPAQ KEYBOARD 3829A569	  	DEVELOPMENT LAB
	291	  	WATERS 2690 H00SHC 176M & H005MH 219M	  	DEVELOPMENT LAB
	292	  	WATERS 2487 J00487 074M	  	DEVELOPMENT LAB
	293	  	COMPAQ HARDWARE 8046FR4Z1MV6	  	DEVELOPMENT LAB
	294	  	SMART UPS GS0036002215	  	DEVELOPMENT LAB
	297	  	MAGNETIC STIRRER 81194767	  	DEVELOPMENT LAB
	302	  	PRESSURE CUFF C-FUSOR 500 SER NO:27D141089-1	  	DEVELOPMENT LAB
	311	  	ELECTRONIC TIMER CLOCK	  	DEVELOPMENT LAB
	312	  	CALCULATOR FX 82 CASIO (ANGELA)	  	DEVELOPMENT LAB
	313	  	CALIPERS - 547-316 SER NO: 02380	  	CHEMISTRY LAB
	314	  	CALCULATOR - R. TODD	  	PRODUCTION
	315	  	CALCULATOR - M. ERWIN	  	PRODUCTION
	316	  	CALCULATOR - J. MCBURNEY	  	PRODUCTION
	317	  	CALCULATOR - M. DOHERTY	  	PRODUCTION
	318	  	CALCULATOR - A. BRENNAN	  	PRODUCTION
	319	  	CALCULATOR - D. BUCHANAN	  	PRODUCTION
	320	  	200g WEIGHT 61448	  	CHEMISTRY LAB
	321	  	CASIO MS 8L CALCULATOR	  	PRODUCTION
	322	  	GILSON P200 P570760	  	CHEMISTRY LAB
	330	  	LAMINAR AIR FLOW A2HB	  	CHEMISTRY LAB
	331	  	BEKO FRIDGE RG910	  	CHEMISTRY LAB
	332	  	BIG DIGIT TIMER CLOCK	  	MICRO LAB
	333	  	BIG DIGIT TIMER CLOCK	  	MICRO LAB
	334	  	QUARTZ DIGITAL THERMOMETER	  	CHEMISTRY LAB
	335	  	ELECTRONIC TIMER CLOCK	  	CHEMISTRY LAB
	338	  	BBL ANAEROBIC JAR	  	MICRO LAB
	339	  	SONICATOR	  	MICRO LAB
	340	  	CALIBRATION BATH	  	MICRO LAB
	341	  	TORCH	  	MICRO LAB
	346	  	AIR SAMPLER SAS SUPER 180	  	MICRO LAB
	347	  	LAF	  	STERILITY SUITE
	348	  	STERITEST PUMP	  	STERILITY SUITE
	349	  	DIGI-THERMOMETER	  	MICRO LAB
	350	  	DIGI-THERMOMETER	  	MICRO LAB
	354	  	DIGI-THERMOMETER	  	STABILITY ROOMS
	359	  	DIGI-THERMOMETER	  	STABILITY ROOMS
	361	  	DIGI-THERMOMETER	  	STABILITY ROOMS
	362	  	DIGI-THERMOMETER	  	STABILITY ROOMS
	363	  	DIGI-THERMOMETER	  	STABILITY ROOMS
	364	  	DIGI-THERMOMETER	  	STABILITY ROOMS
	367	  	25C/60% STABILITY ROOM #3	  	STABILITY ROOMS
	368	  	40C/15% STABILITY ROOM #2	  	STABILITY ROOMS
	369	  	ALLIANCE 2690 HPLC	  	CHEMISTRY LAB
	370	  	WATERS 2487 DUAL DETECTOR	  	CHEMISTRY LAB
	371	  	COMPAQ DESKTOP HARD-DRIVE	  	CHEMISTRY LAB
	374	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	DIANE PERRY
	375	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	MARGARET AGNEW
	376	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	LINDA BURKE
	377	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	PRODUCTION OFFICE
	378	  	CASIO J-120T CALCULATOR	  	CHERIE ARCHER
	379	  	CASIO J-120T CALCULATOR	  	STORES
	380	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	PRODUCTION
	381	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	PRODUCTION
	382	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	PRODUCTION
	383	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	PRODUCTION
	388	  	CALCULATOR-EDDIE HAVERON	  	MULTIVAC 3
	393	  	STAINLESS STEEL SQUARE 316 2.0MM 10X10CM	  	DEVELOPMENT LAB
	394	  	PHENOMENEX DIGI-TIMER	  	DEVELOPMENT LAB
	395	  	COMPAQ V720 HARD DRIVE	  	CHEMISTRY LAB
	396	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	IAN CATHCART
	397	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	IAN BASTON

  

 73 

 Instrument Log Numbers 
  

					
	398	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	JOHN SCULLION
	399	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	STEPHEN THOMPSON
	400	  	CASIO HS-85TE TAX & EXCHANGE CALCULATOR	  	TOMMY COULSON
	401	  	SHARP EL-530L CALCULATOR	  	HEATHER SMITH
	402	  	DIGITALLY CONTROLLED CLOCK	  	MICRO LAB
	404	  	CALCULATOR	  	CHEMISTRY LAB
	405	  	CALCULATOR	  	CHEMISTRY LAB
	407	  	GENEX BETA 1-5ML CS18658	  	DEVELOPMENT LAB
	408	  	GILSON P10ML U70495K	  	DEVELOPMENT LAB
	409	  	METTLER TOLEDO SPIDER 1	  	PRODUCTION
	411	  	SOLAAR AA SPECTROPHOTOMETER	  	CHEMISTRY LAB
	412	  	784 KFP TITRINO TITRATOR	  	CHEMISTRY LAB
	413	  	METROTRIM 703 TI STAND	  	CHEMISTRY LAB
	424	  	CASIO CALCULATOR J120TE	  	PRODUCTION
	431	  	ELX 808μ MICROTITRE PLATE RECORDER	  	ENDOTOXIN TEST ROOM
	432	  	DAEWOO MONITOR	  	ENDOTOXIN TEST ROOM
	433	  	DAEWOO HARD DRIVE	  	ENDOTOXIN TEST ROOM
	434	  	HP LASERJET 1200 SERIES	  	ENDOTOXIN TEST ROOM
	435	  	CALIBRATION PLATE	  	QC OFFICE
	436	  	MEASURING CYLINDER CLASS A 250ML 25046	  	CHEMISTRY LAB
	440	  	MEASURING CYLINDER CLASS A 1000ML 27017	  	CHEMISTRY LAB
	441	  	DIGITAL THERMOMETER	  	MICRO LAB
	442	  	DIGITAL THERMOMETER	  	MICRO LAB
	443	  	DIGITAL THERMOMETER	  	MICRO LAB
	444	  	MONITOR FOR DIONEX 135BM26DA885	  	DEVELOPMENT LAB
	445	  	CASIO CALCULATOR HS8V	  	PRODUCT ON
	446	  	MEASURING CYLINDER CLASS A l000ML 29298	  	CHEMISTRY LAB
	447	  	MEASURING CYLINDER CLASS A l000ML 29299	  	CHEMISTRY LAB
	448	  	MEASURING CYLINDER CLASS A 2000ML 27832	  	CHEMISTRY LAB
	449	  	MEASURING CYLINDER CLASS A 2000ML 27833	  	CHEMISTRY LAB
	451	  	MEASURING CYLINDER CLASS A 250ML J4922	  	CHEMISTRY LAB
	454	  	PH METER 493699	  	CHEMISTRY LAB
	455	  	DIGITAL TIMER	  	MICRO LAB
	456	  	DIGITAL TIMER	  	MICRO LAB
	458	  	CALCULATOR	  	PRODUCTION
	459	  	CALCULATOR	  	PRODUCTION
	460	  	CALCULATOR	  	PRODUCTION
	461	  	CALCULATOR	  	PRODUCTION
	462	  	CALCULATOR	  	PRODUCTION
	464	  	CALCULATOR	  	DEVELOPMENT LAB
	465	  	CALCULATOR	  	CHEMISTRY LAB
	466	  	CALCULATOR	  	CHEMISTRY LAB
	467	  	CALCULATOR	  	CHEMISTRY LAB
	469	  	MEASURING CYLINDER 100ML	  	DEVELOPMENT LAB
	470	  	MEASURING CYLINDER 100ML	  	CHEMISTRY LAB
	471	  	MAX MIN THERMOMETER	  	MICRO LAB
	472	  	CALCULATOR	  	PRODUCTION
	473	  	CALCULATOR	  	PRODUCTION
	474	  	CALCULATOR	  	PRODUCTION
	475	  	CALCULATOR	  	PRODUCTION
	478	  	MAX MIN THERMOMETER	  	MICRO LAB
	479	  	MAX MIN THERMOMETER	  	MICRO LAB
	480	  	MAX MIN THERMOMETER	  	MICRO LAB
	481	  	MAX MIN THERMOMETER	  	MICRO LAB
	482	  	MAX MIN THERMOMETER	  	MICRO LAB
	483	  	MICROPIPETTE 200-1000	  	CHEMISTRY LAB
	484	  	MICROPIPETTE 1000-5000	  	MICRO LAB
	485	  	MICROPIPETTE 200-1000	  	CHEMISTRY LAB
	486	  	CALCULATOR	  	PRODUCTION
	487	  	CALCULATOR	  	PRODUCTION
	488	  	CALCULATOR	  	PRODUCTION
	489	  	CALCULATOR	  	PRODUCTION
	490	  	CALCULATOR	  	PRODUCTION
	491	  	CALCULATOR	  	PRODUCTION
	492	  	PRESSURE CUFF 1000 27A131150	  	CHEMISTRY LAB
	493	  	PRESSURE CUFF 1000 27B251105	  	CHEMISTRY LAB
	494	  	PRESSURE CUFF 500 27D141089	  	CHEMISTRY LAB
	495	  	BEAKERS	  	CHEMISTRY LAB
	496	  	VOLUMETRIC FLASKS	  	CHEMISTRY LAB
	497	  	MEASURING CYLINDERS	  	CHEMISTRY LAB
	498	  	CONICAL FLASKS	  	CHEMISTRY LAB
	499	  	PIPETTES	  	CHEMISTRY LAB
	500	  	WATER TANK	  	CHEMISTRY LAB
	501	  	HPLC PHIALS	  	CHEMISTRY LAB
	502	  	PI PUMPS	  	CHEMISTRY LAB
	503	  	BUNSEN BURNERS	  	CHEMISTRY LAB & MICRO LAB
	523	  	VALPROBE	  	MICRO LAB
	524	  	VALPROBE	  	MICRO LAB
	525	  	VALPROBE	  	MICRO LAB
	526	  	VALPROBE	  	MICRO LAB

  

 74 

 Instrument Log Numbers 
  

					
	527	  	VALPROBE	  	MICRO LAB
	528	  	VALPROBE	  	MICRO LAB
	529	  	VALPROBE	  	MICRO LAB
	530	  	VALPROBE	  	MICRO LAB
	531	  	VALPROBE	  	MICRO LAB
	532	  	VALPROBE	  	MICRO LAB
	533	  	VALPROBE	  	MICRO LAB
	534	  	VALPROBE	  	MICRO LAB
	535	  	VALPROBE	  	MICRO LAB
	536	  	VALPROBE	  	MICRO LAB
	537	  	VALPROBE	  	MICRO LAB
	538	  	VALPROBE	  	MICRO LAB
	539	  	VALPROBE	  	MICRO LAB
	540	  	VALPROBE	  	MICRO LAB
	541	  	VALPROBE	  	MICRO LAB
	542	  	VALPROBE	  	MICRO LAB
	543	  	VALPROBE	  	MICRO LAB
	544	  	VALPROBE	  	MICRO LAB
	545	  	VALPROBE	  	MICRO LAB
	546	  	VALPROBE	  	MICRO LAB
	547	  	VALPROBE	  	MICRO LAB
	548	  	VALPROBE	  	MICRO LAB
	549	  	VALPROBE	  	MICRO LAB
	550	  	VALPROBE	  	MICRO LAB
	551	  	VALPROBE	  	MICRO LAB
	552	  	VALPROBE	  	MICRO LAB
	553	  	TLC TANK	  	CHEMISTRY LAB
	554	  	STORAGE CABINETS	  	CHEMISTRY LAB
	555	  	VACUUM FILTER FLASKS	  	CHEMISTRY LAB
	584	  	stainless steel trolley (2 tier)	  	MICRO LAB
	585	  	stainless steel trolley (4 tier)	  	STERILITY SUITE
	586	  	stainless steel trolley (2 tier)	  	STERILITY SUITE
	587	  	stainless steel trolley (2 tier)	  	MICRO LAB
	588	  	stainless steel trolley (4 tier)	  	STERILITY SUITE
	589	  	stainless steel trolley (3 tier)	  	MICRO LAB
	593	  	Laboratory Swivel Operator chair	  	STERILITY SUITE
	594	  	Laboratory Swivel Operator chair	  	STERILITY SUITE
	598	  	Media Waste wheeled bins	  	MICRO LAB
	599	  	Waste Paper Bin	  	MICRO LAB
	602	  	Waste General Bin	  	MICRO LAB
	604	  	Waste Plastic Bin	  	MICRO LAB
	619	  	1 Litre Duran Bottle	  	MICRO LAB
	620	  	1 Litre Duran Bottle	  	MICRO LAB
	621	  	1 Litre Duran Bottle	  	MICRO LAB
	622	  	1 Litre Duran Bottle	  	MICRO LAB
	623	  	1 Litre Duran Bottle	  	MICRO LAB
	624	  	1 Litre Duran Bottle	  	MICRO LAB
	625	  	1 Litre Duran Bottle	  	MICRO LAB
	626	  	1 Litre Duran Bottle	  	MICRO LAB
	627	  	1 Litre Duran Bottle	  	MICRO LAB
	628	  	1 Litre Duran Bottle	  	MICRO LAB
	639	  	500 ml Duran Bottle	  	MICRO LAB
	640	  	500 ml Duran Bottle	  	MICRO LAB
	641	  	500 ml Duran Bottle	  	MICRO LAB
	642	  	500 ml Duran Bottle	  	MICRO LAB
	643	  	500 ml Duran Bottle	  	MICRO LAB
	644	  	500 ml Duran Bottle	  	MICRO LAB
	645	  	500 ml Duran Bottle	  	MICRO LAB
	646	  	500 ml Duran Bottle	  	MICRO LAB
	647	  	500 ml Duran Bottle	  	MICRO LAB
	648	  	500 ml Duran Bottle	  	MICRO LAB
	649	  	500 ml Duran Bottle	  	MICRO LAB
	650	  	500 ml Duran Bottle	  	MICRO LAB
	651	  	500 ml Duran Bottle	  	MICRO LAB
	686	  	500 ml Gelman Filtration Units	  	MICRO LAB
	687	  	500 ml Gelman Filtration Units	  	MICRO LAB
	688	  	500 ml Gelman Filtration Units	  	MICRO LAB
	689	  	500 ml Gelman Filtration Units	  	MICRO LAB
	690	  	500 ml Gelman Filtration Units	  	MICRO LAB
	691	  	300 ml Gelman Filtration Units	  	MICRO LAB
	692	  	300 ml Gelman Filtration Units	  	MICRO LAB
	693	  	300 ml Gelman Filtration Units	  	MICRO LAB
	694	  	300 ml Gelman Filtration Units	  	MICRO LAB
	695	  	300 ml Gelman Filtration Units	  	MICRO LAB
	696	  	300 ml Gelman Filtration Units	  	MICRO LAB
	697	  	300 ml Gelman Filtration Units	  	MICRO LAB
	698	  	300 ml Gelman Filtration Units	  	MICRO LAB
	699	  	300 ml Gelman Filtration Units	  	MICRO LAB
	700	  	300 ml Gelman Filtration Units	  	MICRO LAB
	701	  	300 ml Gelman Filtration Units	  	MICRO LAB

  

 75 

 Instrument Log Numbers 
  

					
	702	  	300 ml Gelman Filtration Units	  	MICRO LAB
	703	  	300 ml Gelman Filtration Units	  	MICRO LAB
	704	  	300 ml Gelman Filtration Units	  	MICRO LAB
	705	  	300 ml Gelman Filtration Units	  	MICRO LAB
	706	  	300 ml Gelman Filtration Units	  	MICRO LAB
	707	  	300 ml Gelman Filtration Units	  	MICRO LAB
	708	  	300 ml Gelman Filtration Units	  	MICRO LAB
	709	  	300 ml Gelman Filtration Units	  	MICRO LAB
	710	  	300 ml Gelman Filtration Units	  	MICRO LAB
	732	  	VISCOMETER	  	CHEMISTRY LAB
	733	  	VISCOMETER	  	CHEMISTRY LAB

  

 76 

					
	 PRODUCT

	  	 SER NUM

	  	 FULL NAME

	 Computer
	  	 	  	 
	Evo N400c	  	7J1CJMWZD00P	  	Alan McGahie
	Evo N410c	  	7J28KVBZP04G	  	Bob McConnell
	iPaq	  	8049DZF2011V	  	Alison Mackness
	iPAQ Desktop	  	8109JDVZ1305	  	Jean Graham
	OptiPlex GX100	  	RFYM0	  	DIANE PERRY
	5	  	 	  	 
	 DESKJET PRINTER
	  	 	  	 
	Lexmark Z52	  	09320367489	  	DEVELOPMENT LAB
	Epson STYLUS COLOUR 600	  	AAKOO20760	  	Jacqueline Steward
	Epson Stylus C62	  	EJXT147351	  	CHEMISTRY LAB
	HP DESKJET 660C	  	ES83V182TX	  	Alan McGahie
	HP DESKJET 880C	  	ES8AG441XG	  	CHEMISTRY LAB
	HP Deskjet 895 Cxi	  	ES91P1C1YN	  	DEVELOPMENT LAB
	HP DESKJET 815C	  	ES95L1305H	  	QC OFFICE
	HP Deskjet 895 Cxi	  	ES96G130GW	  	DEVELOPMENT LAB
	HP DESKJET 930C	  	ESOAW160H6	  	Angela Armstrong
	HP Deskjet 840C	  	HU0B31Y16M	  	CHEMISTRY LAB
	HP Deskjet 895 Cxi	  	HUO1A1N2PV	  	Bob McConnell
	DESKJET 895CXI	  	HUO1O1P1JT	  	John Armstrong
	HP Deskjet Printer 5552	  	MY27VIM05T	  	CHEMISTRY LAB
	Deskjet 5552	  	MY2A91M2F2	  	DEVELOPMENT LAB
	CP1700	  	SG1B6210XR	  	Jean Graham
	15	  	 	  	 
	 DESKTOP
	  	 	  	 
	OPTIPLEX E1	  	44119409	  	QC OFFICE
	EVO	  	6S1CJX8Z502S	  	CHEMISTRY LAB
	COMPAQ IPAQ	  	8029DZD20065	  	IVEX SALES
	iPaq	  	8045DZF2010D	  	Geoffrey Craig
	COMPAQ IPAQ LEGACY FREE C500	  	8045DZF2010R	  	Jean Graham
	COMPAQ DESKPRO EXM	  	8046FR4Z1MV6	  	DEVELOPMENT LAB
	COMPAQ IPAQ	  	8052DZD2000X	  	Angela Armstrong
	iPAQ Desktop	  	8108JDVZ00G8	  	John Armstrong
	iPAQ Desktop	  	8108JDVZ00GB	  	Margaret Agnew
	iPAQ Desktop	  	8108JDVZ00H4	  	DIERDRE LEMON
	iPAQ Desktop	  	8108JDVZ00HB	  	Michael Cotter
	COMPAQ IPAQ	  	8108JDVZ00HS	  	Michael Cotter
	iPAQ Desktop	  	8108JDVZ00JF	  	Jacqueline Steward
	iPAQ Desktop	  	8110JDVZ0328	  	Jacqueline Steward
	COMPAQ Deskpro EXM 933	  	8125FR4Z042L	  	CHEMISTRY LAB
	COMPAQ IPAQ	  	8143JDVZ00LS	  	Eleanor Anderson
	COMPAQ EVO D310 P4-2.0G 40GB 256MB CD LAN WXPP	  	FR22824598	  	Donna Stewart
	OPTIPLEX Gs	  	LWBWB	  	DEVELOPMENT LAB
	VENTURIS 575	  	PC54004598	  	CHEMISTRY LAB
	VENTURIS 575	  	PC54004599	  	CHEMISTRY LAB
	VENTURIS FX5100	  	PC63504071	  	LABEL OFFICE PRODUCTION IVEX
	VENTURIS 5100	  	PC63504088	  	PRODUCTION OFFICE - CLOCKIN
	DIGITAL PC 3000	  	PC83407877	  	CHEMISTRY LAB
	OptiPlex GX1 350L+	  	QGKW5	  	DIANE PERRY
	OPTIPLEX GXI	  	QGKWJ	  	FRANK HEALEY
	OPTIPLEX GX1	  	R48RQ	  	DEVELOPMENT LAB
	OPTIPLEX GX1	  	R4SR1	  	CHEMISTRY LAB
	OPTIPLEX GX100	  	RFYMG	  	LABEL OFFICE PRODUCTION IVEX
	28	  	 	  	 
	 Dot Matrix Printer
	  	 	  	 
	Epson FX-1170	  	2JA7007826	  	QC OFFICE
	Epson FX-1170	  	2JA7122973	  	DIANE PERRY
	2	  	 	  	 
	 EXPANSION UNIT
	  	 	  	 
	COMPAQ EVO N410C EXP UNIT CD	  	1J28KX22G10M	  	Bob McConnell
	ARMADA M300	  	3J07DFP1RKSK	  	QC OFFICE
	EVO N400C EXPANSION UNIT DVD	  	71J19JMWZA0GZ	  	QC OFFICE
	3	  	 	  	 
	 LASER PRINTER
	  	 	  	 
	LASERJET 2200D	  	FRFGM00795	  	CHEMISTRY LAB
	HP LASERJET 2100 TN	  	NLCBQ4Q916	  	GSS PRODUCTION OFFICE

  

 77 

 10/03/2004 
  

					
	 PRODUCT

	  	 SER NUM

	  	 FULL NAME

	LASERJET 4L	  	NLCC586120	  	CHEMISTRY LAB
	3	  	 	  	 
	 MONITOR
	  	 	  	 
	IIYAMA S500M1 15” MONITOR	  	 	  	John Armstrong
	Digital Monitor	  	&M62101799	  	DIANE PERRY
	S510	  	010BB65NDV15	  	DIANE PERRY
	S510	  	035BB24ND384	  	Angela Armstrong
	S710	  	043GC24KF535	  	DEVELOPMENT LAB
	17” Monitor upgrade	  	114CG24KH499	  	CHEMISTRY LAB
	S710	  	117CG24KD331	  	Geoffrey Craig
	COMPAQ MONITOR S720	  	134CL26EA720	  	CHEMISTRY LAB
	S720	  	139CL26SC534	  	Eleanor Anderson
	S720	  	144CL26LH298	  	Alan McGahie
	Digital Monitor	  	1K73064687	  	Jean Graham
	Digital Monitor	  	1K74083557	  	QC OFFICE
	828FI	  	22795B0APP79	  	DEVELOPMENT LAB
	828FI	  	22795B0APY	  	CHEMISTRY LAB
	828F1	  	22795C0VCP29	  	LABEL OFFICE PRODUCTION IVEX
	COMPAQ 17IN S7500 COLOUR MONITOR 2-TONE CARBON/SILVER	  	233CP24LJ166	  	Donna Stewart
	COMPAQ TFT5015 15” DISPLAY	  	242BQ29XE154	  	Jacqueline Steward
	TE1438A	  	30383830	  	CHEMISTRY LAB
	Digital Monitor	  	7M61029452	  	IVEX SALES
	Digital Monitor	  	7M61030203	  	DEVELOPMENT LAB
	Digital Monitor	  	7M62209614	  	Bob McConnell
	Digital Monitor	  	7M62209618	  	DIERDRE LEMON
	Digital Monitor	  	7M622Q9596	  	PRODUCTION OFFICE - CLOCKIN
	Digital Monitor	  	8Q54213085	  	CHEMISTRY LAB
	Acer 1569i	  	9172702003	  	CHEMISTRY LAB
	Digital Monitor	  	A100400031	  	John Armstrong
	Digital Monitor	  	A173603359	  	Michael Cotter
	Digital Monitor	  	A182925604	  	CHEMISTRY LAB
	S500MI	  	TIDNOCBO61331	  	Alison Mackness
	29	  	 	  	 
	 NOTEBOOK
	  	 	  	 
	ARMADA M300	  	7J08FM74P02E	  	QC OFFICE
	N400c	  	7J26JMWZBOOF	  	QC OFFICE
	2	  	 	  	 
	 Printer
	  	NLBB382644	  	CHEMISTRY LAB
	HP LJ 4L	  	 	  	 
	1	  	 	  	 
	 Projector
	  	 	  	 
	VPL-CS2 LCD PROJECTOR SVGA 600	  	18532	  	Jean Graham
	1	  	 	  	 
	 SCANNER
	  	 	  	 
	5470C	  	CN1621I021	  	Angela Armstrong
	ASTRA 610P	  	H6W0E48104154	  	CHEMISTRY LAB
	2	  	 	  	 
	 WYSE SCREEN
	  	 	  	 
	WY-120	  	09I10A02698	  	John Armstrong
	1	  	 	  	 

  

 78 

  
 SCHEDULE 4 

 
 Contracts 
  
 Confidentiality Agreement with Baxter Healthcare Limited 
 Confidentiality Agreement with Baxter SA/NV 
 Supply Agreement with Baxter
S.A. 
 Technical Agreement with Baxter Healthcare Limited 
 Technical Agreement with Biosol S.p.A. 
 Technical Agreement with Boots Company PLC 
 Agreement with Ciba Vision Ophthalmics GmbH 
 Agreement with Ciba Vision Ophthalmics UK Limited 
 Contract Manufacturing Agreement with Ciba Vision AG (Draft) 
 Development Agreement with COBE BCT Inc. 
 Non-Disclosure Agreement with COBE BCT Inc. 
 Technical Contract with Coloplast Continence Care Division 
 Commercial Agreement for Stability Development and Validation
with Edwards Lifesciences BV (Draft) 
 Manufacturing and Supply Agreement with Edwards Lifesciences AG (Draft) 
 Mutual Confidentiality Agreement with Edwards Lifesciences SA (Draft) 
 Manufacturing and Supply Agreement with Excorim AB 
 Contract Manufacturing Agreement with Fresenius Kabi Limited 
 Manufacturing and Supply Agreement with Gambro BCT 
 Riboflavin Stability
Contract with Gambro BCT Inc. 
 Manufacturing and Supply Agreement with Hospal International Marketing Management S.N.C. and Gambro Lundia AB 
 Agreement with Haemonetics S.A. (December 1995) 
 Agreement with
Haemonetics S.A. (February 1996) 
 Agreement with Haemonetics S.A. (August 1996) 
 Agreement with Haemonetics S.A. (September 1997) 
 Agreement with Haemonetics S.A. (September 1997) 

Agreement with Haemonetics S.A. (September 1997) 
 Non-Disclosure
Agreement with IV Direct Limited 
 Mutual Non-Disclosure Agreement with J.F.Melin Pharmacien 
 Confidentiality Agreement with Kendle International Inc. and Technomark Consulting Services Limited 
 Confidentiality
Agreement with Laboratoires UPSA 
 Manufacturing and Supply Agreement with Maelor Pharmaceuticals Limited 
 Mutual Non-Disclosure Agreement with Maelor Pharmaceuticals Limited 
 Confidentiality Agreement with Maelor Pharmaceutical Supplies Limited 
 Confidentiality Agreement with Mindset BioPharmaceuticals (USA) Inc.

  

 79 

 Manufacturing and Supply Agreement with ML Laboratories PLC 
 Assignment and Novation Agreement with ML Laboratories PLC and Shire Pharmaceutical Contracts Limited 
 Confidentiality
Agreement with ML Laboratories Limited 
 Mutual Non-Disclosure Agreement with Novirio Pharmaceuticals Inc. 
 Mutual Non-Disclosure Agreement with NxStage Medical Inc. 
 Manufacturing and
Supply Agreement with NxStage Medical Inc. (Draft) 
 Confidentiality Agreement with Nycomed Ireland 
 Manufacturing and Supply Agreement with Organon Laboratories Ltd (Draft) 
 Manufacturing Agreement with Seton Healthcare Group PLC 
 Secrecy Agreement with Stedim S.A. 
 Mutual Non-Disclosure Agreement with Technoflex S.A. 
 Agreement of Intent
with Technoflex S.A. 
 Mutual Non-Disclosure Agreement with Water First Limited National Health Services tender contracts: 
 Yorkshire NHS Trusts Pharmacy Consortium 
 Scottish Healthcare Supplies

 Central Services Agency (Northern Ireland) 
  

 80 

  
 SCHEDULE 5 

 
 Assumed Employees 
  

									
	 NAME

	  	 	  	EMP NO.

	  	DEPT

	  	JOB TITLE

	 Wendy
	  	Barkley	  	20021	  	72	  	Sr. Logistics Administrator
	 Martin
	  	Kane	  	20024	  	72	  	Storeperson
	 John
	  	Armstrong	  	20113	  	72	  	Logistics Manager
	 Linda
	  	Burke	  	20004	  	73	  	Senior Operator
	 Rhonda
	  	Dickson	  	20010	  	73	  	Process Operator
	 Margaret
	  	Smyth	  	20016	  	73	  	Process Operator
	 Irene
	  	Beggs	  	20035	  	73	  	Process Operator
	 Paul
	  	Maguire	  	20060	  	73	  	Senior Operator
	 Donna
	  	Manson	  	20062	  	73	  	Senior Operator
	 Ann
	  	Neill	  	20074	  	73	  	Senior Operator
	 Pamela
	  	Rudden	  	20084	  	73	  	Senior Operator
	 Sylvia
	  	Topping	  	20085	  	73	  	Process Operator
	 Lindsay
	  	Kennedy	  	20100	  	73	  	Senior Operator
	 Sharon
	  	McAllister	  	20166	  	73	  	Senior Operator
	 Norma
	  	Thompson	  	20199	  	73	  	Process Operator
	 Barbara
	  	McKeown	  	20204	  	73	  	Process Operator
	 Robert
	  	Smith	  	20209	  	73	  	Process Operator
	 Leanne
	  	Stewart	  	20213	  	73	  	Process Operator
	 Kerry
	  	Gilmore	  	20217	  	73	  	Process Operator
	 George
	  	Smith	  	20223	  	73	  	Senior Operator/Technician
	 Edreen
	  	McGregor	  	20229	  	73	  	Process Operator
	 Christine
	  	Rea	  	20241	  	73	  	Process Operator
	 Robert
	  	Marshall	  	20244	  	73	  	Process Operator
	 Ann-Marie
	  	Magee	  	20261	  	73	  	Process Operator
	 Jacki
	  	Kirkpatrick	  	20262	  	73	  	Process Operator
	 Amanda
	  	Graham	  	20266	  	73	  	Senior Operator
	 James
	  	Robinson	  	20278	  	73	  	Process Operator
	 Barbara
	  	Brennan	  	20284	  	73	  	Process Operator
	 Olwen
	  	Robinson	  	20286	  	73	  	Process Operator
	 Hugh
	  	Graham	  	20295	  	73	  	Process Operator
	 Morton
	  	Robinson	  	20296	  	73	  	Process Operator
	 Laura
	  	McCambridge	  	20306	  	73	  	Process Operator
	 Bronagh
	  	O’Neill	  	20308	  	73	  	Process Operator
	 Judith
	  	Agnew	  	20336	  	73	  	Process Operator
	 Paul
	  	Smyth	  	20337	  	73	  	Process Operator
	 Stephanie
	  	Crawford	  	20342	  	73	  	Process Operator
	 Jim
	  	Thompson	  	20356	  	73	  	Process Operator
	 Pat
	  	Johnston	  	20357	  	73	  	Process Operator
	 Catherine
	  	Baston	  	20364	  	73	  	Process Operator
	 Kieran
	  	Kane	  	20366	  	73	  	Process Operator
	 Alese
	  	Mitchell	  	20369	  	73	  	Process Operator

  

 81 

									
	 Shane
	  	McGeown	  	20370	  	73	  	Label Store Senior Operator
	 Terence
	  	Dalrymple	  	20383	  	73	  	Process Operator
	 Shirley
	  	Holden	  	20384	  	73	  	Senior Operator
	 Sharon
	  	Kemp	  	20386	  	73	  	Process Operator
	 Maureen
	  	Shannon	  	20388	  	73	  	Process Operator
	 Shirley
	  	McCalmont	  	20389	  	73	  	Process Operator
	 Darren
	  	Mitchell	  	20405	  	73	  	Production Manager
	 Margaret
	  	Carter	  	 	  	 	  	 
	 June
	  	Horner	  	20385	  	74	  	Process Operator
	 Robert
	  	Saunderson	  	20413	  	74	  	Cleaning Operative
	 Shiralee
	  	Hoy	  	20422	  	74	  	Cleaning Operative
	 David
	  	Spence	  	20423	  	74	  	Temp Cleaning Operative
	 James
	  	Holden	  	20006	  	76	  	Compound Room Technician
	 Fiona
	  	Long	  	20076	  	76	  	Disp & Comp Technician
	 Rona
	  	Apsley	  	20087	  	76	  	Senior Operator
	 Edwin
	  	Flynn	  	20106	  	76	  	Dispensary Technician
	 Jim
	  	Bell	  	20270	  	76	  	Disp & Comp Technician
	 Iain
	  	Baston	  	20033	  	77	  	Autoclave Operator
	 Iain Michael
	  	Mulholland	  	20110	  	77	  	Senior Operator
	 John
	  	Scullion	  	20111	  	77	  	Senior Operator
	 Stephen
	  	Thompson	  	20235	  	77	  	Autoclave Operator
	 Mary Jo
	  	Geoghegan	  	20008	  	78	  	Production Supervisor
	 Eleanor
	  	Anderson	  	20013	  	78	  	Production Co-ordinator
	 Sarah Ann
	  	Scullion	  	20015	  	78	  	Senior Operator
	 Carol
	  	Gorman	  	20048	  	78	  	Supervisor
	 Caroline
	  	McAllister	  	20063	  	78	  	Senior Operator Grade 4
	 Joyce
	  	Jones	  	20065	  	78	  	Senior Operator
	 Dorothy
	  	Buchanan	  	20078	  	78	  	Senior Operator
	 Maura Ann
	  	Doherty	  	20082	  	78	  	Senior Operator
	 Richard
	  	Todd	  	20120	  	78	  	Senior Operator
	 Ann
	  	Brennan	  	20153	  	78	  	Senior Operator
	 Francis
	  	Healy	  	10187	  	79	  	Engineering Supervisor
	 Geoffrey
	  	Craig	  	20118	  	79	  	Engineering Admin Assistant
	 Maurice Victor
	  	Wright	  	20127	  	79	  	Maintenance Engineer
	 J Patrick
	  	Brazier	  	20189	  	79	  	Maintenance Engineer
	 William
	  	Ogilby	  	20410	  	79	  	Maintenance Engineer
	 Jacqueline
	  	Steward	  	20129	  	80	  	Receptionist
	 Deirdre
	  	Lemon	  	20132	  	80	  	Office Supervisor
	 Michael
	  	Cottor	  	20136	  	81	  	QA Clerk
	 Jean
	  	Graham	  	 	  	 	  	 
	 Paula
	  	Kearney	  	20140	  	81	  	QCT
	 Robert
	  	McConnell	  	20144	  	81	  	Project Manager
	 Angela
	  	Armstrong	  	20145	  	81	  	Lab Manager, Chemistry IV
	 Andrew
	  	McDonald	  	20146	  	81	  	Solutions Monitor
	 Alan
	  	McGahie	  	20147	  	81	  	Quality Assurance Manager
	 Ruth
	  	Wilson	  	20205	  	81	  	Senior Operator
	 Thomas
	  	Surgenor	  	20208	  	81	  	Validation Technician
	 Diane
	  	Perry	  	20252	  	81	  	Quality Unit Clerk

  

 82 

									
	 Lisa
	  	Gilmour	  	20253	  	81	  	Analyst
	 Julie
	  	Morton	  	20257	  	81	  	Microbiologist
	 Margaret
	  	Agnew	  	20311	  	81	  	Quality Unit Clerk
	 Heather
	  	Smith	  	20349	  	81	  	Development Analyst
	 Patricia
	  	Connolly	  	20375	  	81	  	Analyst (Micro)
	 Donna
	  	Stewart	  	20401	  	81	  	Quality Compliance Officer
	 Seona
	  	McKee	  	20407	  	81	  	QC Analyst
	 Ciara
	  	Greenan	  	20408	  	81	  	Temporary Lab Technican
	 Maureen
	  	O’Leary	  	20409	  	81	  	QC Analyst
	 Audrey
	  	McKillop	  	20414	  	81	  	Quality Unit Clerk
	 Angela
	  	Morrison	  	20419	  	81	  	Lab Analyst
	 Shirley Anne
	  	Boal	  	20424	  	81	  	Quality Compliance Officer
	 Steven
	  	Castles	  	20425	  	81	  	QC Analyst
	 James
	  	McKelvey	  	20149	  	82	  	Managing Director
	 Kelli
	  	Heggarty	  	11534	  	93	  	Microbiologist

  

 83 

  
 SCHEDULE 6 

 
 The Buyer’s Guarantee 
  

	1.	GUARANTEE 

  
 The Buyer’s Guarantor irrevocably and unconditionally: 
  

	1.1	guarantees to the Seller as principal obligor the due and punctual performance and observance by the Buyer of all of its obligations under this Agreement; and

  

	1.2	undertakes to indemnify the Seller against all losses, damages, costs and expenses incurred by the Seller arising from any failure by the Buyer to perform and/or observe any of its
obligations under this Agreement, provided the Buyer shall not be liable to pay any such losses, damages, costs or expenses to the extent that such losses, damages, costs or expenses arise from or have increased due to any actions taken or omissions
made by the Seller or any member of the Seller’s Group, 

  
 (together “this Buyer’s Guarantee”). 
  

	2.	CONTINUING SECURITY 

  
 This Buyer’s Guarantee is to be a continuing security which shall remain in full force and effect until all of the obligations of the Buyer under this Agreement shall have been fulfilled or shall have expired in
accordance with the terms of this Agreement and this Buyer’s Guarantee is to be in addition, and without prejudice to, and shall not merge with, any other right, remedy, guarantee, indemnity or security which the Seller may now or hereafter
hold in respect of all or any of the obligations of the Buyer under this Agreement. 
  

	3.	BUYER’S PROTECTIONS 

  
 The liability of the Buyer’s Guarantor under this Buyer’s Guarantee shall not be affected, impaired or discharged by reason of any act, omission, matter or
thing which, but for this provision, might operate to release or otherwise exonerate the Buyer’s Guarantor from its obligations hereunder including, without limitation: 
  

	3.1	any amendment, variation or modification to, or replacement of this Agreement in accordance with Clause 23 of this Agreement unless such amendment would result in increasing the
liability of the Buyer’s Guarantor and has not been acquiesced in and executed by the Buyer’s Guarantor; and 

  

	3.2	the taking, variation, compromise, renewal, release, refusal or neglect to perfect or enforce any rights, remedies or securities against the Buyer or any other person;

  

	3.3	any time or indulgence or waiver given to, or composition made with, the Buyer or any other person; or 

  

 84 

	3.4	the Buyer becoming insolvent, going into receivership or liquidation or having an administrator appointed. 

  

	4.	FURTHER PROTECTION 

  
 This Buyer’s Guarantee shall continue in full force and effect notwithstanding: 
  

	4.1	that any purported obligation of the Buyer or any other person to the Seller (or any security therefor) becomes wholly or partly void, invalid or unenforceable for any reason
whether or not known to the Seller or the Buyer’s Guarantor; or 

  

	4.2	any incapacity or any change in the constitution of, or any amalgamation or reconstruction of, the Buyer’s Guarantor or the Buyer or any other matter whatsoever.

  

	5.	PRIMARY OBLIGATIONS 

  
 This Buyer’s Guarantee shall constitute the primary obligations of the Buyer’s Guarantor and the Seller shall not be obliged to make any demand on the Buyer before enforcing its rights against the
Buyer’s Guarantor under this Guarantee, but Seller shall make demand on the Buyer at least contemporaneously with its demand on the Buyer’s Guarantor. 
  

	6.	WAIVER 

  
 No delay or omission of the Seller in exercising any right, power or privilege under this Guarantee shall impair such right, power or privilege or be construed as a waiver of such right, power or privilege nor shall
any single or partial exercise of any such right, power or privilege preclude any further exercise thereof or the exercise of any other right, power or privilege. 
  

	7.	INVALIDITY 

  
 If at any time any one or more of the provisions of this Guarantee is or becomes invalid, illegal or unenforceable in any respect under any law, the validity, legality and enforceability of the remaining provisions
hereof shall not be in any way affected or impaired thereby. 
  

	8.	ASSIGNMENT 

  
 In the event of a change of control of the Buyer’s Guarantor, the Buyer’s Guarantor shall be free to assign, sub-contract or otherwise transfer this guarantee or its rights and obligations hereunder to
another member of the Buyer’s Group. 
  

 85 

  
 SCHEDULE 7 

 
 The Seller’s Guarantee 
  

	1.	GUARANTEE 

  
 The Seller’s Guarantor irrevocably and unconditionally: 
  

	1.1	guarantees to the Buyer as principal obligor the due and punctual performance and observance by the Seller of all of its obligations under this Agreement; and

  

	1.2	undertakes to indemnify the Buyer against all losses, damages, costs and expenses incurred by the Buyer arising from any failure by the Seller to perform and/or observe any of its
obligations under this Agreement, provided the Seller shall not be liable to pay any such losses, damages, costs or expenses to the extent that such losses, damages, costs or expenses arise from or have increased due to any actions taken or
omissions made by the Buyer or any member of the Buyer’s Group, 

  
 (together “this Seller’s Guarantee”). 
  

	2.	CONTINUING SECURITY 

  
 This Seller’s Guarantee is to be a continuing security which shall remain in full force and effect until all of the obligations of the Seller under this Agreement shall have been fulfilled or shall have expired
in accordance with the terms of this agreement and this Seller’s Guarantee is to be in addition, and without prejudice to, and shall not merge with, any other right, remedy, guarantee, indemnity or security which the Buyer may now or hereafter
hold in respect of all or any of the obligations of the Seller under this Agreement. 
  

	3.	BUYER’S PROTECTIONS 

  
 The liability of the Seller’s Guarantor under this Seller’s Guarantee shall not be affected, impaired or discharged by reason of any act, omission, matter or
thing which but for this provision might operate to release or otherwise exonerate the Seller’s Guarantor from its obligations hereunder including, without limitation: 
  

	3.1	any amendment, variation or modification to, or replacement of this Agreement in accordance with Clause 23 of this Agreement unless such amendment would result in increasing the
liability of the Seller’s Guarantor and has not been acquiesced in and executed by the Seller’s Guarantor; and 

  

	3.2	the taking, variation, compromise, renewal, release, refusal or neglect to perfect or enforce any rights, remedies or securities against the Seller or any other person;

  

	3.3	any time or indulgence or waiver given to, or composition made with, the Seller or any other person; or 

  

 86 

	3.4	the Seller becoming insolvent, going into receivership or liquidation or having an administrator appointed. 

  

	4.	FURTHER PROTECTION 

  
 This Seller’s Guarantee shall continue in full force and effect notwithstanding: 
  

	4.1	that any purported obligation of the Seller or any other person to the Buyer (or any security therefor) becomes wholly or partly void, invalid or unenforceable for any reason
whether or not known to the Seller or the Seller’s Guarantor; or 

  

	4.2	any incapacity or any change in the constitution of, or any amalgamation or reconstruction of, the Seller’s Guarantor or the Seller or any other matter whatsoever.

  

	5.	PRIMARY OBLIGATIONS 

  
 This Seller’s Guarantee shall constitute the primary obligations of the Buyer’s Guarantor and the Seller shall not be obliged to make any demand on the Seller before enforcing its rights against the
Seller’s Guarantor under this Guarantee, but the Buyer shall make demand on the Seller at least contemporaneously with its demand on the Seller’s Guarantor. 
  

	6.	WAIVER 

  
 No delay or omission of the Buyer in exercising any right, power or privilege under this Guarantee shall impair such right, power or privilege or be construed as a waiver of such right, power or privilege nor shall
any single or partial exercise of any such right, power or privilege preclude any further exercise thereof or the exercise of any other right, power or privilege. 
  

	7.	INVALIDITY 

  
 If at any time any one or more of the provisions of this Guarantee is or becomes invalid, illegal or unenforceable in any respect under any law, the validity, legality and enforceability of the remaining provisions
hereof shall not be in any way affected or impaired thereby. 
  

	8.	ASSIGNMENT 

  
 In the event of a change of control of the Seller’s Guarantor, the Seller’s Guarantor shall be free to assign, sub-contract or otherwise transfer this guarantee or its rights and obligations hereunder to
another member of the Seller’s Group. 
  

 87 

  
 SCHEDULE 8 

 
 Data Room Index 
  

	1.1	Statutory books of Ivex Pharmaceuticals Limited 

  

	1.2	Statutory books of Galen Research Laboratories Limited and Galen (UK) Limited 

  

	2.1	MHRA Marketing Authorisations – Ivex Pharmaceuticals Limited 

  
 Intraneal No. 1 
 Intraneal No. 2 

Intraneal No. 4 
 Plegivex Cardioplegia
Solution 
 Sterile Chlorhexidine Solution for Irrigation 0.02% w/v 
 Sterile Chlorhexidine Solution for Irrigation 0.05% w/v 
 Sterile Chlorhexidine Solution 1.0% w/v 
 Sterile Chlorhexidine Solution 1.0% w/v (Red) 
 Sterile Chlorhexidine Solution 0.5% w/v 
 Sterile Chlorhexidine Solution 0.05% w/v 
 0.5% w/v Chlorhexidine in 70% v/v Industrial Methylated Spirit 
 Chlorhexidine Gluconate Solution 5.0% w/v 
 Surgiscrub 
 Darrow’s Solution for Infusion 
 Ringer’s Solution for Infusion 
 CPD-50 Solution 
 Glucose 50% w/v IV Infusion BP 
 Half Strength
Hartmann’s Solution with 5% w/v Glucose IV Infusion 
 0.45% w/v Sodium Chloride and 5% w/v Glucose IV Infusion 
 Metrovex 
  
 MHRA Marketing Authorisations – Galen Research Laboratories Limited 
  
 Sterile Water for Irrigation 
 Sodium Chloride 0.9% w/v for Irrigation 
 Sodium Chloride 0.9% w/v for IV Infusion BP 
 Dextrose Injection BP 5% w/v 
 Dextrose
Injection BP 10% w/v 
 Sodium Chloride 0.9% w/v and Dextrose 5% w/v Injection BP 
 Sodium Lactate IV Infusion BP 
 Compound
Sodium Lactate IV Infusion BP 
 Sodium Chloride 0.45% w/v IV Infusion BP 
 Sodium Chloride 0.18% w/v and Dextrose 4% w/v Injection BP 
 Sterile Chlorhexidine Solution 0.05% w/v 
 Potassium Chloride 0.3% w/v and Sodium Chloride 0.9% w/v Injection
BP 
 Potassium Chloride 0.3% w/v and Dextrose 5% w/v IV Infusion BP 
 Potassium Chloride 0.2% w/v and Sodium Chloride 0.9% w/v IV Infusion BP 
 Potassium Chloride 0.2% w/v and Glucose 5% w/v IV Infusion BP 
 Intraneal No. 3 
 Potassium Chloride 0.15% w/v and Sodium Chloride 0.9% w/v IV Infusion BP 
 Potassium Chloride 0.15% w/v and Glucose 5% w/v IV Infusion BP 
 Potassium Chloride 0.15% w/v, Sodium
Chloride 0.18% w/v and Glucose 4% w/v IV Infusion BP 
 Glucose 20% w/v IV Infusion BP 
 Mannitol 10% w/v IV Infusion BP 
 Mannitol 20%
w/v IV Infusion BP 
  

 88 

 Sterile Sodium Citrate Solution 3% w/v for Irrigation 
 Sterile Chlorhexidine Solution 1.0% w/v 
 Sterile Chlorhexidine Solution 0.5% w/v 
 Sterile Chlorhexidine Solution 0.05% w/v 
 Sodium Chloride 0.45% w/v, Potassium Chloride 0.15% w/v and Glucose 5% w/v IV Infusion 
 Potassium Chloride 0.2% w/v, Sodium Chloride 0.18% w/v and Glucose 4% w/v IV Infusion BP 
 Potassium Chloride 0.3% w/v, Sodium Chloride 0.18% w/v and Glucose 4% w/v IV Infusion BP 
  
 IMB Marketing Authorisations – Ivex Pharmaceuticals Limited 
  
 Sterile Water for Irrigation 
 Sodium Chloride 0.9% w/v for Irrigation 
 Metronidazole Infusion 5mg/ml (Metrovex) 
  
 IMB
Marketing Authorisations – Galen Research Laboratories Limited 
  
 Sodium Chloride IV Infusion BP 0.9% w/v 
 Sodium Chloride IV Infusion BP 0.45% w/v 
 Glucose IV Infusion BP 5% w/v 
 Glucose IV
Infusion BP 10% w/v 
 Sterile Water for Irrigation 
 Sodium Lactate Injection BP – 500ml 
 Sodium Lactate Injection BP – 1000ml 
 Compound Sodium Lactate IV Infusion BP 
 Sodium Chloride 0.18% w/v and Dextrose 4% w/v IV Infusion BP 
 Sodium Chloride 0.9% w/v and Dextrose 5% w/v IV Infusion BP

  
 VMD Marketing Authorisations (UK) – Ivex Pharmaceuticals
Limited 
  
 Isolec 
 Vetivex 20 
 Vetivex 1 
 Isolec 
 Vetivex 6 
 Vetivex 18 
 Vetivex 3 
 Vetivex 9 (Ringer’s Solution for Injection) 
  
 VMD Marketing Authorisations (RoI) – Ivex Pharmaceuticals Limited 
  
 Isolec 
  
 Medical Devices Registrations – Ivex Pharmaceuticals Limited 
  
 Sterac Water 
 Sterac Saline 
 Sterac Saline 20ml 
 Emergency Eye Wash 
 Cathcare S 
 Cathcare W 
 Cathcare R 
 Cathcare G 
 Cathcare C 
 Glycine 1.5% w/v for Irrigation 
 Haemodialysis Solutions 
  
 Facility Approvals - Ivex Pharmaceuticals Limited 
  
 Establishment Inspection Report by FDA 
 Lloyd’s Register Quality Management System Standards 
  

 89 

 Medicinal Product FDA Site Registration 
 Medical Device FDA Site Registration 
 MHRA
Manufacturer’s Licence 
 MHRA Manufacturer’s “Specials” Licence 
 MHRA Wholesale Dealer’s Licence 
  

	3.1	UK patent office trademark registrations for: 

  
 VetIvex 
 Plegivex 
 Cathcare 
 Intraneal 
 Sterexidine 
 Sterac 
 Metrovex 
 Haemovex 
 Clinisol 
 Intraven 
 Cetexidine 
 Clinilyte 
 Clinivex 
  
 Republic of Ireland patent office trademark registrations for: 
  

Metrovex 
 Haemovex 
  

	4.1	Galen Holdings plc 2002 Annual Report and Accounts 

 Galen
Holdings plc 2003 Interim Report and Accounts 
 Galen (UK) Limited report and financial statements for period to 30 September 2002

 Galen Research Laboratories Limited financial statements for y/e 30 September 2002 
  

	4.2	Ivex Pharmaceuticals Limited Annual Report for y/e 30 September 2002 

 Ivex Pharmaceuticals Limited Annual Report for y/e 30 September 2003 
  

	4.3	Ivex Pharmaceuticals Limited projections from 1 October 2003 to 30 September 2005 

  

	4.4	General ledger reports at 30 September 2003, 30 November 2003 and 29 February 2004 

  

	4.5	Aged debtors report at 30 September 2003 and 29 February 2004 

  

	5.2	Listing of debtors balances > 2 months old: period from February to November 2003 

 Listing of potential bad debts at 31 December 2003 
  

	5.4	Analysis of sales by category by customer (1 October 1999 to 30 September 2003) 

  

	5.6	Confidentiality Agreement with Baxter Healthcare Limited 

 Confidentiality Agreement with Baxter SA/NV 
 Supply Agreement with Baxter S.A. 
 Technical Agreement with Baxter Healthcare Limited 
 Technical Agreement with Biosol S.p.A. 
 Technical Agreement with Boots Company PLC 
 Agreement with Ciba Vision Ophthalmics GmbH 
 Agreement with Ciba Vision Ophthalmics UK Limited 
 Contract Manufacturing Agreement with Ciba Vision AG
(Draft) 
 Development Agreement with COBE BCT Inc. 
 Non-Disclosure Agreement with COBE BCT Inc. 
 Technical Contract with Coloplast Continence Care Division 
 Commercial Agreement for Stability Development and Validation with
Edwards Lifesciences BV (Draft) 
  

 90 

 Manufacturing and Supply Agreement with Edwards Lifesciences AG (Draft) 
 Mutual Confidentiality Agreement with Edwards Lifesciences SA (Draft) 
 Manufacturing and Supply Agreement with Excorim AB 
 Contract Manufacturing Agreement with Fresenius Kabi
Limited 
 Manufacturing and Supply Agreement with Gambro BCT 
 Riboflavin Stability Contract with Gambro BCT Inc. 
 Manufacturing and Supply Agreement with Hospal
International Marketing Management S.N.C. and Gambro Lundia AB 
 Agreement with Haemonetics S.A. (December 1995) 
 Agreement with Haemonetics S.A. (February 1996) 
 Agreement with Haemonetics S.A. (August 1996) 
 Agreement with Haemonetics S.A. (September
1997) 
 Agreement with Haemonetics S.A. (September 1997) 
 Agreement with Haemonetics S.A. (September 1997) 
 Non-Disclosure Agreement with IV Direct Limited 
 Mutual Non-Disclosure Agreement with J.F.Melin Pharmacien

 Confidentiality Agreement with Kendle International Inc. and Technomark Consulting Services Limited 
 Confidentiality Agreement with Laboratoires UPSA 
 Manufacturing and Supply Agreement with Maelor Pharmaceuticals Limited 
 Mutual Non-Disclosure Agreement with Maelor Pharmaceuticals
Limited 
 Confidentiality Agreement with Maelor Pharmaceutical Supplies Limited 
 Confidentiality Agreement with Mindset BioPharmaceuticals (USA) Inc. 
 Manufacturing and Supply Agreement with ML Laboratories PLC 
 Assignment and Novation Agreement with ML
Laboratories PLC and Shire Pharmaceutical Contracts Limited 
 Confidentiality Agreement with ML Laboratories Limited 
 Mutual Non-Disclosure Agreement with Novirio Pharmaceuticals Inc. 
 Mutual Non-Disclosure Agreement with NxStage Medical Inc. 
 Manufacturing and Supply Agreement with NxStage
Medical Inc. (Draft) 
 Confidentiality Agreement with Nycomed Ireland 
 Manufacturing and Supply Agreement with Organon Laboratories Ltd (Draft) 
 Manufacturing Agreement with Seton Healthcare Group PLC 
 Secrecy Agreement with Stedim S.A. 
 Mutual Non-Disclosure Agreement with Technoflex S.A. 
 Agreement of Intent with Technoflex S.A. 
 Mutual Non-Disclosure Agreement with Water First Limited 
  

	5.7	National Health Services tender contracts: 

  
 Yorkshire NHS Trusts Pharmacy Consortium 
 Scottish Healthcare Supplies 
 Central Services Agency (Northern Ireland) 
  

	5.10	Sales and marketing literature re: Isolec and VetIvex products 

  

	5.11	Ivex Pharmaceuticals Limited: index of product prices 

  

	5.12	Overview of customer service organisation 

  

	5.13	Analysis of sales by product for y/e 30 September 2002 

 Mapping of product sales codes to related MHRA Marketing Authorisations 
  

	5.15	Ivex strategy statement 

  

	6.2	Detailed listing of stock on hand (units and value) at 30 September 2003 

 Analysis of stock provision movement in y/e 30 September 2003 
 Report of shelf-life expiry dates on finished
goods in stock at 9 January 2004 
  

	6.3	Details of stock write-offs during 2002 and 2003 

  

 91 

	6.5	Report of purchases by supplier from 1 October 2001 to 30 September 2003 

  

	7.1	Aged creditors report at 30 September 2003 

 Listing of
‘open’ purchase orders at 5 January 2004 
  

	7.5	Report of goods receipts for 2002 and 2003 (raw materials and starting materials) 

  

	8.1	Analysis of prepayments and accrued liabilities at 30 September 2003 

  

	9.1	Listing of plant equipment to transfer as part of transaction 

 Listing of laboratory equipment to transfer as part of transaction 
 Invoice analysis re: cost of plant and laboratory equipment to
transfer as part of transaction 
 Listing of computer hardware and software to transfer as part of transaction 
  

	9.5	Weekly plant equipment maintenance records for 2003 

  

	9.7	Schedule of car leases (including monthly costs and lease expiry dates) 

 Vehicle Management Services Agreements 
 Maintenance contract with Waters Chromatography Ireland Limited

  

	10.1	Corporation tax computation for year ended 30 September 2002 

 Company tax returns (CT600) for year ended 30 September 2002 
 Corporation tax computation for year ended 30 September 2003
(Draft) 
  

	10.2	VAT returns (quarterly basis) for year ended 30 September 2003 

  

	10.3	PAYE and NIC returns (monthly basis) for period April 2003 to September 2003 

  

	12.1	Galen Holdings plc insurance summary for Larne site (details provided re: buildings, contents, stock and business interruption coverages only) 

  

	13.1	Waste disposal regulations and compliance records 

  

	13.2	Environmental licences: 

  
 Department of Environment (NI) consent to discharge trade effluent 
 BSI Certificate of Registration for Environmental Management System 
 BSI continuing assessment visit report
(13 March 2003) 
  
 Oil spillage report dated June 19, 1994

  

	13.3	Department of Health, Social Services and Public Safety licences: 

  
 Possession of morphine 
 Possess, produce and
supply of fentanyl 
  

	13.4	Details of recycling programs 

  

	14.1	Employee details: 

  
 Name 
 Department 
 Job title 
 Annual salary (basic) 

Number of hours worked (per week) 
 Employee pension contribution % 
 Permanent Health Insurance 
 Life Cover 
 Private Medical Insurance

 Car 
 Bonus 
  

 92 

 Executive Share Options 
 Age 
 Length of service 
 Savings-Related Share Option Scheme contributions 
  

	14.2	Ivex Pharmaceuticals Limited organisation chart (January 2004) 

  

	14.3	Terms and conditions of employment for Ivex senior management: 

  
 James McKelvey 
 Allyn Keown 
 Bob McConnell 
 Alan McGahie 
 John Armstrong 
 Darren Mitchell 

Francis Healy 
 Angela Armstrong

 Eleanor Anderson (nee McEvoy) 
 Donna Stewart 
 Julie Morton 
  
 ‘Standard’ terms and conditions of employment: 
  
 Managerial 
 Over £8.25 per hour

 Under £8.25 per hour (production operative) 
 Under £8.25 per hour (non-production operative) 
 Temporary worker 
  

	14.4	Employee Information Binder (updated May 2003) 

  

	14.5	Union Recognition and Procedural Agreement 

  

	14.7	Employee Tribunal cases since January 2002 

  

	14.8	Galen Limited No. 2 Retirement Benefits Scheme (with Scottish Life) 

 Galen Limited Group Personal Pension plan (with Standard Life) 
 Galen Limited Occupational Pension plan
(with Standard Life) 
  

	14.9	Galen Holdings Limited Savings-Related Share Option Scheme 

 Rules of the Galen Holdings plc Approved and Unapproved Share Option Schemes 
 Galen Holdings plc 2000 US (Executive) Option Scheme
(amended May 13, 2003) 
 Executive share options issued to Ivex senior management (14 November 2002) 
  

	14.10 	List of ‘key’ employee resignations during 2002 and 2003 

  

	14.11 	Employee benefit plans: 

  
 Life Assurance 
 Long Term Disability

 VIP Executive Business Express 
 Cost of private medical insurance (per month) for Ivex senior management 
  

	14.13 	List of employees on long term sickness leave 

	          	List of employees on maternity leave 

  

	16.1	Analysis of production capacity per line per single shift (by product volume) 

  

	16.3	Listing of Ivex materials in stability chambers 2, 3 and 4 

  

	16.4	Standard Operating Procedures (SOPs): 

  
 Production 
  

 93 

 Quality Control 
 Quality Assurance 
 Microbiology 
 Engineering 
 Stores 
 Administration 
  

	16.5	Manufacturing flow chart 

  

	16.9	Plant and laboratory equipment ‘gap’ analysis 

  

	16.14 	Manufacturing variances per line (December 2002 to October 2003) 

  

	16.15 	Details of operations related software: 

  
 TREND - building management system 
 PEMAC
– planned engineering maintenance and stores control system 
  

	16.19 	Quality complaints received from customers (2002 and 2003) 

	          	Medical/Technical information requests (2002 and 2003) 

	          	Quality complaints made to suppliers (2003) 

  

	16.20 	Production deviations during 2002 and 2003 

  

	17.1	Health and Safety Policy Handbook 

 Accident statistics
1996-2002 
 Accident and occupational ill health report summary for 2003 
 Health and Safety claims made during 2002 and 2003 
 Fair Employment Monitoring Return (February 2002 to February 2003) 
 Environmental incident reports for 2001-2003 
 Northern Ireland Fire Brigade exemption notice 
  

	19.1	Summary of current stability studies 

  

 94 

  
 SCHEDULE 9 

 
 Business Intellectual Property and IP Licences 
  
 Business Intellectual Property 
  
 As disclosed in the Data Room 
  
 IP Licences 
  
 As disclosed in the Data Room 
  

 95 

					
	 Signed by GEOFFREY ELLIOTT
 For and on behalf of
IVEX
 PHARMACEUTICALS LIMITED
	  	 )
 )
	 	  

  

			
	 EXECUTED and DELIVERED
 as a Deed by ROBERT
WHITEFORD
 who was appointed under a Power of
 Attorney dated
28th April 2004
 For and
on behalf of GALEN HOLDINGS, plc.
	  	 )
 )
  
	 	  

  

			
	 Signed by GARY HEATH
 for and on behalf of
GAMBRO
 NORTHERN IRELAND LIMITED:
	  	 )
 )
	 	  

			
	 EXECUTED and DELIVERED
 as a Deed by
 DAVID PEREZ and another authorized
 representative of Gambro BCT,
Inc.,
 for and on behalf of GAMBRO BCT, INC.
	  	 )
 )
  
	 	  
  

  

  

 96

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]